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DISSERTATION ABSTRACT 
 
 
Preclinical and Clinical Pharmacologic Studies of 
  
9-Nitrocamptothecin and its 9-Aminocamptothecin Metabolite 
 
 
William C. Zamboni, Pharm.D. 
 
 
University of Pittsburgh, 2005 
 
 
The camptothecins are DNA topoisomerase I-interactive anticancer agents and have a 
wide range of antitumor activity.  Currently approved camptothecin analogues (i.e., topotecan 
and irinotecan) are only available for IV administration.  9-Nitrocamptothecin (9NC) is 
administered orally and is partially metabolized to an active metabolite, 9-aminocamptothecin 
(9AC).  As with other camptothecin analogues, 9NC and 9AC undergo a reversible, pH-
dependent reaction between the active-lactone and inactive-hydroxy acid forms.  In vitro and in 
vivo preclinical studies suggest that protracted administration of low doses of camptothecin 
analogues produces better antitumor activity than the less frequent administration of higher 
doses.  Oral administration of 9NC could mimic the protracted schedule and maximize patient 
convenience.  However, the optimal oral dose and schedule of 9NC and other camptothecin 
analogues are currently unclear.  In addition, oral administration of camptothecin analogues has 
been characterized by extensive inter- and intra-patient variability in bioavailability.  The 
primary goal of this dissertation research was to evaluate the pharmacokinetics and 
pharmacogenetics of 9NC and its 9AC metabolite in preclinical models and in patients as part of 
phase I and II trails. 
 v
 Daily administration of 9NC orally for 5 days per week for two consecutive weeks 
repeated every four weeks is tolerable and may be an active regimen in patients with gastric or 
pancreatic cancers.  The responses seen in xenografts models evaluating the same regimen of 
9NC as evaluated in the phase I study occurred at systemic exposures that are tolerable in 
patients.  There was significant inter- and intra-patient variability in the pharmacokinetics of 
9NC and 9AC when 9NC was administered under fasting conditions.  Most of the drug remained 
in the 9NC form with an overall ratio of 9NC to 9AC of 4:1.  Co-administration of 9NC with 
food reduces the oral absorption of 9NC; however there was no difference in the exposure of 
9AC.  The functional consequences of known single nucleotide polymorphisms in genes of 
known ATP-binding cassette (ABC) transporters were evaluated as potential sources of the 
pharmacokinetic variability of 9NC and 9AC.  Our findings suggest that the inter-individual 
variability in the disposition of 9AC, but not 9NC, may be influenced, in part, by ABCG2 
genotype.  The factors associated with the high inter- and intra-patient variability remain unclear.  
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1.0  
CHAPTER 1: 
 
 
 
 
Cellular, Pharmacokinetic, and Pharmacodynamic Aspects of Response to Camptothecins:  
Perspectives to Improve Response 
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1.1 INTRODUCTION 
Camptothecins are a class of anticancer agents that are the prototypical DNA 
topoisomerase I (topo I) inhibitors and appear to be active in human cancers previously resistant 
to chemotherapy (1).  Members of the camptothecins, such as topotecan, irinotecan, 9-
aminocamptothecin (9-AC), and 9-nitrocamptothecin (9-NC), are analogs of the plant alkaloid 
20(S)-camptothecin (Table 1) (2).  Camptothecin analogs occur in equilibrium between the 
active-lactone and inactive-hydroxy acid forms (Figure 1) (3).  These agents interact with topo I 
and DNA to form cleavage complexes, and prevent resealing of the topo I-mediated DNA single 
strand breaks (4,5).  This interaction eventually leads to double-strand DNA breaks and 
apoptosis, or cell death. 
 
 
 
 
Figure 1.  Chemical structure of camptothecin lactone and conversion to the hydroxy acid form.  
Locations of the structural modifications noted in Table 1 are indicated. 
 
 
 
 
 
 
 
 
 
 
 
OH- 
H+ 
 3
Table 1. Camptothecin Derivatives 
  
Compound R7 R9 R10 
Camptothecin H H H 
9-AC H NH2 H 
9-NC H NO2 H 
Topotecan H CH2NH(CH3)2 OH 
Irinotecan C2H5 H 
 
SN-38 C2H5 H OH 
DB-67 t-Bu(CH3)2Si H OH 
 
 
The molecular mechanisms of selectivity and cellular resistance associated with 
camptothecins have been extensively reviewed (1).  Factors influencing resistance include 
reduction in the formation of cleavage complexes due to mutations in topo I that render the 
enzyme drug-resistant and decreased topo I activity.  Topo I protein levels are commonly 
decreased in camptothecin-resistant cell lines including those with well-characterized topo I 
mutations.  In addition, certain factors following the formation of the cleavage complex, such as 
DNA repair, cell cycle check points, and apoptosis can produce resistance to the camptothecins.  
It is likely that the selectivity and effectiveness of camptothecin analogs depends on the 
deficiencies in DNA repair, cell cycle regulation, and apoptosis associated with topo I in cancer 
cells, whereas normal cells can adapt more effectively to topo I-mediated DNA damage (1). 
Results of preclinical and clinical studies suggest that camptothecin analogs have a wide 
range of antitumor activity against adult and pediatric solid tumors and leukemias (6,7).  
Preclinical studies evaluating the antitumor response of camptothecin analogs have shown 
significant activity against solid tumor xenografts, with the greatest antitumor responses found 
with protracted continuous schedules (7-9).  Preclinical studies also suggest a lack of cross-
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resistance with other anticancer agents and that maintenance of an exposure threshold may be 
required to achieve optimal cytotoxicity (6,10-12). 
Even though camptothecin analogs have a wide range of antitumor activity, this activity 
is not the same for each member of the class.  Topotecan (Hycamptin®) is approved by the U.S. 
Food and Drug Administration (FDA) for the treatment of metastatic carcinoma of the ovary 
after failure of initial or subsequent chemotherapy and for the treatment of small cell lung cancer 
sensitive disease after failure of first-line therapy (13).  Irinotecan (Camptosar®) is approved by 
the FDA as first-line therapy for the treatment of patients with metastatic colorectal cancer in 
conjunction with 5-fluorouracil and leucovorin (14).   
9-NC is currently in Phase III trials for the treatment of newly diagnosed and refractory 
pancreatic cancer (15-16).  Newer agents such as homocamptothecins and silatecans are now in 
preclinical and early clinical development (17-21).  As with the differences in antitumor activity 
among camptothecin analogs, the toxicity profile is unique to each agent.  The primary dose-
limiting toxicities of topotecan are neutropenia and thrombocytopenia (3,22,23).  Bone marrow 
suppression may occur with irinotecan and 9-NC; however, the primary toxicities associated 
with these agents are diarrhea and cystitis, respectively (24-27).  The exact mechanisms for the 
differences in antitumor effect and toxicities of the camptothecin analogs are unknown. 
In addition to the molecular factors associated with camptothecin-induced cytotoxicity, 
there are several pharmacokinetic and pharmacodynamic aspects of camptothecins that have 
been related to antitumor response and toxicity.  These factors consist of cellular mechanisms of 
resistance including active cellular efflux, modulation of topo I and II; the influence of protein 
binding on lactone stability, structural modifications that have been developed to improve 
lactone stability; and alterations in the metabolism of camptothecins.  Many of these factors have 
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been evaluated in the clinical setting to improve response.  However, the optimal treatment 
schedule of camptothecins is currently unknown. 
 
1.2 CELLULAR MECHANISMS OF RESISTANCE 
Efflux 
 Resistance to chemotherapeutic agents is a major clinical complication in cancer therapy, 
in many cases resulting in treatment failure.  One common mechanism of resistance is the 
reduction in cellular concentration of anticancer agents via efflux by multi-drug resistance pumps 
(MDR).  Prior studies have shown insignificant differences in accumulation of camptothecins in 
P-glycoprotein (P-gp) positive and negative cells (28,29).  In addition, when cell lines displayed 
a decrease in cellular accumulation, this decreased accumulation was not associated with P-gp or 
multi-drug resistance associated protein (MRP).  However, new evidence suggests camptothecins 
undergo cellular efflux modulated by an alternative anionic pump (30,31).  Gupta and colleagues 
reported the absorption of camptothecin across Caco-2 cells was mediated by passive diffusion 
and active transport (30).  Although the active transporter was not identified, the authors 
speculated that the absorptive transport of camptothecin was mediated by common transporters 
such as organic anion, organic cation, and/or bile acid transporters. Vanhoefer and colleagues 
evaluated the effect of the dihydropyridine analogue, PAK-200S, on P-gp mediated resistance to 
topotecan in human breast cancer cells resistant to adriamycin (MCF-7/adr) and ovarian tumor 
cells resistant to doxorubicin, daunorubicin, idarubicin, and etoposide (A2780/Dx5) (32).  
Despite prior reports that camptothecins are not significantly affected by P-gp, cellular exposure 
to PAK-200S at a non-cytotoxic concentration almost completely reversed resistance to 
topotecan in both cell lines (28,29).  Cellular topotecan lactone levels were about 2.5-fold lower 
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in the resistant breast cancer cell line compared to the wild type.  Exposure to PAK-200S 
completely restored cellular topotecan concentrations in resistant cells as compared to the 
parenteral cells with no effect on the drug concentrations in parental MCF-7 cells lacking P-gp 
expression.  Similar results were reported for the ovarian cell lines.  Furthermore, the addition of 
PAK-200S in the presence of topotecan significantly increased the induction of protein linked 
DNA breaks.  These results suggest that the reversal of P-gp mediated resistance to topotecan by 
PAK-200S is related to restoration of drug concentrations of topotecan rather than a direct effect 
on topoisomerases.   
The efflux of camptothecins from cells has previously been reported to be associated with 
to the breast cancer resistance protein (BCRP/MXR/ABCG2).  Topotecan and mitoxantrone 
resistant cell lines (T8 and MX3, respectively) both displayed a decreased accumulation of drug 
caused by an enhanced energy-dependent efflux (33).  The authors reported overexpression of 
the breast cancer resistance protein/mitoxantrone resistance/placenta-specific ATP-binding 
cassette (BCRP/MXR/ABCG2).  This plasma-membrane protein transported 70 - 80% of the 
intracellular topotecan out of the cell within 30 seconds (33,34).  These results suggest that the 
efficient efflux of topotecan by BCRP/MXR/ABCG2 may have clinical relevance for patients 
being treated with topotecan, but extended studies will be required to analyze the possible 
contribution of BCRP to clinical multidrug resistance. 
The ABC transporter superfamily contains membrane proteins that transport a wide 
variety of substrates across extra-and intracellular membranes.  These substrates include 
metabolic products, lipids and sterols, and drugs (36,37).  Over-expression of certain ABC 
transporters occurs in cancer cell lines and tumors that are multidrug resistant (38-42).  
Phylogenetic analysis has identified 48 human ABC transporters and assigned them to seven 
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distinct subfamilies of proteins (43).  ABC transporters have been reported to alter the 
pharmacokinetics of camptothecin analogues and are associated with camptothecin resistance 
(44,45). 
 ABCB1 (PGP/MDR1) was the first human ABC transporter to be cloned and also to be 
identified as conferring an MDR phenotype to cancer cells (38-44).  ABCB1 is expressed in the 
kidney, liver, intestine, adrenal gland, blood brain barrier and hematopoetic stem cells (42). 
ABCB1 transports colchicine, etoposide, doxorubicin, and vinblastine, as well as lipids and 
steroids.  The effects of three single nucleotide polymorphisms (SNPs) of ABCB1 (1236C>T, 
3435C>T, 2677G>A/T) have been evaluated in preclinical and clinical trials (43).  ABCC2 
(MRP2/cMOAT) is expressed in canalicular cells in the liver (46,47).  It functions as an 
important efflux pump that transports organic ions from the liver to the bile.  The ABCG2 gene 
(formally known as the MXR/BCRP/ABCP) encodes a half transporter with a nucleotide-binding 
fold-transmembrane domain orientation (38,46).  ABCG2 is expressed in stem cells, the placenta, 
and the intestine (48,49).  ABCG2-associated proteins transport mitoxantrone, methotrexate, and 
camptothecin analogues such as topotecan, diflomotecan, and SN-38 (38,50,51).   
 To combat the efflux of camptothecins by BCRP, Erlichman and colleagues evaluated the 
effect of BCRP inhibition by CI1033 (PD 183805), a quinazoline-based HER family tyrosine 
kinase inhibitor, in combination with SN-38, topotecan, and camptothecin (35).  The 
combination of CI1033 with SN-38 was synergistic in T98G glioblastoma cells and HCT8 
colorectal carcinoma cells.  The increased activity of SN-38 and topotecan in combinations with 
CI1033 was secondary to an increased intracellular accumulation of SN-38 and topotecan, 
coupled with an increase in the number of covalent topo I DNA complexes stabilized by SN-38 
or topotecan.  To address the possibility that CI1033 was inhibiting BCRP, drug accumulation 
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and cytotoxicity were examined in MDA-MB-231 cells transfected with DNA encoding BCRP.  
CI1033 increased the steady-state level of SN-38 and topotecan by 7.8 ± 1.0 and 2.2 ± 0.5-fold, 
respectively.  The accumulation of CI1033 was 4.9 ± 0.1-fold lower in cells transfected with 
BCRP, suggesting that CI1033 is a substrate for BCRP (35).  The results of this study indicate 
that CI1033 may modulate the accumulation and subsequent cytotoxicity of topo I inhibitors, but 
the clinical effect may vary depending on the camptothecin derivative analyzed.   
 The presence of P-gp in the luminal side of the intestinal epithelium may reduce the oral 
bioavailability of drugs.  Jonker and colleagues evaluated the effect of P-gp on the oral 
bioavailability of topotecan in mice deficient for P-gp and wild type mice (52).  A two-fold 
decrease in the AUC of topotecan, when administered orally, was observed in mice positive for 
P-gp in comparison to wild type mice.  However, there was no significant difference in the 
pharmacokinetics of topotecan after IV administration in either mice group.  These results 
suggest that P-gp is mainly important in modulating the oral uptake of topotecan (52).  In 
addition, these results suggest the oral absorption and achievable AUC of topotecan may be 
influenced clinically by varying expression of P-gp in patients and that modulators of P-pg may 
increase the oral bioavailability of topotecan (53). 
 Modulation of anionic excretion or efflux may also alter the systemic, renal, and non-
renal pharmacokinetics of camptothecins.  Zamboni and colleagues31 reported the inhibition of 
anionic renal tubular secretion of topotecan when administered with probenecid, an inhibitor of 
anionic tubular transport in the proximal tubule of the kidney (54).  The co-administration of 
topotecan lactone or hydroxy acid with probenecid significantly decreased topotecan lactone, 
total, and hydroxy acid systemic clearance in mice (P < 0.05).  In addition, probenecid decreased 
the renal and non-renal clearance of topotecan (31).  Clinically, these results suggest the 
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combination of topotecan with agents that compete for anionic renal tubular secretion could 
increase systemic exposure to the active lactone moiety, with a subsequent increase in toxicity 
and or antitumor efficacy. 
 
Modulation of topoisomerase I and II 
 As treatment of cancer continues to progress, many new compounds will be evaluated 
and studied in combination with other chemotherapeutic agents.  The combination of various 
agents can lead to discoveries of additive, synergistic, or even antagonistic effects.  Several 
preclinical studies have evaluated the ability of anticancer agents to modulate topo I expression 
and, therefore, affect the activity of camptothecins (55-60). 
Kano and colleagues reported the additive effects of sequential paclitaxel and SN-38 in a 
series of human cancer cell lines (55).  Interestingly, the simultaneous exposure of the cells to 
paclitaxel and SN-38 produced antagonistic effects in some cell lines while producing an 
additive effect in others.  These results are similar to those published by Kaufmann and 
colleagues which showed simultaneous exposure to topotecan and vincristine or paclitaxel 
produced antagonistic effects against A549 human non-small cell lung cancer cells (57).  
Madden and colleagues reported the effects of low-level taxane exposure on the activity of topo I 
inhibitors in MCF-7 and MDAH B231 human breast cancer cells (58).  Prior treatment with 
paclitaxel or docetaxel decreased the IC50 for 9-AC and topotecan by nearly 10-fold.  No 
difference was reported from controls for the reverse sequence or simultaneous drug exposure.  
These results suggest taxane exposure prior to camptothecin exposure impacts the cytotoxicity 
by increasing topo I expression in a sequence-dependent manner.  In addition, Hallin and 
colleagues reported the increase in expression and activity of topo I and II after taxane treatment 
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in human breast cancer cell lines (59).  The increase in topo I was associated with a taxane-
induced G2/M blockade as depicted by the increase percent of cells in G2 after taxane exposure.  
Although cell culture studies have shown that the simultaneous exposure of cells to a 
topo I inhibitor and a topo II inhibitor can result in antagonism (56), Eder and colleagues 
reported no therapeutic antagonism with the combinations of irinotecan and doxorubicin or 
etoposide in mice bearing the EMT-6 mammary tumor (60).  The administration of irinotecan 
alone increased the expression of topo II and decreased the expression of topo I while the 
administration of etoposide or doxorubicin alone increased the expression of topo I and 
decreased the expression of topo II.  Levels of topo I and II were decreased with concomitant 
administration of irinotecan and etoposide or doxorubicin, while sequential administration 
reflected the effect of the last agent administered.  These results suggest that combinations and 
sequences of topo I and topo II inhibitors may produce greater cytotoxicity than either agent 
alone. 
The combination of topotecan and vincristine has demonstrated greater than additive 
effects in mice with pediatric solid tumor xenografts including neuroblastoma, 
rhabdomyosarcoma, and brain tumors (61).  Topotecan was administered as an IV bolus daily for 
5 days on 2 consecutive weeks with cycles repeated every 21 days over a period of 8 weeks.  
Vincristine was administered IV every 7 days at a fixed dose of 1 mg/kg.  The therapeutic effect 
of combining topotecan with vincristine was greater than additive in most tumor models of 
childhood solid tumors.   Toxicity data suggested that this regimen could be administered to mice 
with only moderate reductions in the dose levels for each agent.  In addition, there was no 
pharmacokinetic interaction between topotecan and vincristine.  The mechanism of this 
synergistic interaction is unknown suggesting a cellular effect (61).  Several preclinical and 
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clinical studies evaluating the sequence of administration of camptothecins, and topo II inhibitors 
and taxanes are now being performed. 
 
1.3 LACTONE STABILITY  
Lactone stability of topotecan 
The lactone ring is a structural requirement for effective biologic activity of 
camptothecins.  Prior data indicate a closed α-hydroxylactone ring is important for passive 
diffusion of these drugs into cancer cells and for successful interaction with topo I (60-66).  
Therefore, factors that influence or shift the lactone-carboxylate equilibrium of camptothecins 
may alter the function of these agents. 
One factor that clearly affects the camptothecin lactone-carboxylate equilibrium is 
protein binding.  Early research found human serum albumin (HSA) to have a 200-fold binding 
preference for camptothecin carboxylate over the lactone form (57).  In the presence of HSA, the 
carboxylate form was preferentially bound shifting the lactone-carboxylate equilibrium in favor 
of the carboxylate (Figure 2). This provided an explanation for the rapid hydrolysis of 
camptothecin in the presence of HSA.  This effect appears to be limited to HSA, as rapid and 
complete ring opening was not reported in the presence of albumin or plasma from mouse, rat, 
dog, rabbit, or bovine sources.  Thus, these species have higher equilibrium levels of 
camptothecin lactone relative to humans (68).  While HSA has the ability to shift the 
camptothecin lactone-carboxylate equilibrium to the right, other components (low-density 
lipoprotein, α1-acid glycoprotein, red blood cells) found in human whole blood have the ability 
to stabilize the lactone ring (68,69).  The enhanced stability of the camptothecin lactone ring in 
whole blood may be attributed to its ability to partition into lipid bilayer structures, especially of 
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red blood cells (RBCs) (67,70,71).  The intercalation of camptothecin within the acyl chain 
region of the bilayer protects the lactone ring from hydrolysis (67).  Despite the RBCs protective 
effect of the camptothecin lactone form, a certain fraction of the administered drug will 
hydrolyze in human blood.  
 
 
Figure 2.  Depiction of the effects of protein binding in human blood on lactone stability. DB-67, a 
silatecan, displays improved lactone stability relative to SN-38 and the lipophilic experimental agents 
10,11-methylenedioxycamptothecin (10,11-MDCPT) and 7-ethyl-10,11-methylenedioxycamptothecin (7-
E-10,11-MDCPT).  Stability profiles were determined using HPLC methods.  All experiments were 
conducted at pH 7.4 and 37°C.  Each data point represents the average of three or more determinations 
with an uncertainty of 10% or less.  Reprinted with permission from reference (75). 
 
Gender-dependent differences in the pharmacokinetics of topotecan in adults may result 
from the interaction between camptothecins and RBCs (72).  Loos and colleagues reported a 1.4-
fold higher clearance of topotecan lactone in males compared to females (P = 0.0082).  After 
correction for body surface area, the apparent topotecan lactone clearance remained 1.3-fold 
higher in males compared to females (P = 0.0076).  In addition, the lactone to total ratio of the 
AUC of topotecan was significantly higher in females compared to males.  Individual hematocrit 
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values were consistently lower in females (P < 0.023) and were a significant predictor of 
topotecan lactone clearance.  The authors concluded that there is a significant gender-dependent 
difference in the pharmacokinetics of topotecan as a result of physiologic differences in the 
hematocrit values between men and women. 
 
Structural modifications 
Since the closed, active lactone ring is a structural requirement for effective biologic 
activity of the camptothecins, many researchers have investigated various modifications of the 
camptothecins in an effort to promote lactone stability yet retain antitumor efficacy (62).  An 
approach to a more stable topo I inhibitor has included structural modifications that eliminate the 
highly preferential binding of the carboxylate form to HSA and thus reduce the rate of 
hydrolysis.  In addition, the discovery of lactone stabilization through lipid bilayer partitioning 
has led to the design of more lipophilic analogues in order to promote partitioning of these agents 
into the lipid bilayers of erythrocytes and protect the active lactone form from hydrolysis. 
 
Silatecans 
 The synthesis of 7-silycamptothecins by adding a silyl group at position 7 with various 
substitutions at position 10 has demonstrated increased stability of the lactone ring (17,18).  The 
addition of a silyl group may limit drug inactivation by both protein binding and hydrolysis of 
the lactone ring, and enhance lipophilicity, which would increase in vivo activity while possibly 
limiting toxicity (Table 1) (73).  The majority of these new compounds demonstrate potencies 
comparable to or better than other camptothecin derivatives.  Two of the leading members of this 
class, DB-67 and karenitecin, are in preclinical and phase II development, respectively.  
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Preclinical nonhuman primate and phase I clinical studies of karenitecin indicated the percent 
lactone was 104% and 87 ± 11%, respectively (19,74).  DB-67 was found to have more potent 
antitumor activity than topotecan, and at least comparable to SN-38, against a panel of five high-
grade glioma cell lines (75).  Although the results of this study are promising for the future 
treatment of human gliomas, it is unclear if the increased stability of the lactone ring in human 
blood and its potentially increased lipophilicity will translate into increased activity in humans.  
One potential problem is that silatecans are highly protein bound and have low penetration into 
the cerebrospinal fluid (CSF) (19). 
 
Homocamptothecins 
To further stabilize the lactone ring, Lesueur-Ginot and colleagues expanded the E-ring 
of camptothecin to a seven member β-hydroxylactone ring with the insertion of a methylene 
spacer between 20-OH and the carboxyl moiety (Figure 3) (20).  This new lactone E-ring 
modified compound has been termed a homocamptothecin and provides a less reactive lactone 
with enhanced stability and decreased protein binding in human plasma in comparison to 
camptothecin.  In addition, in vitro studies demonstrated greater antiproliferative effects and 
higher levels of DNA cleavage after exposure to homocamptothecin compared to camptothecin 
(20).   
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Figure 3.  Chemical structures of the homocamptothecin, BN 80245, and the fluorinated 
homocamptothecin, BN 80915.  Reproduced with permission from reference (21). 
 
Philippart and colleagues reported two homocamptothecins, BN 80245 and BN 80915 exerted 
higher antiproliferative activity than camptothecin, topotecan, and SN-38 (21).  Bailly and 
colleagues reported higher levels of protein-DNA complexes in P388 leukemia cells treated with 
homocamptothecin than those treated with camptothecin (76).  The slow hydrolysis of 
homocamptothecin instead of the fast equilibrium between the lactone and carboxylate of 
camptothecin may account for its improved in vivo activity.  Also, homocamptothecin has been 
found to induce DNA cleavage at T↓G sites more efficiently than camptothecin and induce DNA 
cleavage at additional sites unseen with camptothecin containing an AAC↓G motif. These 
observed differences could further stabilize the lactone moiety and broaden the cytotoxicity 
profile of these drugs (76). 
 
Homosilatecans 
Homocamptothecins have been further modified to form homosilatecans (18).  In 
addition to the expanded β-hydroxylactone E-ring, each of the homosilatecans also contains a 
silylalkyl functionality at the 7-position.  As with the silatecans, this functionality group 
increases the lipophilicity while reducing the strength of carboxylate interactions with HSA.  
BN 80245:  R = H 
BN 80915:  R = F 
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Two homosilatecans, DB-90 and DB-91, contain amino and hydroxyl groups at the 10-position, 
respectively, to further reduce binding of the carboxylate form to HSA.  Homosilatecans display 
improved lipophilicty and stability in human whole blood compared to camptothecin and 
topotecan.  Interestingly, homosilatecans display similar stabilities in human and mouse blood, 
which contrasts with the interspecies variations in blood stabilities observed for camptothecins 
(18).  Thus, preclinical animal modeling and efficacy studies with the homosilatecans may be 
predictive of their use in a clinical setting.  
 
1.4 METABOLISM AND EXCRETION 
Oxidative metabolism 
 Initial preclinical studies suggested the camptothecins did not undergo significant 
oxidative metabolism.  However, recent preclinical and clinical studies report clinically 
significant oxidative metabolism and drug interactions. 
 
9-Aminocamptothecin  
Grossman and colleagues reported an increased 9AC dose requirement in patients with 
newly diagnosed glioblastoma multiforme or recurrent high grade astrocytomas concomitantly 
receiving cytochrome P-450 (CYP) enzyme inducing anticonvulsants (EIA) (77).  In addition, 
grade III or IV myelosuppression did not occur in 29 patients who received 9AC 850 mg/m2/day 
continuous infusion for three days with co-administration of phenytoin, phenobarbtial, 
carbamazepine, and/or valproic acid.   In contrast, two of three patients not taking EIAs 
developed grade IV myelosuppression.  Steady state total 9AC plasma levels were 3-fold lower 
in patients on anticonvulsants than in patients receiving anticonvulsants.  The maximum 
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tolerated dose (MTD) of 9AC in an additional 27 patients on EIAs was 1776 μg/m2/day in 
patients with newly diagnosed tumors and 1611 μg/m2/day for patients with recurrent disease.  
The exact mechanism of why patients receiving EIAs were able to tolerate significantly higher 
doses of 9AC is unclear; however, the EIAs in this study have a wide range of CYP activation. 
 
Topotecan  
The combination of other camptothecins with EIAs has also resulted in altered 
pharmacokinetic disposition of camptothecins.  Topotecan is known to undergo oxidative 
metabolism to form the metabolite N-desmethyl topotecan. This reaction is presumably followed 
by two oxidation steps leading to a nitroso-derivative, which could potentially be a suicide 
inhibitor of CYP 3A (78).  An increase in lactone and total topotecan clearance from 43.4 ± 1.9 
L/h/m2 to 62.9 ± 6.4 L/h/m2, and 20.8 ± 2.8 L/h/m2 to 30.6 ± 4.1 L/h/m2, respectively (P < 0.05), 
has been reported in a pediatric patient receiving phenytoin (78). There was a 2-fold increase in 
the N-desmethyl oxidative metabolite of topotecan when co-administered with phenytoin.  The 
concentration versus time profiles of topotecan and N-desmethyl topotecan with and without co-
administration of phenytoin are presented in figure 4.  In addition, a population pharmacokinetic 
study reported that co-administration of phenytoin was a significant covariate in predicting 
topotecan clearance (79).  Ma and colleagues reported a tripling of the trough cyclosporine 
concentration during a 10 day course of topotecan with only a 30% increase in cyclosporine dose 
(80).  In addition, on day 8 of the topotecan therapy, the N-desmethyl topotecan systemic 
exposure doubled despite a 20% reduction in topotecan dose compared with day 1.  In addition, 
Goldwasser and colleagues reported a 3-fold increase in the Cmax of cyclosporine in a patient 
receiving concomitant topotecan (81).  No change in plasma total or topotecan lactone was 
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reported. These results suggest that topotecan may undergo significant oxidative metabolism and 
may act as a CYP 3A inhibitor.  However, studies using human liver microsomes are needed to 
fully elucidate potential drug interactions and toxicity. 
 
Figure 4.  Implication of coadministration of topotecan with phenytoin.  Depiction of  total topotecan and 
total N-desmethyl topotecan concentration-time plots after a simulated dose of 2.0 mg/m2 administered 
alone and in combination with phenytoin.  Lines represent total topotecan (A, ⎯) and total N-desmethyl 
topotecan (a, ⎯) alone, and total topotecan (B, ---) and total N-desmethyl topotecan (b, ---) in 
combination with phenytoin.  The plasma AUC of total topotecan after administration of topotecan alone 
and in combination with phenytoin was 81.3 and 52.4 ng/ml·hr, respectively.  The plasma AUC of total 
N-desmethyl topotecan after administration of topotecan alone and in combination with phenytoin was 
2.9 and 4.0 ng/ml·hr, respectively.  Reprinted with permission from reference (78). 
 
When camptothecin analogs are combined with other anticancer agents, the sequence of 
administration may influence potential metabolic interactions.  Zamboni and colleagues 
evaluated the combination of topotecan and docetaxel administered in different sequences (82).  
On cycle 1, docetaxel was administered on day 1 and topotecan on days 1 to 4.  On cycle 2, 
topotecan was administered on days 1 to 4 and docetaxel was administered on day 4.  During 
cycle 2, the clearance of docetaxel was decreased by 50% (75.6 ± 79.6 L/h/m2 vs 29.2 ± 17.3 
L/h/m2, P = 0.046).  The mean absolute neutrophil count (ANC) nadir in cycle 2 was also lower 
 19
than in cycle 1, 2808 ± 4518/μL and 4857 ± 6738/μL, respectively (P = 0.02).  Since docetaxel is 
metabolized by CYP 3A4, the results of this study suggest prior topotecan treatment decreased 
docetaxel clearance via inhibition of CYP 3A which was associated with an increase in the 
severity of neutropenia (83,84). 
 
Irinotecan  
Irinotecan undergoes oxidative metabolism to form 7-ethyl-10-[4-N-(5-aminopentanoic 
acid)-1-piperidino] carbonyloxycamptothecin (APC) (Figure 5) (95).  In an effort to establish the 
oxidative enzymatic pathway involved in the formation of APC, Haaz and colleagues 
investigated the metabolism of irinotecan in human liver microsomes (95).  The oxidation of the 
distal piperidine ring of APC was found to be catalyzed primarily by CYP3A.  The CYP 3A 
selective inhibitors, ketoconazole and troleandomycin, inhibited APC formation by 98 and 
100%, respectively.  The clinical relevance of these findings is uncertain at this time because 
APC has 500-fold less antitumor activity compared to SN-38. 
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Figure 5.  Metabolic schema for irinotecan.  The enzymatic formation of the active metabolite SN-38 and 
hydrolysis of both irinotecan and SN-38 to their hydroxy acid forms are shown.  Irinotecan also 
undergoes oxidative metabolism to form the APC metabolite, while SN-38 undergoes glucuronidation to 
form SN-38 glucuronide.  Reprinted with permission from reference (93). 
 
Clinical studies have identified drug interactions between irinotecan and EIAs.   Gajjar 
and colleagues reported a 2-fold increase in irinotecan clearance and a 3-fold decrease in SN-38 
area under the concentration time curve (AUC) in children receiving EIAs compared to those not 
taking EIAs (14.1 ± 6.6 vs 46.4 ± 14.0 ng·hr/mL, respectively; P = 0.007) (86).  However, the 
mean APC AUC was not statistically different between the two groups (126.4 ± 47.9 vs 117.5 ± 
26.0 ng·hr/mL, respectively; P = 0.73).  Due to the complicated metabolic disposition and high 
intrapatient variability of irinotecan, controlled clinical trials are required to further elucidate 
clinically significant drug interactions.  
CYP3A4 
UGT1A1 
CES2 CES1 
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Conversion of Irinotecan to SN-38  
 Irinotecan is a prodrug that is activated primarily in the liver by carboxylesterase (CE) 
enzymes to form an active metabolite, SN-38 (Figure 5) (87).   Humerickhouse and colleagues 
evaluated the kinetics of irinotecan hydrolysis by the two human liver CE iso-forms (hCE-1 and 
hCE-2) using purified enzymes from human liver and the effect of these two enzymes on 
irinotecan cytotoxicity (88).  The hCE-2 had a 12.5-fold higher affinity for irinotecan and a 5-
fold higher maximal rate of irinotecan hydrolysis when compared with hCE-1. These data 
indicate that hCE-2 is a high-affinity, high-velocity enzyme with respect to irinotecan and is 
likely to play a substantial role in irinotecan activation in human liver and intestine. Also, CE 
isolated from human intestinal biopsies has demonstrated activation of irinotecan and may be 
responsible for gut toxicity associated from irinotecan (89).   
 Recently, a mouse strain Esl(e), with low levels of Es-1 RNA, has been identified that 
demonstrates a 3-fold decrease in total plasma esterase activity in comparison to control mice 
(74).  These mice carry an allele of the esterase locus Es-1 that results in reduced plasma esterase 
enzyme activity.  These mice demonstrated a 5-fold decrease in conversion of irinotecan to SN-
38 as compared to control mice.  These results suggest that the reduced levels of Es-1 esterase 
present in Esl(e) mice are due to down-regulation of gene transcription, and this plasma esterase 
is responsible for the majority of irinotecan metabolism in mice (90).  However, enzymes other 
than CE may be involved in the activation of irinotecan.  The conversion of irinotecan to SN-38 
by butyrlcholinesterase isolated from humans, horses, and mice, has also been reported in vitro 
(91,92).  
There is high interpatient variability in the pharmacokinetics of irinotecan and 
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SN-38.  The expression of CE in tissue and tumor may account for this pharmacokinetic 
variability.  Increases in irinotecan and SN-38 systemic exposures have been reported in mice 
bearing human neuroblastoma xenografts when compared to non-tumor bearing mice after both 
IV and oral administration (93).  Guichard and colleagues reported  significantly lower 
camptothecin CE activity and increased topo I activity in human primary colorectal tumors in 
comparison to normal tissue (94).  The local activation of irinotecan is an important 
consideration secondary to different metabolic pathways between hepatocytes and tumor cells.  
In hepatocytes, irinotecan is converted to SN-38 which can then be glucuronidated to SN-38G, 
an inactive metabolite excreted in the bile (95).  Also, irinotecan can be inactivated by hepatic 
CYP 3A to APC (85).  In contrast, inactivation of irinotecan by CYP 3A in human colorectal 
tumors is unlikely as only low levels of this enzyme are expressed in this tissue (96).  Therefore, 
the production of the active, cytotoxic metabolite, SN-38, may come from both local tumor as 
well as hepatic conversion from irinotecan. 
 Future investigations with irinotecan will involve producing tumor-specific cytotoxicity 
with various enzyme/prodrug combinations.  Researchers have discovered rabbit CE is 100 to 
1000 fold more efficient at converting irinotecan to SN-38 in vitro and 12 to 55 fold more 
efficient in sensitizing transfected cells to irinotecan in vitro than human CE (97).  Irinotecan 
treatment of immune-deprived mice with Rh30 rhabdomyosarcoma cells expressing rabbit 
carboxylesterse resulted in regression and no recurrence of tumors after treatment whereas, 
tumor recurrence was noted in 7/7 mice bearing control Rh30 xenografts and in 2/7 mice bearing 
Rh30 xenografts that expressed the human enzyme.  Therefore, the combination of irinotecan 
with rabbit carboxylase may be a beneficial combination.  Future research is investigating the 
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adenoviral delivery of an ornithine decarboxylase promoter of rabbit CE cDNA cassette for 
potential virus-directed enzyme prodrug therapy applications (98). 
 
Glucuronidation of SN-38 
 SN-38 undergoes glucuronidation by hepatic uridine diphosphate 
glucuronosyltransferases (UGTs) to form the inactive SN-38 glucuronide (SN-38G) metabolite 
(Figure 5).  The glucuronidation of SN-38 to SN-38G is the major elimination pathway of SN-38 
and is thought to protect against irinotecan-induced gastrointestinal toxicity. Lalitha and 
colleagues reported glucuronidation of SN-38 by the UGT-1A1 (99). Therefore, patients with 
low UGT-1A1 activity, such as those with Gilbert’s syndrome and Crigler-Najjar syndromes I 
and II may be at an increased risk for irinotecan toxicity.  SN-38 and SN-38G are primarily 
excreted in bile and emptied into the gastrointestinal tract (100).  SN-38G can then be 
deconjugated by intestinal flora to SN-38, with accumulation of SN-38 in the intestine as a 
possible cause of diarrhea attributed to irinotecan administration (99). 
Since a genetic predisposition for decreased glucuronidation of SN-38 may exist in 
patients with low UGT-1A1 activity, researchers have investigated a potential relationship 
between UGT-1A1 phenotypes with UGT-1A1 promoter polymorphism.  Phenotypic 
measurements of SN-38 and bilirubin glucuronidation in human liver microsomes were 
performed in vitro (101).  Based on the presence of an additional TA repeat [(TA)7TAA] in the 
TATA sequence of UGT-1A1 in Gilbert’s syndrome, genotypes were assigned as:  7/7 
homozygous for the (TA)7TAA allele; 6/6, homozygous for the (TA)6TAA allele; and 6/7, 
heterozygous with 1 of each allele.  Nine percent of screened liver samples were found to be 
homozygous for allele 7 (7/7), 43% were homozygous for allele 6 (6/6), and 48% were 
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heterozygous (6/7).  SN-38 glucuronidation rates were significantly lower in homozygotes of 
(TA)7TAA allele (7/7) and heterozygotes (6/7) compared with homozygotes of (TA)6TAA allele 
(P < 0.01).  Glucuronidation of SN-38 and bilirubin were significantly lower in the 7/7 and 6/7 
groups compared with the 6/6 group.  These results suggest that the UGT-1A1 promoter 
genotype would be a good predictor of SN-38 glucuronidation in an in vitro setting.  However, it 
is unclear if such a phenotype-genotype correlation will exist in vivo and ultimately allow 
individualization of irinotecan therapy to improve its therapeutic index. 
To evaluate the relationship between irinotecan disposition and toxicity, a biliary index 
was developed to estimate the relationship between gastrointestinal toxicity and SN-38 
glucuronidation (95).  The biliary index consisted of a biliary ratio (AUCSN-38/ AUCSN-38G), to 
express the free concentration of SN-38 in bile, multiplied by the AUCCPT-11 to control for 
individual variability in the amount of available drug.  A significantly higher biliary index was 
observed in patients with grade 3 to 4 diarrhea compared to patients with grade 0 to 2 diarrhea (P 
= 0.03) (79).  The elevated biliary indexes were possibly secondary to higher dose levels in some 
studies or possibly due to low glucuronidation rates.  However, wide interpatient variability was 
noted, which may cause insufficient precision to warrant clinical application (102,103).  
Studies have evaluated ways to decrease the diarrhea associated with irinotecan by 
modulating the metabolism of irinotecan and SN-38.   In an effort to modulate the 
glucuronidation of SN-38, irinotecan has been administered with either valproic acid, an 
inhibitor of glucuronidation, or phenobarbital, an inducer of oxidative metabolism.88  
Pretreatment of Wistar rats with valproic acid caused a 99% inhibition in the formation of SN-
38G leading to a 270% increase in the AUC of SN-38 compared with the control rats.  The 
irinotecan estimations were unchanged in the two groups.  Pretreatment with phenobarbital 
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resulted in a 1.7-fold increase in the AUC of SN-38G and a concomitant 31% and 59% reduction 
in the AUCs of SN-38 and irinotecan, respectively.  It is currently unclear if the modulation of 
irinotecan, SN-38, and SN-38G disposition by valproic acid or phenobarbital can prevent the 
diarrhea associated with irinotecan.   
In addition, modulation of irinotecan with cyclosporine has been reported in an effort to 
reduce biliary excretion of irinotecan and its metabolites and potentially reduce their 
gastrointestinal toxicity (105).  Cyclosporine pretreatment resulted in an average increase of 
339%, 361%, and 192% in the AUC of irinotecan, SN-38, and SN-38G, respectively.  Analysis 
of clearance of irinotecan indicated a 55% and 81% reduction in the average renal and non-renal 
clearances, respectively.  Although the exact mechanism of the decrease is not evident, 
cyclosporine related cholestasis could be one of the factors.  
 
1.5 TREATMENT REGIMENS 
Preclinical studies 
The optimal treatment regimens for the camptothecins have not been identified.  
Moreover, the optimal schedule of administration of topotecan, irinotecan, and other 
camptothecin analogs may not be the same.  Studies of camptothecin analogs in mice bearing 
human adult and pediatric tumors suggest they are among the most active agents evaluated (6-9).  
The antitumor activity of the camptothecins is highly schedule dependent, where daily low-dose 
protracted schedules (i.e., daily for 5 consecutive days) have greater efficacy than more intense 
shorter schedules of administration (i.e., once every three weeks) (7,9).  However, the dose 
administered per day and subsequent plasma concentration must be above a critical threshold to 
produce tumor regression (6,7).  For example, prolonged (i.e., daily for 5 days per week for eight 
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consecutive weeks) administration of doses below this critical threshold may not achieve 
antitumor response, whereas administration of camptothecins on an intermittent (i.e., daily for 5 
days per week x 2 weeks repeated every 4 weeks) schedule may allow for administration of 
higher doses per day that achieve drug exposures above this critical threshold (7,16).   This 
schedule specificity is based on the steep relationship between camptothecin exposure and 
response (i.e., antitumor or toxicity). 
 Preclinical studies suggest protracted schedules of administration produce greater 
antitumor effect than bolus administration (9,104,105).  Studies evaluating colon and pediatric 
solid tumor xenografts demonstrated that administration of topotecan and irinotecan daily for 5 
days for 2 consecutive weeks every 3 weeks was equally or more effective and less toxic than 
shorter treatment schedules with higher doses (9).  In addition, preclinical studies with L1210 
leukemia and several human tumor xenografts have demonstrated repeated intermittent treatment 
was superior to a single injection administration (106,107).  Moreover, comparing the 
administration of irinotecan daily for 5 consecutive days for 1 week versus daily for 5 
consecutive days for 2 weeks, both repeated every 21 days, and at the same cumulative dose per 
21-day cycle, showed that the 2 week administration schedule produced significantly greater 
antitumor response (Figure 6) (7).  These effects are consistent with the S-phase specific 
cytotoxic action of these agents (1). 
There has been a shift from the use of syngeneic transplantable murine tumors to the use 
of human tumor xenografts for the identification and development of anticancer agents 
(6,79,108).  However, there is limited data that human tumor xenografts are better in identifying 
agents that ultimately prove efficacious in human cancers or in the clinical setting.  The failure of 
these models to predict the drug response may be due to species differences as mice may be able 
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to tolerate more or less of an agent compared to humans.  The primary concern is that efficacy 
studies in xenografts are performed at dose levels that are several fold higher than doses tolerated 
in humans.   
 
Figure 6.  Improved antitumor activity of irinotecan against neuroblastoma xenografts with protracted 
schedule of administration.  One 5-day cycle (A, C) or two 5-day cycles (B, D) repeated every 21 days 
over 8 weeks.  Cumulative dose per cycle was 25 mg/kg (A, B) or 6.25 mg/kg (C, D), (E) control; (F) 
relative tumor volumes for treatment groups.  Reprinted with permission from reference (7). 
 
To address this issue, the minimum effective dose of topotecan and associated systemic exposure 
were determined against a panel of neuroblastoma xenografts and compared to the maximum 
tolerated dose in pediatric Phase I trials (6,23).  The same topotecan regimen in a Phase I 
pediatric trial was used in the xenograft studies.  Analysis of the topotecan lactone systemic 
exposures associated with antitumor activity in the xenograft model were tolerable and achieved 
clinical response in the Phase I study (23).  As a result, the topotecan regimen used in the 
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preclinical and Phase I studies is currently being evaluated as a Phase II window study in patients 
with high risk neuroblastoma. 
Alternatively, the comparison of xenograft models and early human trials can help to 
explain why a specific agent may not be effective in patients.  9AC is a topo I inhibitor with 
activity against xenografts from childhood solid tumors; however, clinical trials with this 
compound have been disappointing, resulting in discontinuation of further development.  The 
protracted administration of IV and oral 9AC therapies, daily for 5 days for 1, 2, or 3 weeks and 
for 1 or 3 cycles was evaluated in mice bearing human solid tumor xenografts by Kirstein and 
colleagues (99).  The tumors were found to be highly sensitive to 9-AC therapy, but the systemic 
exposure required for antitumor effect was in excess of that achievable in patients.  These data 
support that for some anticancer agents, including camptothecins, more detailed preclinical 
studies evaluating the minimum effective dose and associated systemic exposure may be of value 
in the analysis of antitumor activity in clinical trials and in guiding clinical drug development.  
 
Clinical Studies 
As stated earlier, preclinical studies suggest protracted daily administration of 
camptothecins achieve the greatest antitumor activity (7,9).  The FDA approved schedule for 
topotecan, 1.5 mg/m2/day IV for 5 consecutive days repeated every 21 days, follows this theory.  
However the FDA approved treatment regimen for irinotecan, 125 mg/m2 IV once a week for 4 
weeks followed by a 2 week rest or 350 mg/m2 IV once every 3 weeks, does not (14).  To 
address these issues, alternative treatment regimens of irinotecan and topotecan are now being 
evaluated (7,25,110-112). 
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Single bolus administration if irinotecan may saturate the ability of CE to convert 
irinotecan to SN-38 and result in a lower formation of SN-38 (113).  Thus, prolonged daily 
schedules of irinotecan are being evaluated by several groups (7,25,111).  Blaney and colleagues 
evaluated irinotecan administered as a 60-minute infusion daily for 5 days every 21 days in 
children with refractory solid tumors (95).  The recommended Phase II doses were 39 and 50 
mg/m2/day in heavily and less-heavily pretreated patients, respectively.  Furman and colleagues 
directly translated a protracted irinotecan schedule from a xenograft model to a Phase I trial in 
children with refractory solid tumors.7  Administration of irinotecan daily for 5 days per week for 
2 consecutive weeks repeated every 21 days was well tolerated with an MTD of 20 mg/m2/day 
and achieved significant antitumor response.  This study implies that data obtained from 
xenograft models can be effectively translated into the design of clinical trials.  In addition, the 
relative extent of conversion and SN-38 systemic exposure achieved with this schedule was 
much greater than reported from adults and children administered larger intermittent doses (113).  
The optimal treatment regimen for topotecan is currently unclear (112,114).  Hoskins and 
colleagues performed a randomized Phase II study of two schedules of topotecan in previously 
treated patients with ovarian cancer (114).  Patients were randomized to either topotecan 1.5 
mg/m2/day as a 30-minute infusion for 5 days (qd x 5) repeated every 21 days or topotecan 1.75 
mg/m2 administered as a 24-hour infusion once a week for 4 weeks repeated every 6 weeks.  The 
response rate in the qd x 5 arm was 22.6% (95% confidence interval [CI], 9.6% to 41.2%), which 
was significantly superior to 24-hour topotecan arm, 3.1% (95% CI, 0.1% to 16%) (P = 0.026).  
However, the qd x 5 arm was more toxic with 94% of patients experiencing grade 3 or 4 
granulocytopenia as opposed to 52% in the other arm.  The authors concluded that the qd x 5 
schedule remains the schedule of choice. To simulate the xenograft data, topotecan is also being 
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evaluated on a daily for 5 days per week for 2 consecutive weeks repeated every 4 weeks 
schedule in Pediatric Phase II studies (115,116).  Alternatively, administration of topotecan daily 
for 3 days repeated every 3 weeks is being evaluated to reduce the bone marrow suppression 
associated with topotecan and reduce the logistical difficulties associated with IV administration 
for 5 consecutive days (112). 
 
Oral administration 
Oral administration of camptothecins would mimic the protracted schedule used 
successfully in preclinical models, maximize patient convenience, minimize the use of clinical 
resources, and achieve a favorable pharmacokinetic profile based on low gastric pH, which may 
favor retention of the drug in the active-lactone form (7,117-121).  Preliminary data suggest that 
the oral formulation of topotecan has efficacy similar to that of the IV formulation in patients 
with recurrent or refractory ovarian and small-cell lung cancer (122,123).  However, oral 
absorption of anticancer agents, especially camptothecins, is characterized by extensive inter- 
and intrapatient variability in oral bioavailability (110,119,121,124).  Given the high interpatient 
variability in topotecan exposure after oral administration, it is interesting to note that flat dosing 
(i.e., dose based on mg instead of mg/m2) of topotecan resulted in the same systemic exposure 
compared with the more complex dosing per body surface area (125).  Topotecan is presently 
supplied in gelatin capsules and is administered on an empty stomach, although administration of 
topotecan with a high fat meal only led to a small decrease in the rate of absorption but not the 
extent of absorption (126).  Oral administration of topotecan is associated with lower peak 
concentration and longer mean residence time than IV topotecan with average oral 
bioavailability of 30% (range of 10% to 50%) (24,122).  The lactone to carboxylate ratios of 
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topotecan after oral administration were higher or comparable after oral administration as 
compared to IV administration (24).  
The chemical properties of camptothecins lend to the possibility that a decrease in the 
gastric pH could shift the lactone-carboxylate equilibrium towards the lactone form and increase 
oral absorption and bioavailability of the agents.  Therefore, topotecan and other camptothecins 
are usually administered orally in conjunction with an acidic beverage, such as fruit juice or cola.  
However, it is currently unclear if this process affects bioavailability.  The administration of 
ranitidine prior to oral topotecan resulted in a slightly faster rate of absorption, but the overall 
extent of absorption was not altered (127).  Thus, in patients administered ranitidine, dosage 
adjustments of topotecan are not required.  However, it is currently unknown if significant 
changes in gastric pH or co-administration with other agents will alter the oral bioavailability of 
topotecan.      
Gerrits and colleagues evaluated the pharmacokinetic and pharmacodynamic 
relationships from four Phase I trials of oral topotecan using different treatment schedules (24).  
There was no difference in the pharmacokinetics of topotecan among the different regimens.  
Topotecan administered daily for 5 days repeated every 3 weeks was associated with limited 
interpatient variability and similar dose intensity as compared with other schedules of oral 
administration.  However, there were differences in the toxicity profile associated with the 
different treatment regimens.  Topotecan administered daily for 5 days produced uncomplicated 
and non-cumulative granulocytopenia as the primary toxicity, whereas the oral administration of 
topotecan for 10 and 21 consecutive days may result in unpredictable, severe, and uncontrollable 
diarrhea. Thus for these reasons and patient convenience, the authors recommended the single 
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daily administration of topotecan for 5 consecutive days repeated every 3 weeks for Phase II 
trials. 
 Oral administration of irinotecan may take advantage of several factors associated with 
its pharmacokinetics and metabolism (25).  The high concentration of tissue carboxylesterases in 
the gut and liver may promote conversion of irinotecan to SN-38 (25,110,124).  This, coupled 
with first pass effect after oral administration may increase the concentration of SN-38 
systemically and in the liver, the primary site of colon cancer metastases (25,110).  After oral 
administration of irinotecan, there was an association between the irinotecan dose and SN-38 
systemic exposure, suggesting that there was no saturation in the conversion of irinotecan to SN-
38 by CE (110,124).  In addition, there was a high ratio of SN-38 to irinotecan systemic exposure 
suggesting that the oral administration resulted in significant presystemic formation of SN-38 
(110,124).  In a Phase I pediatric study, the ratio of SN-38 to irinotecan systemic exposure was 
approximately 3-fold higher after oral as compared to IV administration (124).  However, the 
actual exposure of SN-38 after oral administration was significantly lower as compared to IV 
administration.     
9NC is an oral camptothecin analog currently in Phase III studies for pancreatic 
carcinoma administered daily for 5 days per week for 8 consecutive weeks (128-130).  The 
pharmacokinetic disposition of 9NC is relatively complicated.  9NC should be administered on 
an empty stomach, because administration with fatty food decreases oral bioavailability by 50% 
(131).  9NC undergoes metabolism to form an active-metabolite, 9-AC (130,132,133).  However, 
approximately 80% of the drug remains in the 9-NC form (15,133).  Repeated daily dosing of 
9NC results in accumulation of all forms of the drug (15,133).  In addition, 9NC undergoes 
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primarily non-renal elimination117, thus there is the potential for drug interactions involving 
oxidative metabolism and biliary elimination.  
In current Phase II and III trials, 9NC is administered at 1.25 to 1.5 mg/m2/day for 5 days 
per week for 8 consecutive weeks (15,128,131,132).  Dose-limiting toxicities (DLT) on the eight 
week schedule of 9NC are neutropenia and hematuria (15,128).  To increase the dose 
administered per day and to avoid toxicities that occur in the 3rd and 4th weeks of the consecutive 
week schedule, a Phase I study of 9NC administered orally daily for 5 days per week for 2 
consecutive weeks repeated every 4 weeks has potential clinical advantages compared to the 
continuous regimen (16,133).  
 
Pharmacokinetically guided dosing 
 Most anticancer agents are characterized by extensive interpatient variability in systemic 
disposition (134).  The standard doses derived from studies do not allow for this pharmacokinetic 
variability (134).  Thus, when standard doses based on weight or body surface area are used, this 
variability leads to a wide range of systemic exposures and alterations in effect (ie, antitumor or 
toxicity).  Previous studies with methotrexate and carboplatin have defined the relationships 
between drug exposure and effect (ie, antitumor effect and response), and have individualized 
treatment based on patient specific pharmacokinetic parameters (135,136).  Pharmacokinetically 
guided dose adjustments may be used to account for pharmacokinetic variability achieve a target 
systemic exposure, and to optimize the therapeutic index of chemotherapeutic agents (99,137-
139).  
Pharmacokinetically guided dose adjustments have been used to achieve a maximum 
tolerated systemic exposure of topotecan and limit the interpatient variability in exposure of 
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topotecan (115,137).  Preclinical in vitro and in vivo studies can be used to define the target 
concentration or AUC (6,11).  Dose adjustments of topotecan administered as 30-minute and 
120-hour infusions have been used to achieve target plasma exposures measured as AUC and 
steady-state concentration, respectively (115,137).  In addition, individualizing topotecan doses 
to achieve target drug exposures in the CSF have been performed in patients with primary and 
metastatic central nervous system (CNS) tumors (140). 
A Phase I trial of topotecan in pediatric patients with refractory solid tumors was 
performed to determine if the variability in topotecan systemic exposure could be reduced by 
using a pharmacokinetic-guided dosing strategy (115,116).  The topotecan target AUC in plasma 
was defined by the AUC associated with antitumor activity in the xenograft models and was 
associated with clinical response in children with neuroblastoma in a prior Phase I trial (6,23).  
Topotecan was administered as a 30-minute infusion daily for 5 consecutive days for 2 weeks 
repeated every 4 weeks, and doses were individualized based on the patient’s topotecan systemic 
clearance.  The pharmacokinetically-guided dosing strategy adjusted topotecan doses to attain 
the desired plasma AUC in 75% of the targeting opportunities and significantly reduced the 
variability in topotecan systemic exposure. 
 Individualizing topotecan treatment has also been used to attain an exposure duration 
threshold (EDT) in the CSF (11,140,141).  Embryonal CNS tumors such as medulloblastoma 
have a high propensity to disseminate throughout the subarachnoid space suggesting that the 
CSF is an important source of drug exposure (11).  The target EDT in the CSF was determined 
by in vitro studies that defined the concentration and length of topotecan exposure associated 
with 99% inhibition of cell growth (11).  These results defined the EDT as a topotecan lactone 
concentration of  > 1 ng/mL for 8 hours.  Studies in a nonhuman primate model reported 
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prolonging the topotecan IV infusion from the standard 30-minutes to 4-hours at a target plasma 
AUC achieved the EDT throughout the neuroaxis as presented in Figures 7a and 7b (11).   
 
 
Figure 7a and 7b.  Improved topotecan neuroaxis EDT in nonhuman primate model with prolonged IV 
infusion. Topotecan (TPT) lactone concentration-time profiles in the plasma, fourth ventricular CSF, and 
lumbar CSF after a TPT dose of 2.0 mg/m2 administered over 30-minutes (a) and 4 hours (b).  Individual 
data points and best-fit line of the data are represented for TPT lactone concentrations in the plasma (♦, ---
), fourth ventricular CSF (▲, ―), and lumbar CSF (●, ---).  Reprinted with permission from reference 
(11). 
 
The ability of a 4-hour as compared to the standard 30-minute topotecan infusion to prolong the 
topotecan exposure in the CSF was confirmed in a patient with breast cancer metastatic to the 
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CNS (141).  This approach has also been used to individualize doses to attain cytotoxic exposure 
of topotecan in the CSF of children with high-risk medulloblastoma (140).  As with the Phase I 
study of topotecan in pediatric patients with refractory solid tumors, doses were individualized 
based on the patient’s topotecan systemic clearance.  As a result of dose individualization, 73% 
of studies achieved the target plasma AUC.  Among those patients with CSF studies that attained 
the target plasma topotecan AUC, 90% achieved a putative cytotoxic exposure of topotecan in 
the CSF (i.e. 1 ng/mL for 8 hours).   Thus, individualizing therapy based on patient specific 
pharmacokinetic parameters can be used to target drug concentrations at the site of the tumor.  
These studies demonstrate the ability to develop treatment strategies of systemically 
administered topotecan to enhance cytotoxic exposure in the CSF.   
There are several logistical issues associated with individualizing anticancer therapy 
based on cytotoxic exposures of agents, such as the turn around time associated with obtaining 
blood samples, quantitation of drug concentrations using analytical chemistry methods, and 
performing pharmacokinetic analyses (137,138).  However, studies using a maximum tolerated 
systemic exposure (MTSE) approach have the potential to determine the maximum tolerated 
plasma exposure of anticancer agents with fewer patients than more traditional Phase I designs.  
In addition, the results of these pharmacokinetic studies can greatly add to the understanding of 
the pharmacology and pharmacodynamics of anticancer agents. Moreover, individualizing 
therapy to achieve a target cytotoxic exposure may increase antitumor effect and decrease 
treatment related toxicity.  
 
1.6 CONCLUSIONS  
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Camptothecin analogs are a class of anticancer agents with a wide range of antitumor 
activity, toxicities, and pharmacokinetic and pharmacodynamic features related to response.  
There are several cellular mechanisms which may alter the cytotoxicity of the camptothecins.  
The modulation of camptothecins by efflux pumps (P-gp, BCRP/ABC) may alter the cellular 
exposure of these agents and subsequent cytotoxicity.  In addition, the presence of efflux pumps 
in the intestinal lining and kidney influence the oral bioavailibility and elimination pathways, 
respectively.  Future studies are needed to investigate the combination of camptothecins with 
pump inhibitors and evaluate the antitumor efficacy, toxicity, and modulation of 
pharmacokinetics associated with these combinations.  In addition, modulation of topo I and II 
may affect clinical activity of the camptothecins; however well designed clinical studies are 
needed to evaluate sequence and timing of administration of camptothecins and other drugs that 
can modulate topo I and II. 
  Preclinical studies suggest protracted schedules of administration achieve the greatest 
antitumor response; however the optimal schedule of administration may be unique to each 
camptothecin analog.  Future preclinical and clinical studies for each camptothecin analog 
directly comparing alternative schedules of administration are required to address these issues.  
The issues related to the optimal schedule of administration of anticancer agents are not unique 
to the camptothecins (142).  However, the optimal treatment regimens for camptothecins 
administered IV and orally are currently unknown.  To adequately determine the optimal 
treatment schedule for each camptothecin, randomized Phase I and II trials may be required.  
Moreover, the questions regarding schedule of administration emphasizes the importance of 
Phase IV (post approval) studies in which the majority of clinical and pharmacologic drug 
development occurs (142). 
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The toxicities associated with the camptothecins are not uniform to the class.  In general, 
the camptothecin analogs induce bone marrow suppression; however the dose limiting toxicities 
of topotecan, irinotecan, and 9NC are neutropenia, diarrhea, and cystitis, respectively.  With the 
exception of irinotecan-induced diarrhea, the mechanisms associated with these differences in 
toxicities are currently unknown.  The mechanism of camptothecin-induced cystitis is also 
currently unknown; however the incidence of cystitis is not associated with the percentage of 
drug excreted renally or the percent of drug in the lactone form in the urine (143).  The clinical 
significance of the cellular and systemic pharmacokinetic and pharmacodynamic factors, such as 
modulation of topo I and cellular efflux, must be evaluated in clinical studies.  In addition, 
phenotypic factors and drug interactions associated with the metabolism of camptothecins must 
be evaluated in clinical trials. 
 
1.7 INTRODUCTION TO DISSERTATION 
The primary objective of this dissertation research was to evaluate the pharmacokinetics, 
pharmacodynamics, and pharmacogenetics of 9NC and its 9AC metabolite in preclinical models 
and in patients as part of phase I and II trails.  We hypothesized that pharmacokinetic, 
pharmacodynamic, and pharmacogenetic principles can be used in the optimization of the 
chemotherapeutic treatment of cancer, such as 9NC. Information obtained from preclinical and 
clinical translational studies can greatly add to the understanding of the pharmacology of 9NC 
and allow for the rational design of therapeutic regimens.  The application of these principles 
have not been applied to the development of 9NC, especially the comparisons of drug exposures 
in preclinical models and in clinical trials and the evaluation of known SNP polymorphisms in 
the ABC transporter genes as related to the pharmacokinetic disposition of 9NC and 9AC.  In 
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addition, previous pharmacokinetic studies of 9NC have not evaluated the disposition of the 
active-lactone forms of 9NC and 9AC. 
Full descriptions of the study design and methods used in this research are outlined in 
each chapter.  The aim of Chapter 2 was to compare the 9NC and 9AC systemic exposure 
associated with antitumor response in mice bearing human tumor xenografts to those reported in 
a phase I study of 9NC that used the s same intermittent schedule as in the xenografts studies and 
use allometric scaling analysis to normalize the data.  The goal of Chapter 3 was to perform 
phase I studies of intermittent regimens of 9NC in order to determine the maximum tolerated 
dose (MTD) and toxicities associated with each regimen and evaluate the pharmacokinetics of 
9NC and its 9AC metabolite.  The purpose of Chapter 4 was to examine the inter- and intra-
patient pharmacokinetic variability and the urine recovery of 9NC and 9AC.  The aim of Chapter 
5 was to evaluate the plasma disposition of 9NC and 9AC after administration of 9NC with and 
without food in a randomized cross over study.  The goal of Chapter 6 was to evaluate the 
functional consequence of known SNP polymorphisms in the transporter genes ABCB1, ABCC2, 
and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC. 
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2.0  
CHAPTER 2: 
 
 
 
Relationship between Plasma Exposure of 9-Nitrocamptothecin and its 9-Aminocamptothecin 
Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts 
 
 61
2.1 ABSTRACT 
Purpose: 9-nitrocamptothecin (9NC) has completed phase III studies in patients with newly 
diagnosed and refractory pancreatic cancer; however the optimal 9NC treatment regimen is 
unclear. We used an intermittent schedule of 9NC to evaluate the relationship between plasma 
exposure of 9NC and its 9-aminocamptothecin (9AC) metabolite and antitumor response in mice 
bearing human colon carcinoma xenografts.   
Methods: 9NC was administered orally at 0.44, 0.67, or 1.0 mg/kg/d qd x 5d x 2 weeks repeated 
q 4 weeks for 2 cycles to female C.B-17 SCID mice bearing HT29 or ELC2 human colon 
xenografts.  Pharmacokinetic studies were performed after oral administration of 0.67 mg/kg x 1.  
Serial samples were obtained and 9NC and 9AC lactone concentrations in plasma were 
determined by HPLC analysis with fluorescence detection.  The areas under plasma 
concentration versus time curve (AUC) from 0 to infinity for 9NC and 9AC were calculated.   
Results: The antitumor activity of 9NC was dose-dependent in both colon xenografts.  At all 
doses, 9NC treatment resulted in significant antitumor activity in both xenografts as compared to 
vehicle-treated and control groups and achieved levels of tumor regression that met criteria 
(minimum %T/C ≤ 40%) for antitumor activity.  In mice bearing HT29 xenografts, the 9NC and 
9AC lactone AUCs after administration of 9NC at 0.67 mg/kg were 41.3 ng/ml●h and 5.7 
ng/ml●h, respectively.   
Conclusions: The responses seen in these xenograft models occurred at systemic exposures that 
are tolerable in adult patients.  These results suggest that the intermittent schedule of 9NC may 
be an active-regimen in patients with colo-rectal cacinoma. 
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2.2 INTRODUCTION 
9-nitrocamptothecin (9NC, rubitecan, RFS2000) has completed phase III studies in 
patients with newly diagnosed and refractory pancreatic cancer. However, the optimal dose, 
schedule, and route of administration of 9NC and other camptothecin analogues, such as 
topotecan and irinotecan, are currently unclear (1-5).  In vitro and in vivo preclinical studies 
suggest protracted administration of low-doses of camptothecin analogues achieve better 
antitumor activity than does less frequent administration of higher doses (6-9).  Repeated oral 
administration of 9NC could mimic the protracted schedule, maximize patient convenience, and 
minimize the use of health care resources. However, oral administration of camptothecin 
analogues has been associated with extensive inter- and intra-patient variability in bioavailability 
(10-13).  In addition, the antitumor activity associated with camptothecin analogues, such as 
topotecan and irinotecan, may require a dose that achieves a systemic exposure above an 
exposure threshold (8,9,14,15).  As a result, continuous and prolonged administration of low 
doses of camptothecins, which achieve systemic exposures below this threshold, may not 
produce an antitumor response. Thus, the highly schedule-dependent antitumor activity, steep 
relationship between systemic exposure and antitumor activity, and pharmacokinetic variability 
associated with oral absorption of camptothecin analogues, require studies evaluating the 
relationship between drug exposure and antitumor effect in preclinical and clinical studies. This 
process has been used in the development of topotecan, irinotecan, and 9-aminocamptothecin 
(9AC) (6,9,16). 
9NC is administered orally and is partially metabolized to an active-metabolite, 9-
aminocamptothecin (9AC) (5,13,17,18).  As with other camptothecin analogues, 9NC and 9AC 
undergo a reversible, pH-dependent hydrolysis between the active lactone and inactive hydroxy 
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acid forms (19). At acidic pH, the lactone form predominates, and at physiologic pH, the 
hydroxy acid form predominates (19-21). However, changes in plasma pH, serum-albumin 
concentration, and route of administration may affect the conversion between the lactone and 
hydroxy acid forms (20,21). Thus, measurement of the active lactone form of the drug may be 
basic to understanding the clinical pharmacology of 9NC and other camptothecin analogues (21-
24).  Due to the differences in oral absorption, elimination, and percentage of 9NC and 9AC 
lactone in mice and humans, comparing the dose or total (sum of lactone plus hydroxyl acid) 
exposure that produces antitumor response in mice and humans would not be appropriate.  We 
evaluated the relationship between plasma exposure of 9NC and 9AC lactone and antitumor 
response in mice bearing human colon carcinoma xenografts.  In addition, we compared the 9NC 
and 9AC systemic exposures associated with antitumor response in the xenograft models to those 
reported in a Phase I study of 9NC that used the same intermittent schedule as in the xenograft 
studies and used allometric scaling analysis to normalize the data (1, 25). 
 
2.3 METHODS 
Mice  
This study was approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh, and all animals were handled in accordance with the Guide to the Care 
and Use of Laboratory Animals (National Research Council, 1996).  Mice (female C.B-17 SCID, 
4-6 weeks of age, specific pathogen-free), were obtained from the National Cancer Institute 
(NCI) Animal Production Program (Frederick, MD), and were allowed to acclimate to the 
University of Pittsburgh Central Animal Facility for 1 week prior to initiation of study.  Mice 
were housed in autoclaved micro isolator caging and were allowed Prolab ISOPRO RMH 3000 
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Irradiated Lab Diet (PMI Nutrition International, Brentwood, MO) and water ad libitum.  Animal 
rooms were maintained at 22 ± 2oC on a 12-hour light and dark cycle with at least 12 air changes 
per hour.  Tri-monthly analysis of sentinel mice (Assessment Plus, Charles River, Boston, MA) 
housed in 1/5 dirty bedding confirmed that the study mice remained murine antibody profile 
(MAP) negative throughout the study. 
 
Tumor Lines, Implantation, and Measurements  
HT29 and ELC2 human colon xenografts were obtained from the NCI Tumor Repository 
(Frederick, MD) and Dr. Janet Houghton at St. Jude Children’s Research Hospital (Memphis, 
TN), respectively, and were MAP test-negative. HT29 and ELC2 cells were passaged in C.B-17 
SCID female mice.  When the tumors reached 500 to 1000 mm3 (500 to 1000 mg), the tumors 
were harvested and approximately 25-mg fragments were implanted subcutaneously on the right 
flank of study mice using aseptic techniques.  Mice were observed twice daily. Body weights and 
tumor measurements were recorded twice weekly. Tumor volumes were calculated from the 
formula: length x (width)2/2, where length is the longest diameter, and width is the shortest 
diameter perpendicular to the length (25,26).  Median days to one and two doublings of tumor 
volume and median optimal %T/C [(ratio of median tumor volume for treatment group (T) to 
median tumor volume for control group (C)) x 100] were calculated (26). 
 
Efficacy Studies 
Efficacy studies were performed in female C.B-17 SCID mice bearing HT29 or ELC2 
human colon carcinoma xenografts.  Mice bearing HT29 xenografts were stratified on day 19 
post implantation when the tumor volumes were 26 to 71 mm3.  Mice bearing ELC2 xenografts 
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were stratified on day 17 post-implantation when the tumor volumes were 68 to 195 mm3.  Mice 
were stratified into groups of ten such that the mean body weight and tumor volumes for the 
groups were not statistically different.  The stratification was performed 3 days prior to treatment 
(day –3).   
9NC, obtained from Supergen, Dublin, CA, was prepared in 1 mM phosphoric 
acid:polyethylene glycol 400:2% N,N-dimethylacetamide acid  (48:50:2, v/v/v).  9NC 
concentrations of 0.1 mg/ml, 0.067 mg/ml, or 0.044 mg/ml were prepared for the 1 mg/kg/d, 0.67 
mg/kg/d, and 0.44 mg/kg/d doses, respectively.  9NC dosing solutions or vehicle were 
administered at 0.01 ml/g body weight using a curved, 20 gauge, oral gavage needle attached to a 
1 ml syringe. Mice (n = 10 per group) bearing HT29 xenografts were treated with 9NC daily for 
5 days per week for 2 consecutive weeks repeated every 4 weeks for a total of 2 cycles.  To serve 
as a positive control, 5-fluorouracil (5-FU) was prepared at 2 mg/ml in 0.9% NaCl and 
administered at 0.01 ml/g body weight (27).  Mice (n = 10 per group) bearing HT29 tumors were 
treated with 5FU intraperitoneal (IP) at 20 mg/kg/d for 5 days per week for 2 consecutive weeks 
repeated every 4 weeks for a total of 2 cycles (27).  For mice bearing HT29 xenografts, treatment 
days during cycle 1 were days 0 to 4 and days 7 to 11, and treatment days during cycle 2 were 
days 28 to 32 and days 35 to 39.  At the completion of the study, mice were euthanized by CO2 
inhalation, and complete necropsies were performed. 
Mice (n = 10 per group) bearing ELC2 xenografts were treated with 9NC at the same 
doses and on the same schedules as mice bearing HT29 xenografts; however the mice bearing 
ELC2 tumors received only the first 5 days of the treatment of the second cycle.  The study was 
terminated early because the tumor volumes in the control and vehicle-treated groups reached 
2,000 m3, and the mice in these groups had significant (> 10%) loss of body weight.  Treatment 
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days during cycle 1 were days 0 to 4 and days 7 to 11, and treatment days during cycle 2 were 
days 28 to 32.  At the completion of the study, mice were euthanized by CO2 inhalation, and 
complete necropsies were performed. 
 
Pharmacokinetic Studies 
Plasma pharmacokinetic studies were performed in C.B-17 SCID mice bearing HT29 
xenografts at 27 days post-tumor implantation and in non-tumor bearing mice. Mice were 
stratified into three mice per group such that the mean body weight and tumor volumes were not 
statistically different (28).  
Animals were fasted overnight prior to dosing and 9NC was administered at 0.67 mg/kg 
as a single oral dose.  After dosing, mice (n = 3 per time point) were euthanized by CO2 
inhalation, and blood (approximately 1 ml) was collected, by cardiac puncture using heparinized 
syringes, at 0.08, 0.25, 0.5, 1, 1.5, 2, 4, 6, 7, 18, 24, and 48 h after 9NC administration.  In 
addition, vehicle-treated mice were euthanized at 5 min after administration using the same 
procedure as stated above.  Blood was transferred to microcentrifuge tubes and immediately 
placed on ice until centrifuged.  
 
Sample Preparation 
 Plasma was prepared by centrifuging blood samples at 13,000 x g at room temperature 
for 4 min.  For analysis of 9NC lactone, solid phase extraction (SPE) was used to separate the 
lactone and hydroxy acid forms of 9NC and 9AC (13).  Waters OASIS HLB columns (1 ml, 30 
mg; Milford, MA) were used for the SPE.  The columns were conditioned with 1 ml of methanol 
and equilibrated with 1 mL of water prior to loading plasma samples (0.2 ml) on the columns.  
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The columns were then washed with 1 ml of methanol:water (5:95, v/v) to remove the hydroxy 
acid forms of 9NC and 9AC.  9NC lactone was then eluted with 0.5 ml of methanol and stored at 
-80°C until analyzed.  For analysis of 9AC lactone, plasma was processed using methanol 
extraction as previously described and stored at -80°C until analyzed (13). 
 
High Performance Liquid Chromatography (HPLC) Analysis 
 The concentrations of 9NC and 9AC lactone in plasma were quantitated using an HPLC 
assay with fluorescence detection modified from that described in our previous pharmacokinetic 
studies in humans (13).  Because 9NC is not highly fluorescent and 9AC is, 9NC lactone was 
measured by chemically reducing 9NC to 9AC (13,29,30).  The concentration of 9NC was 
calculated by subtracting the concentration of 9AC from the concentration of 9NC plus 9AC 
after the conversion of 9NC to 9AC (13,30).  The lower limit of quantitation (LLQ) for 9NC 
lactone was 0.5 ng/ml, and the assay was linear from 0.5 ng/ml to 100 ng/ml.  The LLQ for 9AC 
lactone was 0.3 ng/ml, and the assay was linear from 0.3 ng/ml to 100 ng/ml.  When expressed as 
a percentage coefficient of variation, the within-day and between day variation in 9NC and 9AC 
lactone triplicate standards in plasma were < 15%.   
 
Pharmacokinetic Analysis 
Compartmental pharmacokinetic methods were used to analyze the 9NC and 9AC lactone 
plasma concentration versus time data from mice bearing HT29 human colon tumors and non-
tumor bearing mice.  Compartmental modeling was performed with the ADAPT II computer 
program (31).  The estimation procedure and variance model used in the compartmental 
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pharmacokinetic analysis was maximum likelihood estimation and linear models for the variance 
of the additive errors, respectively.  Different pharmacokinetic model structures were considered 
to characterize the disposition of 9NC and 9AC in plasma.  In the model development, one- and 
two-compartment models were evaluated to describe the systemic disposition of 9NC and 9AC.  
Akaike’s Information Criteria (AIC), Schwartz Criteria, estimated error of the model parameters, 
and residual analysis were use to select the model structure that maximized the fit accuracy and 
simultaneously minimized the number of model parameters.  The final model structure used for 
the pharmacokinetic analysis produced identifiable parameters in both groups. 
A 4-compartment model with an oral absorption compartment was simultaneously fit to 
the mean plasma concentration versus time profiles of 9NC and 9AC (31).  Individual 
parameters estimated by the model included: the rate constant describing oral absorption (ka), 
intercompartmental rate constants for 9NC (k12, k21) and 9AC (k34, k43), the rate constant 
describing conversion of 9NC to 9AC (k13), the elimination rate constants for 9NC (k10) and 9AC 
(k30), and the apparent volume of the central compartments for 9NC (Vc1/F)and 9AC (Vc3/F)  
The apparent clearance (CL/F) and half-life (t1/2) of 9NC and 9AC lactone were calculated using 
standard equations (32). The areas under the 9NC and 9AC lactone plasma concentration versus 
time curves (AUC) from 0 to infinity were calculated using the log trapezoidal method by 
simulating the concentration versus time data based upon model-specific parameters (32). 
 
Allometric Scaling 
Allometric scaling was used to compare the disposition of 9NC and 9AC lactone in 
patients with refractory solid tumors and in mice bearing HT29 human colon xenografts (1,25).  
The 9NC and 9AC lactone concentration versus time data in patients was from a phase I study of 
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orally administered 9NC daily for 5 consecutive days per week for two weeks repeated every 4 
weeks (1).  Pharmacokinetic studies were performed on day 1 after a single dose of 9NC at 2.4 
mg/m2 (n = 9), which was the maximum tolerated dose (MTD).  The mean 9NC and 9AC lactone 
concentration at each time point was used in the allometric calculations.   
Allometric scaling is based on the power-law relationship between physiological and 
pharmacokinetic processes and body weight among mammals (25).  Complex Dedrick Plots 
were used to normalize the concentration versus time profiles in patients and mice (25).  
Interspecies concentrations and time were normalized by dividing the plasma concentration 
(ng/ml) by the dose (mg/kg) and by dividing the time (h) by body weight0.25 (kg).  The 9NC and 
9AC lactone AUCs from 0 to last measured concentration-time point for the Complex Dedrick 
Plots were calculated using the log trapezoidal method (32). 
 
Statistics  
Body weights and tumor volumes from both of the efficacy studies were analyzed for 
statistical significance using the statistical software package Minitab (Minitab Inc., State College 
PA) (28).  Values were expressed as the mean ± SD and median.  Mean data were analyzed by 
one-way ANOVA followed by pair-wise comparisons using Dunnett’s test.  Median data were 
analyzed using Kruskal-Wallis followed by pair-wise comparisons by Mann-Whitney test (28).  
The a priori level of significance was set at P = 0.05. 
 
2.4 RESULTS 
Efficacy and Toxicity 
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Tumor growth curves for HT29 and ELC2 xenografts are presented in Figure 1 and 
Figure 2, respectively.  Days to 1 and 2 doublings of tumor volume and median optimal %T/C 
for HT29 and ELC2 xenografts are presented in Table 1 and Table 2, respectively.  9NC 
treatment resulted in significant antitumor activity in both human colon xenografts as compared 
to the vehicle-treated and control groups (P < 0.05) (26).  All doses of 9NC in both xenografts 
lines achieved levels of activity that met criteria for antitumor activity (minimum %T/C ≤ 40%) 
(26).  
Table 1. Doubling Times for Tumor Volume and Median Optimal % T/C 
for HT29 Human Colon Xenografts 
 
Treatment Groups 
(n=10) 
Days to 1 Doubling of 
Tumor Volume 
 
Days to 2 Doublings of 
Tumor Volume 
 
Median 
Optimal % T/C 
 Mean ± SD 
(Median) 
Mean ± SD 
(Median) 
% 
(Day) 
Control 5.3 ± 2.0 
(5.0) 
22.5 ± 7.3 
(21.0) 
 
--- 
5FU 20 mg/kg 8.8 ± 2.9  
(10.0) 
33.3 ± 14.0 
(34.0) 
44.7 
(43) 
9NC 1 mg/kg 48.7 ± 12.0a,b,c 
(52.5) 
58.7 ± 5.1a,b,c 
(59.7) 
9.8 
(43) 
9NC 0.67 mg/kg 28.9 ± 8.7a 
(29.0)b 
46.9 ± 5.6a 
(47.9)b 
23.0 
(43) 
9NC 0.44 mg/kg 25.5 ± 10.3a 
(26.6)b 
42.0 ± 6.9a 
(41.5) b 
34.7 
(43) 
Vehicle 6.9 ± 2.3 
(6.5) 
30.9 ± 6.7 
(30.1) 
73.1 
(43) 
T = median tumor volume in treated group; C = median tumor volume in control group. 
 
aSignificantly different as compared to control and vehicle at P ≤ 0.05 as determined by Dunnett’s Test. 
 
bSignificantly different as compared to control and vehicle at P ≤ 0.05 as determined by Mann-Whitney 
Test. 
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cSignificantly different as compared to 0.67 and 0.44 mg/kg at P ≤ 0.05 as determined by Mann-Whitney 
Test. 
Table 2. Doubling Times for Tumor Volume and Median Optimal % T/C 
for ELC2 Human Colon Xenografts 
 
Treatment Groups 
(n=10) 
Days to 1 Doubling of 
Tumor Volume 
 
Days to 2 Doublings of 
Tumor Volume 
 
Median 
Optimal % T/C 
 Mean ± SD 
(Median) 
Mean ± SD 
(Median) 
% 
(Day) 
Control 10.6 ± 3.7 
(10.5) 
24.1 ± 6.6 
(26.0) 
 
--- 
9NC 1 mg/kg >35.0a,b,c 
(>35.0) 
>35.0a,b,c 
(>35.0) 
18.4 
(35) 
9NC 0.67 mg/kg 34.2 ± 2.5a,b,c 
(>35.0) 
>35.0a,b,c 
(>35.0) 
21.8 
(35) 
9NC 0.44 mg/kg 25.7 ± 8.9a 
(26.9)b 
34.8 ± 4.2a 
(>35.0)b 
31.1 
(35) 
Vehicle 12.2 ± 5.6 
(13.3) 
24.2 ± 5.7 
(25.1) 
111.8 
(35) 
T = median tumor volume in treated group; C = median tumor volume in control group. 
 
aSignificantly different as compared to control and vehicle at P ≤ 0.05 as determined by Dunnett’s Test. 
 
bSignificantly different as compared to control and vehicle at P ≤ 0.05 as determined by Mann-Whitney 
Test. 
 
cSignificantly different as compared to 0.44 mg/kg at P ≤ 0.05 as determined by Mann-Whitney Test. 
 
The antitumor activity of 9NC in both xenografts was dose-dependent (Figure 1 and 
Figure 2).  In mice bearing HT29 xenografts, the days to one and two tumor doublings were 
significantly longer after administration of 1 mg/kg as compared to 0.67 mg/kg and 0.44 mg/kg 
(P < 0.05).  For HT29 xenografts, the median optimal % T/C after administration of 1 mg/kg, 
0.67 mg/kg, and 0.44 mg/kg were 9.8 %, 23.0 %, and 34.7 %, respectively, as measured on day 
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43.  In mice bearing ELC2 xenografts, the days to one and two tumor doublings were 
significantly longer after administration of 1 mg/kg and 0.67 mg/kg as compared to 0.44 mg/kg 
(P < 0.05).  For ELC2 xenografts, the median optimal % T/C after administration of 1 mg/kg, 
0.67 mg/kg, and 0.44 mg/kg were 18.4 %, 21.8 %, and 31.1 %, respectively, as measured on day 
35. 
 
Figure 1. Tumor growth curves for mice (n = 10 per group) bearing HT29 human colon carcinoma 
xenografts.  Mice were treated with 9NC at doses of 0.44, 0.67, or 1 mg/kg, or vehicle via oral gavage 
daily for 5 days per week for 2 weeks repeated every four weeks for 2 cycles.  As a positive control, 5FU 
was administered IP at 20 mg/kg daily for 5 days per week for 2 consecutive weeks repeated every four 
weeks for 2 cycles.  The control group received no treatment or vehicle and the vehicle group received 
only the vehicle used in the 9NC formulation.  Treatment (T) days on cycle 1 were days 0 to 4 and days 7 
to 11, and treatment days on cycle 2 were days 28 to 32 and days 35 to 39.  The vertical line at day 0 
represents the start of treatment.  Results are expressed as the mean ± SD tumor volumes. 
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Figure 2. Tumor growth curves for mice (n = 10 mice per group) bearing ELC2 human colon carcinoma 
xenografts.  Mice were treated with 9NC at doses of 0.44, 0.67, or 1 mg/kg, or vehicle via oral gavage 
daily for 5 days per week for 2 weeks repeated every four weeks for 2 cycles.  The control group received 
no treatment or vehicle and the vehicle group received only the vehicle used in the 9NC formulation.  
Mice bearing ELC2 xenografts received only the first 5 days of the treatment of the second cycle. The 
study was terminated early because the tumor volumes in the control and vehicle-treated groups reached 
2,000 mm3, and mice in these groups had significant (> 10%) weight loss.  In mice bearing ELC2 tumors, 
treatment (T) days on cycle 1 were days 0 to 4 and days 7 to 11, and treatment days on cycle 2 were days 
28 to 32. The vertical line at day 0 represents the start of treatment.  Results are expressed as the mean ± 
SD tumor volumes. 
 
The primary toxicity associated with 9NC in mice bearing HT29 and ELC2 human colon 
xenografts was soft stools and diarrhea.  After administration of 9NC at 1 mg/kg in mice bearing 
HT29 and ELC2 xenografts, all mice had soft stools by day 3 of treatment and developed 
diarrhea by day 7 of treatment.  After administration of 9NC at 0.67 mg/kg in mice bearing 
HT29 and ELC2 xenografts, mice had soft stools by day 7 and developed diarrhea by day 9 to 
10.  After administration of 9NC at 0.44 mg/kg and vehicle in mice bearing both tumor 
xenografts, soft stools developed during the second week of treatment.  During the two week 
break in treatment (days 13 to 28), stools became more solid.  The pattern of soft stools and 
diarrhea was similar during cycles 1 and 2.   
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Pharmacokinetic Studies 
Pharmacokinetic studies of 9NC and 9AC lactone were performed in non-tumor bearing 
mice and mice bearing HT29 xenografts after administration of a single dose of 9NC at 0.67 
mg/kg.  The 9NC and 9AC lactone concentration versus time profiles in mice bearing HT29 
xenografts are presented in Figure 3.  In mice bearing HT29 xenografts, peak plasma 
concentrations of 9NC and 9AC were detected at 15 minutes after administration.  The mean ± 
SD peak plasma concentrations of 9NC and 9AC lactone were 45.4 ± 8.1 ng/ml and 4.2 ± 1.4 
ng/ml, respectively.  Pharmacokinetic parameters of 9NC and 9AC in mice bearing HT29 
xenografts are summarized in Table 3.  The 9NC and 9AC lactone AUCs were 41.3 ng/ml●hr 
and 5.7 ng/ml●hr, respectively.   
The 9NC and 9AC lactone concentration versus time profiles in non-tumor bearing mice 
were similar to those in mice bearing HT29 colon xenografts and are presented in Figure 3.  In 
non-tumor bearing mice, peak plasma concentrations of 9NC and 9AC lactone were detected at 
15 minutes after administration.  The mean ± SD peak plasma concentrations of 9NC and 9AC 
lactone were 46.8 ± 27.6 ng/ml and 3.3 ± 1.8 ng/ml, respectively. Pharmacokinetic parameters of 
9NC and 9AC in non-tumor bearing mice are summarized in Table 3.  The 9NC and 9AC lactone 
AUCs were 40.7 ng/ml●hr and 5.2 ng/ml●hr, respectively. 
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Figure 3. 9NC and 9AC lactone concentration versus time profiles in mice bearing HT29 human colon 
xenografts and non-tumor bearing mice after administration of 9NC at 0.67 mg/kg x 1 via oral gavage.  
For mice bearing HT29 tumors, individual data points and best fit line of the data for 9NC lactone (■, ___) 
and 9AC lactone (▲, ___) are presented.  For non-tumor bearing mice, individual data points and 
best fit line of the data for 9NC lactone (□, ---) and 9AC lactone (Δ, ---) are presented.  
Individual concentration versus time points represent the average concentration of 9NC or 9AC 
from three mice at each time point. 
 
Table 3. Pharmacokinetic Parameters of 9NC and 9AC in Mice Bearing HT29 Human Colon 
Xenografts and Non-tumor Bearing Mice 
 
 
Parameters 
 
 
Units 
 
HT29 Bearing 
Mice 
 
Non-Tumor Bearing 
Mice 
9NC AUC ng/mL●h 41.3 39.1 
9NC CL/F L/h/m2 61.6 52.6 
9NC t 1/2 β h 1.2 1.5 
ka h-1 1.2 3.3 
Vc1/F L/m2 4.5 4.0 
k10 h-1 10.8 12.9 
k12 h-1 3.4 3.0 
k21 h-1 0.8 1.2 
k13 h-1 0.8 0.3 
    
9AC AUC ng/mL●h 5.7 5.2 
9AC CL/F L/h/m2 26.3 9.6 
9AC t 1/2 β h 0.6 1.0 
Vc3/F L/m2 1.2 1.1 
k34 h-1 2.8 7.4 
k43 h-1 5.3 1.3 
k30 
 
h-1 21.8 8.8 
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Allometric Scaling Studies 
Complex Dedrick Plots of 9NC and 9AC lactone in patients after administration of 9NC 
at 2.4 mg/m2 (n = 9) and in mice bearing HT29 human colon xenografts after administration of 
9NC at 0.67 mg/kg are presented in Figure 4.  The 9NC and 9AC lactone AUCs for the Complex 
Dedrick Plots in the patients treated at 2.4 mg/m2 were 393 and 60 (ng/ml / mg/kg)●h/kg0.25, 
respectively.  The 9NC and 9AC lactone AUCs for the Complex Dedrick Plots in mice bearing 
HT29 human colon xenografts were 193 and 30 (ng/ml / mg/kg)●h/kg0.25, respectively. 
 
 
 
 
 
 
 
 
Figure 4. Complex Dedrick Plots of 9NC and 9AC lactone in patients after oral administration of 9NC at 
2.4 mg/m2/d and in mice bearing HT29 human colon xenografts after administration of 9NC at 0.67 
mg/kg x 1 via oral gavage.  Interspecies dose and time were normalized by dividing the plasma 
concentration (ng/mL) by the dose (mg/kg) and by dividing the time (h) by body weight0.25 (kg).  Data for 
9NC lactone (■, ___) and 9AC lactone (▲, ___) in a patients and 9NC lactone (□, ---) and 9AC lactone (Δ, -
--) in mice bearing HT29 human colon xenografts concentration versus time profiles are presented.  The 
data presented at each data point are the average of nine patients and three mice. 
 
2.5 DISCUSSION 
It takes a considerable length of time for a drug to be approved for the treatment of 
cancer (33-36).  Thus, there is a need to expedite the preclinical and clinical studies of anticancer 
agents and determine which agents should continue, or be stopped, in development (33,37,38).  
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During the past 25 years, there has been a progressive shift from syngeneic transplantable tumors 
to the use of human tumor xenografts for the identification and development of new anticancer 
agents (6-9,33).  Support for these preclinical studies is based on the proposed improved ability 
of xenograft models to identify agents with clinical utility.  The factors associated with correctly 
predicting the activity of anticancer agents in patients using xenograft models are currently 
unclear (7,9,16,19-21).  Camptothecin analogues are some of the most highly active agents 
evaluated in xenograft models.  However, mice are able to tolerate 10- to 20-fold greater doses 
and systemic exposures of camptothecin analogues (i.e., topotecan, irinotecan, 9AC) compared 
to humans (6,7,9,16).  Therefore, the activity of camptothecins in xenograft models may not 
translate to clinical activity in humans.  To address this issue as related to 9NC, we evaluated the 
relationship between plasma exposure of 9NC and 9AC lactone and antitumor response in mice 
bearing human colon xenografts and compared this to clinically relevant exposures in patients 
(1).  Comparing the lactone forms of 9NC and 9AC overcomes potential differences in the 
lactone to hydroxyl acid ratio associated with protein binding and other factors between mice and 
humans (6).  This process has previously been used in the development of topotecan, irinotecan, 
and 9AC (6,9,16). 
9NC produced significant antitumor activity at all doses evaluated in both human colon 
xenografts.  The 9NC and 9AC lactone AUCs after administration of 9NC at 0.67 mg/kg were 
41.3 and 5.7 ng/mL●hr, respectively.  The dose of 0.67 mg/kg evaluated in the pharmacokinetic 
study was selected based on the greater overall antitumor activity after administration of 0.67 
mg/kg compared to 0.44 mg/kg and less diarrhea after administration of 0.67 mg/kg compared to 
1 mg/kg.  In the Phase I study using the same regimen as in the xenograft studies, 4 of 6 patients 
treated at the MTD (2.4 mg/m2/day) had a 9NC AUC > 41 ng/mL·h (13).  In addition, 5 of the 6 
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patients who responded had a 9NC AUC > 41 ng/mL·h.  In our Phase II study of 9NC 
administered orally daily for 5 days per week for 8 weeks in patients with refractory colon 
cancer, 3 of 8 patients had a 9NC lactone AUC < 41 ng/mL·hr (13,39).  Moreover, there were no 
responders in Phase II studies of 9NC in patients with colon cancer (2,39).  The overall lack of 
9NC response in patients with refractory colon carcinoma raises concerns about the ability of 
mice bearing human colon xenografts to predict 9NC response in humans (19-21).  However, 
this lack of response in the phase II studies may be associated with the low daily exposures 
achieved with this regimen.  The intermittent schedule of 9NC may be an active regimen because 
it achieves exposures that are tolerable in humans and above the exposure associated with 
antitumor response in the colon xenograft models.  
Using the approach comparing the drug exposure associated with response in preclinical 
xenografts models and in patients may also explain the variable clinical response of 
camptothecin analogues (6,9,16).  The topotecan systemic exposure associated with antitumor 
response in the xenograft models of neuroblastoma was tolerable and was associated with 
clinical responses in children with neuroblastoma (9).  Kirstein and colleagues evaluated the 
relationship between 9AC systemic exposure and tumor response in human solid tumor 
xenografts (30).  The systemic exposure of 9AC required for antitumor effect in the xenograft 
models was in excess of that achievable in patients, possibly explaining why 9AC has not 
produced significant antitumor activity in clinical trials (16,40,41).  In our studies, the 
conversion of 9NC to 9AC in mice and patients was similar, with most of the drug remaining in 
the 9NC form.  Thus, the antitumor activity associated with administration of 9NC is most likely 
due to the parent compound and not the 9AC metabolite. 
 79
Even though the exposures of 9NC associated with response in the xenograft models are 
tolerable in clinical trials, there are potential differences in the disposition of 9NC between mice 
and humans, and tumor-specific issues that must be addressed (6,9,13,16,20).  The concentration 
versus time profiles of 9NC and 9AC in mice and humans are different.  Thus, there may be 
differences in the duration of exposure that 9NC and 9AC are maintained above a potential 
threshold required for activity (13,17,18,42-44).  However, the normalized concentration versus 
time profiles in the Complex Dedrick Plots were greater in patients as compared to mice.  The 
relationship between 9NC and 9AC exposure and response may be different for specific tumors, 
and thus these types of studies may need to be performed for each tumor type (13,42-44).  The 
tumor exposures of anticancer agents in xenografts located on the flank of mice may be different 
than the exposure in tumors of patients, and thus evaluating plasma exposures in mice and man 
may not be an accurate comparison (45,46). 
The use of preclinical translational studies may be fundamental to the design and 
interpretation of clinical trials in humans.  The direct comparison of drug exposures will remove 
variability associated with differences in metabolism or elimination and allometric scaling 
analysis can also be used to normalize the concentration versus time profiles in mice and patients 
(6,9,16,25,33-36).  This information can then be used to make informed decisions in the 
development of new anticancer agents for the treatment of solid tumors and other malignancies 
(6,33).  Based on these results presented in our study, we recommend performing phase II studies 
of 9NC using the intermittent schedule of administration.    
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3.0  
CHAPTER 3: 
 
 
 
Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients 
with Advanced Solid Tumors 
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3.1 ABSTRACT 
Purpose:  9-Nitrocamptothecin (9NC) is an oral camptothecin analogue currently administered 
at 1.5 mg/m2/day x 5 days per week in Phase III studies for pancreatic carcinoma.  In an effort to 
increase the dose administered per day and determine if the daily dose or number of days of 
treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules 
of administration. 
Methods: On schedule A, 9NC was administered orally daily x 5 days for 2 weeks every 4 
weeks (1 cycle).  On schedule B, 9NC was administered orally daily x 14 days every 4 weeks (1 
cycle).  Dose levels were determined by adaptive dose finding.  Serial blood samples were 
obtained on day 1 of each schedule for pharmacokinetic studies of 9NC and its 9-
aminocamptothecin (9AC) metabolite, and lactone forms were measured by HPLC. 
Results: The recommended Phase II doses for schedules A and B were 2.43 mg/m2/d and 1.70 
mg/m2/d, respectively, each providing the same dose intensity (i.e., 24 mg/m2/cycle).   The 
primary toxicities on schedules A and B were neutropenia, thrombocytopenia, and diarrhea.  On 
schedule A, 2 patients with gastric cancer and 2 patients with pancreatic cancer had stable 
disease for > 6 cycles.  On schedule B, 1 patient with pancreatic cancer had stable disease for > 6 
cycles, and a patient with pancreatic cancer had a partial response.  There was significant 
interpatient variability in the disposition of 9NC and 9AC.  Most of the drug remained in the 
9NC form with a ratio of 9NC to 9AC of approximately 4 to 1. 
Conclusions:  These studies suggest that 9NC administered on an intermittent schedule is 
tolerable and may be an active regimen in patients with gastric or pancreatic cancers.  Dosing 
9NC on a mg/m2 basis does not  reduce pharmacokinetic variability. 
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3.2 INTRODUCTION 
 The camptothecins are DNA topoisomerase I-interactive anticancer agents and have a 
wide range of antitumor activity (1-3).  Currently approved camptothecin analogues (i.e., 
topotecan and irinotecan) are only available for IV administration (4,5).  9-Nitrocamptothecin 
(9NC) is administered orally and is partially metabolized to an active metabolite, 9-
aminocamptothecin (9AC) (6,7).  As with other camptothecin analogues, 9NC and 9AC undergo 
a reversible, pH-dependent hydrolysis between the active-lactone and inactive-hydroxy acid 
forms (8).  In vitro and in vivo preclinical studies suggest that protracted administration of low 
doses of camptothecin analogues produces better antitumor activity than does less frequent 
administration of higher doses (9-12)  Oral administration of 9NC could mimic the protracted 
schedule and maximize patient convenience (13).  However, oral administration of camptothecin 
analogues has been characterized by extensive inter- and intra-patient variability in 
bioavailability (13-16) 
In Phase II and III studies, 9NC is administered continuously at 1.25 to 1.5 mg/m2/day for 
5 days per week (17,18).  On this schedule, dose reductions and delays in therapy frequently 
occur during weeks 3 to 5 and are due to myelosuppression, diarrhea, and hematuria. In 
xenograft studies, antitumor activity of camptothecin analogues requires a dose that produces a 
systemic exposure above a critical threshold (11,12).  It is possible that administration of 
continuous, low dose 9NC might not produce a systemic exposure above this critical threshold 
and as a result might fail to produce an antitumor response (19).  In contrast, administration of 
9NC on an intermittent schedule (e.g., 2 weeks of treatment followed by 2 weeks off) may allow 
for the administration of a higher dose per day that would produce therapeutic drug 
concentrations, and also avoid toxicities in weeks 3 and 4.   
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Thus, we evaluated two intermittent schedules of 9NC administration with the goals of 
increasing the dose administered per day and the dose intensity and determining if the daily dose 
or number of days of treatment influence toxicity.  The objectives of this study were to: 1) 
determine the maximum tolerated dose (MTD) and toxicities associated with two intermittent 
schedules of 9NC; 2) document any antitumor response to 9NC in patients with various solid 
tumors; and 3) determine the plasma pharmacokinetics of 9NC and 9AC. 
 
3.3 PATIENTS AND METHODS 
Patients 
 Patients 18 years of age or older with a histologically or cytologically confirmed 
malignancy for which no curative or effective therapy was available were eligible for this study.  
Other eligibility criteria included a Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 to 2, adequate bone marrow, hepatic, and renal function as evidenced by the 
following: absolute neutrophil count (ANC) ≥ 1500/μL, platelets ≥ 100,000/μL, total bilirubin ≤ 
1.5 x upper limit of the institutional normal range (ULN), aspartate aminotransferase (AST) ≤ 
1.5 x the ULN if liver metastases were not present and ≤ 4 x the ULN if liver metastases were 
present, and absence of microscopic hematuria.  Prior irradiation to brain metastases was allowed 
if the patient’s neurological status was stable 4 weeks after irradiation.  Prior treatment with 
camptothecin analogues except 9NC was permitted.  Written informed consent, approved by the 
Institutional Review board of the University of Pittsburgh Medical Center, was obtained from all 
patients before they entered the study. 
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Dosage and Administration 
 Two intermittent schedules of 9NC were evaluated. On schedule A, 9NC was 
administered orally daily for 5 days per week for 2 consecutive weeks and repeated every 4 
weeks (one cycle). On schedule B, 9NC was administered orally daily for 14 days and repeated 
every 4 weeks (one cycle). The daily dose was rounded to the nearest 0.25 mg.  On both 
schedules, 9NC was administered daily on an empty stomach and with an acidic beverage (e.g., 
orange juice or cola) (20,21). Patients were required to increase their oral hydration to at least 2 
liters per day during 9NC treatment. 
Dose levels for schedules A were determined by adaptive dose finding (22).  During 
stage I of this two-stage method, doses were escalated by a factor of 1.5 until the first dose-
limiting toxicity (DLT) occurred.  Then, in stage II, escalation was switched to a model-guided 
mode similar to the continual reassessment method (CRM) (23).  In these methods, the MTD is 
defined in terms of a fixed probability that patients in the population experience DLT.  For our 
study, this probability was set to be 0.3.  The DLT experience of all previous cohorts is used to 
select the dose for a new cohort that will have this probability of DLT.  In stage II, the dose-
response model is {log [p/(1-p)] = A + B log (dose)}, where p is the DLT probability, and A and 
B are constants updated during the study.  The two constants are initialized so that p = 0.1 at half 
the dose at which the first DLT is observed, and p = 0.9 at 5 times that dose. Six patients were to 
be entered in the first cohort in this trial; subsequent cohorts were to consist of 3 patients.    
The initial dose level on schedule B was 30% lower than the MTD in schedule A.  Due to 
relatively small dose changes and extensive pharmacokinetic variability in 9NC and 9AC, the 
adaptive dose finding procedure was not used to calculate dose levels for schedule B. 
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Response Assessment 
 After every 2 cycles of treatment, patients with measurable disease were assessed for 
response according to the World Health Organization Criteria (24).  Toxicity was defined by the 
NCI Common Toxicity Criteria version 2.0 (25).  Dose-limiting toxicities (DLT) were defined as 
platelets ≤ 25,000/μL during treatment, ANC ≤ 500/μL for more than 1 week, fever accompanied 
by ANC ≤ 1000/μL, a delay in re-treatment for ≥ 2 weeks for any reason, and all non-reversible 
grade III and IV non-hematologic toxicities except bone pain.  These toxicities were considered 
DLTs only if they occurred during cycle 1. 
 
Pharmacokinetic Sample Collection and Preparation 
 On schedules A and B, serial blood samples for pharmacokinetic analysis were obtained 
on day 1. Blood samples (5 mL) were obtained prior to administration of 9NC, and at 0.25, 0.5, 
1, 2, 3, 6, 8, and 24 hours after administration.  Blood was placed into heparinized tubes and 
centrifuged at 1200 x g at 4° C for 5 minutes.  The resulting plasma samples were then processed 
immediately in order to measure the lactone forms of 9NC and 9AC. 
 The processing for the measurement of the 9NC lactone in plasma was performed using 
solid phase extraction (SPE) with Waters OASIS HLB columns (1 mL, 30 mg) to separate the 
lactone and hydroxy acid forms of 9NC.  Columns were conditioned with 1 mL of methanol and 
equilibrated with 1 mL of water.  Plasma (1 mL) was passed through the column, and the column 
was then washed with 1 mL of 5% methanol in water to remove the hydroxy acid forms of 9NC 
and 9AC.  9NC lactone was then eluted with 1 mL of methanol and stored at -80° C until 
analyzed. 
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For measurement of 9AC lactone, plasma was processed by methanolic extraction (13).  
A total of 600 μL of plasma was added to 1200 μL of cold (-20° C) methanol.  The methanol 
was maintained at –20°C by placing the vials in an insulated cooler containing dry ice.  The 
samples were vortexed and centrifuged at 10,000 x g for 5 min.  The resulting supernatant was 
decanted and stored at  -80°C until analyzed. 
 
High-Performance Liquid Chromatography (HPLC) Analysis 
 
 9NC and 9AC lactone plasma concentrations were measured using an HPLC assay with 
fluorescence detection as described previously (26). Because 9NC is not highly fluorescent, 9NC 
lactone was measured by chemically reducing 9NC to 9AC.  The concentration of 9NC was 
calculated by subtracting the concentration of 9AC from the concentration of 9NC plus 9AC 
after the conversion of 9NC to 9AC using iron reduction.  
 The HPLC system consisted of a Waters 2695 separation module (Waters, Inc. Milford, 
MA), a C18 reverse column [Ultrasphere 5 μm ODS 4.6 x 250 mm, Beckman Coulter, Inc., 
Fullerton, CA], and a C18 guard column (Brownlee C18 7 μm, 15 x 3.2 mm, PerkinElmer Corp., 
Norwalk, CT).  Samples were injected by an autosampler set at 4° C.  The isocratic mobile phase 
consisted of methanol, acetonitrile, and ammonium acetate (10:23:97, v/v/v), pH 5.5, at a flow 
rate of 1.0 mL/min.  Post column acidification (pH 2 – 3) was performed using 0.3 M 
trifluoroacetic acid at 0.3 mL/min (26).  9AC was detected by a Waters #474 fluorescence 
detector with excitation wavelength of 365 nm and emission wavelength of 440 nm, 18-nm 
bandwidth, gain 1000, attenuation 16, with RC filter with fast response setting.  MILLENIUM 
32 software (Waters, Inc.) was used for data collection and analysis.  All the glassware, 
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including the injection vials, were treated with 3% surfasil in toluene (Fisher Scientific Inc., Fair 
Lawn, NJ).  
 The lower limit of quantitation (LLQ) for 9NC lactone was 0.5 ng/mL, and the assay was 
linear from 0.5 ng/mL to 100 ng/mL.  The LLQ for 9AC lactone was 0.3 ng/mL, and the assay 
was linear from 0.3 ng/mL to 100 ng/mL. 
 
Pharmacokinetic Analysis 
 
 Compartmental pharmacokinetic analysis of 9NC and 9AC was performed using ADAPT 
II (27).  A linear model with an oral absorption compartment and one-compartment each for 9NC 
and 9AC was simultaneously fit to 9NC and 9AC concentration versus time profiles. The area 
under the 9NC and 9AC plasma concentration versus time curves (9NC AUC and 9AC AUC) 
from zero to 24 hours were calculated using the log trapezoidal method by simulating the 
concentration versus time data for each patient using patient-specific parameters (27). 
 
Urine Stability Studies 
 
 The stability of lactone and total forms of camptothecin (Supergen, Dublin, CA), 9NC, 
and topotecan (GlaxoSmithKline, Collegeville, PA) in urine at 37° C and at pH of 5 and 6 was 
evaluated over 2 hours.  Camptothecin, 9NC, and topotecan were added to urine to achieve a 
final concentration of 100 ng/mL. Urinary pH was measured at baseline and after the addition of 
the drug.  Hydrochloric acid and sodium hydroxide were used to adjust the urine to the desired 
pH.  Triplicate urine samples (200 μL) were obtained at baseline, and 5 min, 30 min, 60 min, and 
120 min.  As appropriate, samples were processed immediately via solid phase extraction for 
analysis of 9NC lactone and via methanolic extraction for analysis of 9NC total or for 
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camptothecin and topotecan lactone and total as described previously (26).  The percent lactone 
was calculated as (the ratio of lactone concentration to total concentration) x 100. 
 
3.4 RESULTS 
Patient Characteristics 
 
 Patient characteristics are summarized in Table 1.  Twenty-three patients were enrolled 
on schedule A, and 9 patients were enrolled on schedule B.  Six patients on schedule A were not 
evaluable; three patients developed elevated serum bilirubins during cycle 1 (2 due to biliary 
stent blockage); one patient developed increase an in AST; one patient had severe nausea and 
vomiting; and one patient was noncompliant with the oral therapy.  All patients enrolled on 
schedule B were evaluable. 
 On schedule A, dose levels 1, 2, and 3 were 2.0 mg/m2/d (n = 6 evaluable patients), 2.7 
mg/m2/d (n = 4 evaluable patients), and 2.4 mg/m2/d (n = 7 evaluable patients), respectively.  
The starting dose of schedule B was 30% lower than the MTD (i.e., 2.4 mg/m2/d) on schedule A.  
On schedule B, dose levels 1 and 2 were 1.7 mg/m2/d (n = 6 evaluable patients) and 2.4 mg/m2/d 
(n = 3 evaluable patients), respectively. 
 
Toxicity and Tolerability    
 
The toxicity profiles of schedules A and B were similar with diarrhea, nausea, 
neutropenia, and thrombocytopenia as the primary toxicities (7,17,18).  A summary of toxicities 
for evaluable patients on schedule A during cycle 1 are included in Table 2.  On schedule A, the 
most common toxicities for all dose levels were anemia, nausea, and vomiting.  The majority of 
adverse effects reported during cycle 1 were grade 1 or 2.  There was no DLT at 2.0 mg/m2/d.   
 96
Table 1. Patient Characteristics 
 
Characteristics 
 
Schedule A 
 
Schedule B 
 
Male / Female Enrolled (N) 
 
Male / Female Evaluable (N) 
17 / 6 
 
14 / 3 
5 / 4 
 
          5 / 4 
Age (yr) Median 
     
Range (yr) 
55 
 
(37 to 69) 
54 
 
(40 to 68) 
ECOG Performance Status (N) 
    0 
    1 
    2 
 
6 
16 
1 
 
6 
3 
0 
Diagnosis (N) 
    Pancreatic 
    Gastric / Esophageal 
    Colo-rectal 
    NSCLC 
    Hepatocellular / Biliary Tree 
    Unknown Primary, Sarcoma, Thyroid                    
 
9 
2 
4 
2 
3 
1 each 
 
1 
1 
5 
1 
1 
0 
Prior Treatments  
  Median (Range) 
    Prior Chemotherapy 
    Camptothecin analogues 
          Irinotecan (N) 
 
 
2 (0 to 9) 
 
3 
 
 
4 (0 to 8) 
 
6 
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Table 2.  Toxicity Summary for Schedule A During Cycle 1 
 2.0 mg/m2/day 
(n = 6) 
2.4 mg/m2/day 
(n = 7) 
2.7 mg/m2/day 
(n = 4) 
 Grade 
1 - 2 
Grade 
3 - 4 
Grade 
1 - 2 
Grade 
3 - 4 
Grade 
1 - 2 
Grade 
3 - 4 
Anemia 6 --- 4 1* 3 1 
Neutropenia 2 1 1 1* 1 2 
Thrombocytopenia 
 
1 --- --- 1* 2 1 
Diarrhea 1 --- 2 --- 3 --- 
Nausea 2 --- 6 --- 2 --- 
Vomiting --- --- 5 --- 1 --- 
Hematuria 1 --- 1 --- 2 --- 
* One patient at 2.4 mg/m2 developed grade 4 febrile neutropenia leading to sepsis and death.
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Two of 4 evaluable patients at 2.7 mg/m2/d experienced DLT of febrile neutropenia.  The dose 
was then reduced to 2.4 mg/m2/d.  One of 7 patients at 2.4 mg/m2/d developed DLT of febrile 
neutropenia, grade 4 thrombocytopenia, grade 4 anemia, and treatment-related death.  Therefore, 
the recommended Phase II dose for schedule A was 2.4 mg/m2/d.  Six of 17 evaluable patients 
developed grade 1 or 2 hematuria during treatment with 9NC, and four of these patients 
developed hematuria during cycle 1.  Of note, 6 patients were found to have grade 1 or 2 
hematuria during screening and were considered ineligible. 
A summary of toxicities on schedule B during cycle 1 is included in Table 3.  On 
schedule B, the most common toxicities were anemia, diarrhea, thrombocytopenia, nausea, and 
vomiting.  The majority of the adverse effects reported during cycle 1 were grade 1 or 2.  No 
DLT occurred in patients receiving 1.7 mg/m2/d.  As a result the dose was escalated to 2.4 
mg/m2/d.  During cycle 1, 2 of 3 patients treated at 2.4 mg/m2/d developed DLT.  One patient 
developed grade 3 diarrhea and the other patient developed febrile neutropenia with grade 4 
thrombocytopenia. Therefore, the recommended Phase II dose for schedule B was 1.7 mg/m2/d.  
No patients experienced hematuria during treatment on schedule B. 
A total of 77 cycles were administered on schedules A and B.  The occurrence of selected 
grade 3 or 4 toxicities on all cycles were as follows: anemia (n = 8), neutropenia (n = 9), 
thrombocytopenia (n = 5), diarrhea (n = 1), nausea (n = 1), vomiting (n = 1), and hematuria (n = 
1).  Increased neutropenia and thrombocytopenia were seen in patients with higher 9NC and 
9AC total and lactone AUC, however there was no direct relationship between the percentage 
decrease in neutrophils or platelets and 9NC or 9AC exposure. 
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Table 3.  Toxicity Summary for Schedule B During Cycle 1 
  
1.7 mg/m2/day 
(n = 6) 
 
 
2.4 mg/m2/day 
(n = 3) 
 Grade 
1 - 2 
Grade 
3 - 4 
Grade 
1 - 2 
Grade 
3 - 4 
Anemia 4 --- 2 1 
Neutropenia 1 --- 1 1 
Thrombocytopenia 
 
4 --- --- 1 
Diarrhea 4 --- 2 1 
Nausea 2 --- 2 --- 
Vomiting 1 --- 1 --- 
Hematuria --- --- --- --- 
 
Clinical Activity  
 
 Of the 17 evaluable patients on schedule A, 4 had SD.  Two of these patients had gastric 
cancer, and 2 had pancreatic cancer.  The 2 patients with gastric cancer completed 8 cycles of 
treatment at 2.0 mg/m2/d and 6 cycles of treatment at 2.7 mg/m2/d, respectively. The 2 patients 
with pancreatic cancer completed 6 cycles of treatment at 2.0 mg/m2/d and 16 cycles of treatment 
at 2.4 mg/m2/d.  On schedule B, one patient with pancreatic cancer had SD, and one patient with 
pancreatic cancer had a PR.  The patient with SD received 4 cycles of treatment at 2.4 mg/m2/d.  
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The patient with the PR received 8 cycles of treatment at 2.4 mg/m2/d.  None of the patients in 
schedule A or B with SD or PR had received a camptothecin analogue as prior therapy. 
 
9NC and 9AC Pharmacokinetics 
 
 Pharmacokinetic studies were performed on day 1 of both schedules A and B.  On 
schedule A, pharmacokinetic data were not available due to lack of intravenous access in two 
patients and patient refusal in two patients. On schedule B, pharmacokinetic data were available 
for all patients.  
 9NC and 9AC lactone AUCs on schedule A and B are presented in Figure 1 and Figure 2, 
respectively.  There was significant interpatient variability in the exposure of 9NC and 9AC 
lactone.  The 9NC lactone AUCs at individual doses varied from 6 to 16-fold.  On schedule A, 
the mean ∀ SD 9NC lactone AUCs at 2.0, 2.4, and 2.7 mg/m2 were 183 ± 119, 79 ± 54, and 89 ± 
91 ng/mL·h, respectively.  On schedule B, the mean ± SD 9NC lactone AUCs at 1.7 and 2.4 
mg/m2 were 156 ± 113 and 278 ± 218 ng/mL·h, respectively.   
 The 9AC lactone AUCs at individual doses ranged from 6 to 12-fold. On schedule A, the 
mean ± SD 9AC lactone AUCs at 2.0, 2.4, and 2.7 mg/m2 were 34 ± 21, 17 ± 18, and 32 ± 16 
ng/mL·h, respectively.  On schedule B, the mean ∀ SD 9AC lactone AUCs at 1.7 and 2.4 mg/m2 
were 41 ± 17 and 75 ± 70 ng/mL·hr, respectively.  Most of the drug remains in the 9NC form 
with ratios of 9NC to 9AC lactone or total of 4 to 1. 
 The relationships between dose expressed as mg/m2 or mg, and drug exposure were 
evaluated (16,29).  The following measures of drug exposure were evaluated; 9NC and 9AC 
lactone AUC, and the sum of 9NC lactone AUC plus 9AC lactone AUC.  There was no 
relationship between 9NC and 9AC AUC and doses based on mg or mg/m2.  In addition, there 
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was no relationship between dose and Cmin or Cmax of 9NC or 9AC.  Thus, administration of 
9NC doses based on mg or mg/m2 were equally poor predictors of exposure. 
 
 
 
 
 
 
 
 
 
 
 
     2.0   2.4  2.7                 1.7         2.4 
                     Schedule A                       Schedule B 
     9NC Dose (mg/m2/day) 
 
Figure 1. 9NC lactone AUC after administration of 2.0, 2.4, and 2.7 mg/m2/d on schedule A and 1.7 and 
2.4 mg/m2/d on schedule B.  Individual 9NC lactone AUC are represented by ?, and mean 9NC lactone 
AUC are represented by  . 
 
Figure 2. 9AC lactone AUC after administration of 2.0, 2.4, and 2.7 mg/m2/d on schedule A and 
1.7 and 2.4 mg/m2/d on schedule B.  Individual 9AC lactone AUC are represented by ?, and 
mean 9AC lactone AUC are represented by  . 
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Urine Stability 
 
 9NC, camptothecin, and topotecan lactone and total concentrations were evaluated in 
urine at  pH 5 and 6.  The mean ± SD percentage lactone of 9NC in urine at pH 5 at 5 min, 30 
min, 60 min, and 120 min was 93 ± 6 %, 99 ± 3 %, 89 ± 3 %, and 94 ± 8 % respectively. The 
mean ± SD percentage lactone of camptothecin in urine at pH 5 at 5 min, 30 min, 60 min, and 
120 min was 102 ± 7 %, 100 ± 9 %, 98 ± 6 %, and 99 ± 8 %, respectively. The mean ± SD 
percentage lactone of topotecan in urine at pH 5 at 5 min, 30 min, 60 min, and 120 min was 103 
± 5 %, 99 ± 8 %, 101 ± 5 %, and 101 ± 1 %, respectively. 
The mean ± SD percentage lactone of 9NC in urine at pH 6 at 5 min, 30 min, 60 min, and 
120 min was 108 ± 9 %, 79 ± 13 %, 94 ± 4 %, and 78 ± 14 %, respectively. The mean ± SD 
percentage lactone of camptothecin in urine at pH 6 at 5 min, 30 min, 60 min, and 120 min was 
88 ± 4 %, 90 ± 3 %, 87 ± 3 %, and 94 ± 5 %, respectively. The mean ± SD percentage lactone of 
topotecan in urine at pH 6 at 5 min, 30 min, 60 min, and 120 min was 99 ± 6 %, 98 ± 6 %, 89 ± 
14 %, and 91 ± 9 %, respectively. 
 
3.5 DISCUSSION 
 
 In Phase II and III studies, 9NC was administered orally daily x 5 days per week for 8 
weeks (1 cycle); however, the optimal schedule of administration of camptothecin analogues, 
especially 9NC, is unclear (7,17,18).  As a result, we performed the first study evaluating 
intermittent schedules of 9NC and have shown that intermittent schedules of 9NC are tolerable 
and may be active.  The MTD on schedules A and B were 2.4 and 1.7 mg/m2/day, respectively, 
however the dose intensity (24 mg/m2/cycle) was the same for both schedules.  It is currently 
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unclear which of the intermittent schedules of administration is superior.  Schedule A may prove 
to be the optimal intermittent regimen due to administration of a higher daily dose which may be 
above a critical threshold required for antitumor response (12,19).  However, since the exposures 
of 9NC and 9AC are similar due to the high interpatient variability in 9NC and 9AC disposition 
at the MTD of each regimen, administration of 9NC daily for 14 days every 4 weeks (schedule 
B) may be the most appropriate regimen based on the ability to administer treatment for 14 
consecutive days.  The dose intensity achieved on either of the intermittent schedules on our 
study appear less than the dose intensity achieved with the continuous schedule at 1.5 mg/m2 (30 
mg/m2/4 weeks).  However, due to the relatively high pharmacokinetic variability the exposures 
of 9NC and 9AC achieved with both regimens are similar (17,18). Moreover, recent studies 
using the continuous schedule have required dose reductions and delays during weeks 3 to 5, 
thus the dose intensity over 4 weeks is less than the intermittent schedules evaluated in our study 
(17,18).  In our Phase I studies, there were 5 patients with prolonged (i.e., > 6 cycles) stable 
disease, and one patient with pancreatic cancer achieved a PR.  The DLT were neutropenia, 
thrombocytopenia, and diarrhea.  There was significant interpatient variability in the disposition 
of 9NC and 9AC.  Most of the drug remained in the 9NC form with an average 9NC to 9AC 
ratio of 4 to 1.  The fact that most of the administered drug remains in the 9NC form is 
significant because the development of 9AC was stopped due to lack of efficacy (30-32).  
As part of our drug development program of camptothecin analogues, we determined the 
minimum effective dose of 9NC and associated drug exposure in mice bearing human tumor 
xenografts and compared this to the MTD and associated drug exposure in a Phase I trial using 
the same regimen (19).  In the preclinical studies, the 9NC and 9AC lactone AUCs associated 
with the minimum dose that produced a response were 43 and 6 ng/mL·h, respectively.  Of the 6 
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patients with pharmacokinetic studies at 2.4 mg/m2/day, only 2 (i.e., 27.3 and 37.4 ng/mL·h ) had 
9NC AUC < 43 ng/mL·h.  In addition, 5 of the 6 responders on schedule A or B had 9NC AUC > 
43 ng/mL·h.  In our Phase II study of 9NC administered orally daily for 5 days per week for 8 
weeks in patients with refractory colon cancer, 3 of 8 patients had a 9NC lactone AUC < 43 
ng/mL·h (26,33).  Moreover, there were no responders in the Phase II study of 9NC in patients 
with colon cancer.  This lack of response may be associated with the low daily exposures 
achieved with this regimen.  Thus, the intermittent schedule may be more appropriate than the 
continuous 8-week schedule because it can achieve exposures that are tolerable in humans and 
above the target threshold defined in xenograft models.  This information and study design can 
be used to make informed decisions regarding the most appropriate dose and schedule of 
administration of 9NC and other anticancer agents. 
 Several studies have reported significant interpatient variability in the pharmacokinetics 
of some orally administered drugs, especially camptothecin analogues (11,13-16,36,37).  In this 
study, at any given dose of 9NC there was 4 to 16-fold variability in 9NC and 9AC exposure, 
and there was no relationship between dose and AUC.  The method of dose calculation (i.e., mg 
versus mg/m2) did not reduce the variability in drug exposure.  Thus, there is no evidence that 
dosing 9NC on a mg/m2 basis is warranted to reduce the pharmacokinetic variability.  This is an 
important question for future studies to address because the most appropriate method to use for 
calculation of doses for oral administration of 9NC and other anticancer agents is unclear (29).  It 
is currently unclear if the pharmacokinetic variability of 9NC and 9AC are due to variable 
gastrointestinal absorption, hepatic metabolism, and/or biliary elimination. 
The minimal hematuria observed in schedule A and lack of hematuria observed in 
schedule B are in contrast to the 14% of patients that developed grade 3 hemorrhagic cystitis on 
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the prior Phase I study of 9NC, which used an 8-week continuous dosing schedule (7,17).  This 
decreased hematuria may be associated with the extensive oral hydration and/or the break in 
therapy during weeks 3 and 4 used in the intermittent study.  In addition, 6 patients had grade 1 
or 2 hematuria during screening and were ineligible for this study.  Thus, subclinical hematuria 
may occur patients with cancer, and the occurrence of grade 1 or 2 hematuria may not be 
clinically relevant or drug-induced. 
The percent of the 9NC dose recovered in urine as 9NC or 9AC is relatively low (< 15%) 
(26).  However, as stated above, 9NC-induced cystitis has required dose reductions and breaks in 
therapy (7,17,18).  Currently, patients are instructed to consume 2 to 3 L of fluid per day, which 
becomes problematic in patients with gastrointestinal cancers and in patients with cardiac 
conditions.  Thus, it is critical to determine the mechanism of camptothecin analogue-induced 
cystitis and develop feasible treatment options.  Camptothecin and 9NC produce cystitis, 
however the development of cystitis has not been associated with topotecan (7,17,18,34-37).  
The differential of cystitis induced by camptothecin, 9NC, and topotecan is not associated with 
the percentage of drug renally eliminated (13,33,35).  The pH of normal urine ranges from 4.5 to 
6.3 (38), however it is unclear whether the cystitis associated with camptothecin analogues is due 
to the lactone or hydroxy acid forms.  Because of this, we evaluated the stability of total and 
lactone forms of 9NC, camptothecin, and topotecan in urine at pH 5 and 6.  In our study, the 
percentage lactone and equilibrium between lactone and hydroxy acid forms of 9NC, 
camptothecin, and topotecan were similar in urine at pH 5 and 6.  Thus, the relative exposure of 
the lactone form of the camptothecin analogues may not be associated with the development of 
cystitis, and the conversion of lactone to hydroxy acid form via alkalization of the urine may not 
be a feasible treatment option in the prevention of 9NC-induced cystitis.  Alternatively, the 
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lipophilicity and bladder penetration of camptothecin analogues may be related to the 
development of cystitis (41,42). 
 The clinical importance of this study is underscored by the need to evaluate alternate 
schedules of administration prior to the initiation of Phase II and III studies (43,44).  Moreover, 
well designed translational studies, such as those used in the development of 9NC on the 
intermittent schedule and previously used to develop topotecan and irinotecan in pediatric solid 
tumors, can be highly informative when determining the most appropriate regimen to take 
forward in development (11,12,19). The intermittent regimen of 9NC evaluated in this study has 
preclinical rationale, acceptable toxicity, and should be evaluated in Phase II trials, especially in 
patients with pancreatic and gastric cancer. 
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4.1 ABSTRACT 
Purpose:  Oral administration of 9-nitrocamptothecin (9NC), and the formation of its metabolite 
9-aminocamptothecin (9AC), may be associated with high inter- and intra-patient variability.  
Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered 
on 3 different schedules as part of Phase I and Phase II studies. 
Methods: In Phase I schedule A, 9NC was administered orally qd x 5d x 2 wks q 4 weeks (one 
cycle).  On Phase I schedule B, 9NC was administered qd x 14d q 4 weeks (one cycle).  In Phase 
II, 9NC was administered qd x 5d x 8 weeks (one cycle).  Serial blood samples were obtained on 
day 1 and day 10 or 11 for Phase I studies, and day 1 and day 50 for the Phase II study.  
Recovery of 9NC and 9AC in urine was evaluated on day 1 in the Phase I study.  Area under the 
9NC and 9AC plasma concentration versus time curves from 0 to 24 hours (AUC0-24h) were 
calculated using compartmental analysis. 
Results:  Mean ± SD 9NC lactone AUC0-24h on day 1 at the maximum tolerated dose of 
schedules A and B (2.43 and 1.70 mg/m2, respectively) and the Phase II dose (1.5 mg/m2) were 
78.9 ± 54.4, 155.7 ± 112.8, and 48.3 ± 17.5 ng/mL·h, respectively.  Mean ± SD 9AC lactone 
AUC0-24h at these same doses of 9NC were 17.3 ±17.9, 41.3 ± 16.6, and 31.3 ± 12.8 ng/mL·h, 
respectively.  Mean ± SD ratios of 9NC lactone AUC0-24h on day 10 or 11 to day 1 on Phase I A 
and B were 1.27 ± 0.68 and 1.73 ± 1.56, respectively.  Mean ± SD ratios 9AC lactone AUC0-24h 
on day 10 or 11 to day 1 on Phase I A and B were 2.23 ± 1.02 and 1.65 ± 0.97, respectively. The 
recovery of 9NC and 9AC in the urine was < 15%. 
Conclusions:  There is significant inter-and intra-patient variability in the disposition of 9NC 
and 9AC.  9NC and 9AC undergo primarily non-renal elimination. 
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4.2 INTRODUCTION 
 The camptothecin analogues are topoisomerase I-interactive anticancer agents (1-3).  9-
Nitrocamptothecin (9NC) is an orally administered camptothecin analogue (4-6).  In vitro and in 
vivo preclinical studies suggest protracted administration of low doses of camptothecin 
analogues produce greater anti-tumor activity than do less frequent administration of higher 
doses [7,8].  Consistent with the mechanism of action of camptothecin analogues being cell-
cycle-specific, prolonged exposures may be more effective than shorter exposures (9-11).  Daily 
oral administration of 9NC may mimic a protracted parenteral schedule, achieve prolonged 
exposure, and maximize patient convenience.  However, oral administration of camptothecin 
analogues, has been characterized by extensive inter-and intra-patient variability in 
bioavailability (12-16).   
9NC is partially converted to the equipotent metabolite, 9-aminocamptothecin (9AC) 
(7,12,20). The terminal lactone ring is a key structural feature for the antitumor activity of 
camptothecin analogues (17-19). The conversion between lactone and hydroxy acid is reversible 
and is driven by pH and protein binding (17-19).  Acidic conditions favor the lactone whereas 
basic conditions favor the hydroxy acid form. Pharmacokinetic data for 9NC and its conversion 
to 9AC are limited (7,12,20,33,34).  Therefore, we evaluated the plasma and urinary disposition 
of 9NC and 9AC as part of Phase I and Phase II studies investigating 3 different schedules of 
administration. 
In Phase II and III studies, 9NC is administered continuously at 1.25 to 1.5 mg/m2/day for 
5 days per week (21,27).  On this schedule, dose reductions and delays in therapy frequently 
occur during weeks 3 to 5 and are due to myelosuppression, diarrhea, and hematuria. In 
xenograft studies, antitumor activity of camptothecin analogues requires a dose that produces a 
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systemic exposure above a critical threshold (7,8,11).  It is possible that administration of 
continuous, low dose 9NC might not produce a systemic exposure above this critical threshold 
and as a result might fail to produce an antitumor response.  In contrast, administration of 9NC 
on an intermittent schedule (e.g., 2 weeks of treatment followed by 2 weeks off) may allow for 
the administration of a higher dose per day that would produce therapeutic drug concentrations, 
and also avoid toxicities in weeks 3 and 4.  In addition, there is no scientific basis for the 
administration of 9NC or other camptothecins for 5 days per week and then give a drug holiday 
for 2 days (7,8,11, 21,27).  Thus, we evaluated 9NC administered daily for 5 days per week for 2 
weeks repeated every 4 weeks to 9NC administered daily for 14 day repeated every 4 weeks to 
determine if the two day drug holiday affects the deliverable dose or pharmacokinetics.  The 
pharmacokinetics of 9NC and its 9AC metabolite after administration of 9NC on the two 
intermittent schedules and the eight-week schedule are presented in this manuscript.  The clinical 
evaluation from these studies have been described previously (36). 
 
4.3 PATIENTS AND METHODS 
Patients 
Written informed consent, approved by the Institutional Review board of the University 
of Pittsburgh Medical Center, was obtained from all patients before they entered the study.  The 
eligible patients for the Phase I study were 18 years of age or older and had a histologically or 
cytologically confirmed malignancy for which no curative or effective therapy was available.  
Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ 2 and adequate bone marrow, hepatic, and renal function defined as: absolute neutrophil 
count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, total bilirubin ≤ 1.5 x upper limit of the 
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institutional normal (ULN) range, aspartate aminotransferase (AST) ≤ 1.5 x ULN if liver 
metastases were not present and ≤ 4 x ULN if liver metastases were present, and the absence of 
microscopic hematuria.  Prior treatment with camptothecin analogues, except 9NC, was 
permitted.  
Patients eligible for the Phase II study had histologically or cytologically confirmed 
advanced colon carcinoma with measurable disease that had failed to respond or relapsed after 
receiving at least one prior 5-fluorouracil-based chemotherapy regimen for advanced disease or 
had evidence of metastatic disease within 6 months of completion of adjuvant therapy.  Other 
eligibility criteria included an ECOG performance status ≤ 2 and adequate bone marrow, hepatic, 
and renal function defined as:  absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 
109/L, hemoglobin > 10 g/dl, total bilirubin ≤ 2.0 mg/dL, AST and ALT ≤ 3 x ULN if liver 
metastases were not present and ≤ 5 x ULN if liver metastases were present, and serum 
creatinine ≤ 2.0 mg/dL.   Patients with hematuria and those that had previously been treated with 
9NC or any other camptothecin analogue were excluded from the Phase II study.   
 
Dosage and Administration 
 9NC was supplied by the manufacturer, Supergen Inc. (Dublin, CA), as a crystalline 
powder in hard gelatin capsules that contained active drug and lactose excipient.  The capsule 
strengths were 0.5 mg and 1.25 mg.  All doses of 9NC were rounded to the nearest 0.25 mg.  
9NC was administered orally on an empty stomach with an acidic beverage (i.e. orange juice, 
cola) (20,21).  Patients were also instructed to drink 2 to 3 L of fluid per day. 
In the phase II study, 9NC was administered at 1.5 mg/m2/day x 5 days per week.  In the 
Phase I study, two intermittent schedules of 9NC were evaluated.  The phase I study evaluating 
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schedule A was completed prior to the initiation of schedule B.  On schedule A, 9NC was 
administered orally daily for 5 days per week for 2 consecutive weeks and repeated every 4 
weeks (one cycle). On schedule B, 9NC was administered orally daily for 14 days and repeated 
every 4 weeks (one cycle).  On the Phase II study, 9NC was administered for 5 consecutive days 
per week for 8 weeks with no dose escalation.  Dose levels for schedules A were determined by 
adaptive dose finding (22).  In this two-stage method, doses are escalated during stage I by a 
factor of 1.5 until the first dose-limiting toxicity (DLT) occurred.  Then, in stage II, escalation 
switched to a model-guided mode similar to the continual reassessment method (CRM) (23).  
Based on the number of days of treatment per cycle in schedule A and B, the initial dose level on 
schedule B was 30% lower than the MTD in schedule A. The adaptive dose finding procedure 
was not used to calculate dose levels for schedule B due to high pharmacokinetic variability and 
small changes in doses calculated by the adaptive dosing finding method.  For all studies, patient 
diaries and interviews were used as documentation of 9NC administration. 
 
Sample Collection and Preparation 
 On schedules A and B of the Phase I study, serial blood samples for pharmacokinetic 
analysis were obtained on day 1 and day 10 or 11.  Due to scheduling issues, the second 
pharmacokinetic study was performed on day 10 or 11.  On the Phase II study, serial blood 
samples were obtained on days 1 and 50.  For each pharmacokinetic study day, blood samples (5 
mL) were obtained prior to administration of 9NC, and 0.25, 0.5, 1, 2, 3, 6, 8, and 24 h after 
administration.  Blood was placed into heparinized tubes and immediately centrifuged at 1200 x 
g at 4ºC for 5 min.  The resulting plasma sample was then processed immediately in order to 
separate the lactone and hydroxy acid forms of 9NC and 9AC.   
 120
 The processing for the measurement of the 9NC lactone in plasma used solid phase 
extraction (SPE) with Waters OASIS HLB columns (1 mL, 30 mg).  Columns were conditioned 
with 1 mL of methanol and equilibrated with 1 mL of water.  Plasma (1 mL) was passed through 
the column, and the column was then washed with 1 mL of 5% methanol in water to remove the 
hydroxy acid forms of 9NC and 9AC.  9NC lactone was then eluted with 1 mL of methanol and 
stored at -80°C until analyzed.   
For measurement of 9AC lactone, 9NC total (sum of lactone and hydroxy acid) and 9AC 
total, the plasma was processed by methanolic extraction.  A total of 600 μL of plasma was 
added to 1200 μL of methanol on dry ice.  The samples were vortexed and centrifuged at 10,000 
x g for 5 min.  The supernatant was decanted and stored at  -80°C until analyzed.   
 On day 1 and day 10 or 11 of the Phase I studies,  24-h urine collections were performed.  
Total urine volume was measured and a 600 μL sample was processed by the same methanolic 
extraction described above for measurement of 9NC and 9AC total.  
 
High-Performance Liquid Chromatography (HPLC) Analysis 
 
 Because 9NC is not highly fluorescent, 9NC lactone and 9NC total were measured by 
chemically reducing 9NC to 9AC (23).  Reduction of the 9NC to 9AC was accomplished by 
mixing 500 μL of the 9NC sample solution (methanolic extraction for measurement of 9NC total 
or the SPE elution for measurement of 9NC lactone) and 25 μL of 12N HCL.  Then 50 μL of the 
Fe-reduction reagent (25 mg reduced Pentacarbonyl Iron/ml H2O, Sigma Chemical Co., St. 
Louis, MO) was added and the mixture was sonicated for 30 min at 70°C, and then centrifuged at 
13,400 x g for 5 min at 5°C.  For analysis of 9NC lactone, 150 μL of the supernatant was added 
to 100 μL of 0.5 M ammonium acetate (pH 5.5), vortexed, and 100 μL was injected into the 
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HPLC.  For analysis of 9NC total in plasma or urine, 150 μL supernatant was added to 75 μl of 
0.5 M ammonium acetate (pH 5.5), vortexed, and 100 μL was injected into the HPLC.  
 The concentration of 9NC was calculated by subtracting the concentration of 9AC 
present before conversion of 9NC to 9AC from the concentration of 9AC after the conversion of 
9NC to 9AC. For analysis of 9AC lactone, 150 μL of the methanolic extract was added to 10 μL 
of 0.5 M ammonium acetate.  A total volume of 100 μL was then injected into the HPLC.  For 
analysis of 9AC total, 150 μL of the methanolic extract was added to 15 μL of 20% phosphoric 
acid and vortexed.  Then, 10 μL of 0.5 M ammonium acetate (pH 5.5) was added and vortexed, 
and a total volume of 100 μL was injected into the HPLC. 
 The HPLC system consisted of a Waters 2695 separation module (Waters Corp.,  Milford, 
MA), a C18 reverse phase column [Ultrasphere 5 μm ODS 4.6 x 250 mm, Beckman Coulter, Inc., 
Fullerton, CA], and a C18 guard column (Brownlee C18 7 μm, 15 x 3.2 mm, PerkinElmer Corp., 
Norwalk, CT).  Samples were injected by an autosampler set at 4°C.  The isocratic mobile phase 
consisted of methanol:acetonitrile:ammonium acetate (10:23:97, v/v/v), pH 5.5, pumped at a flow 
rate of 1.0 mL/min.  Post column acidification (pH 2 – 3) was performed using 0.3 M 
trifluoroacetic acid at 0.3 mL/min (24).  9AC was detected by a Waters 474 fluorescence detector 
with excitation wavelength of 365 nm and emission wavelength of 440 nm.  MILLENIUM 32 
software (Waters Corporation) was used for data collection and analysis.  All glassware, including 
the injection vials, was treated with 3% surfasil in toluene (Fisher Scientific Inc., Fair Lawn, NJ).  
 
Pharmacokinetic Analysis 
 
 Compartmental pharmacokinetic analysis of 9NC and 9AC was performed using ADAPT 
II (25).  The estimation procedure and variance model used in the compartmental 
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pharmacokinetic analysis was maximum likelihood estimation and linear models for the variance 
of the additive errors, respectively.  Different pharmacokinetic model structures were considered 
to characterize the disposition of 9NC and 9AC in plasma.  In the model development, one- and 
two-compartments models were evaluated to describe the systemic disposition of 9NC and 9AC.  
In addition, we evaluated the use of single and separate apparent volumes of the central 
compartments for 9NC and 9AC.  Akaike’s Information Criteria (AIC), Schwartz Criteria, 
estimated error of the model parameters, and residual analysis were use to select the model 
structure maximizing the fit accuracy while simultaneously minimizing the number of model 
parameters.  The final model structure used for the pharmacokinetic analysis produced 
identifiable parameters in all patients. 
 A linear PK model describing oral administration of 9NC was simultaneously fit to 9NC 
and 9AC concentration versus time profiles. The model contained one-compartment for 9NC 
systemic disposition, subsequent conversion of 9NC to 9AC, and one-compartment for 9AC 
systemic disposition.  Individual parameters estimated were the absorption rate constant (ka), the 
lag time prior to absorption (τ), the apparent volume of the central compartment (Vc/F), the rate 
constant describing conversion of 9NC to 9AC (k12), and the elimination rate constants for 9NC 
(k10) and 9AC (k20).  The apparent clearance of 9NC (9NC CL/F) and 9AC (9AC CL/F) total and 
lactone were calculated using standard equations [i.e. Vc/F x (k10 + k12) and Vc/F x k20, 
respectively] (25,26).  The area under the 9NC and 9AC plasma concentration versus time curves 
(9NC AUC0-24 h and 9AC AUC0-24 h) from zero to 24 hours were calculated using the log 
trapezoidal method by simulating the concentration versus time data from each patient using 
patient-specific parameters (25).  Intra-patient variability of 9NC and 9AC on the Phase I study 
was estimated by the ratio of AUC0-24 h on day 10 or 11 to AUC0-24 h on day 1.  Intra-patient 
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variability of 9NC and 9AC on the Phase II study was estimated as the ratio of AUC0-24 h on day 
50 to the AUC0-24 h on day 1. 
 In another attempt to evaluate the intra-patient variability in the disposition of 9NC and 
9AC, patient-specific pharmacokinetic parameters describing the disposition of 9NC and 9AC on 
day 1 were used to simulate the 9NC and 9AC AUC0-24 h expected in each patient on day 10, and 
the simulated AUC0-24 h were compared with the 9NC and 9AC AUC0-24 h actually measured in 
each patient on day 10.  
  
Statistical Analysis 
 
 Statistical analysis was performed using the two-sided Wilcoxon signed rank test.  The 
level of significance was set at P < 0.05. 
 
4.4 RESULTS 
 
High-Performance Liquid Chromatography (HPLC) Analysis 
 
As stated in the methods section, 9NC was measured indirectly as 9AC.  There was no 
endogenous materials in plasma and urine that interfered with measurement of 9AC. With the 
chromatography conditions described, 9AC eluted at 7.1 min.  The sample preparation described 
results in > 90% recovery of 9AC when compared to the direct injection of an equivalent amount 
of 9AC in mobile phase.  The conversion of 9NC to 9AC via the reduction method described was 
54 ± 4.6%.  When stored at – 80ΕC the percentage change in measured concentration of 9NC 
and 9AC lactone and total from baseline was < 10% at 2 months.  The stability of 9NC and 9AC 
lactone and total on the autosampler at 24 h was > 90%. 
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The lower limit of quantitation (LLQ) for 9NC lactone in plasma and 9NC total in plasma 
and urine was 0.5 ng/mL, and the assay was linear from 0.5 ng/mL to 100 ng/mL. The 
correlation coefficients for three successive 9NC lactone triplicate standard curves in plasma and 
9NC total triplicate standard curves in plasma or urine were > 0.99. When expressed as a 
percentage coefficient of variation, the within-day and between day variation in 9NC lactone in 
plasma and total in plasma and urine triplicate standards was always < 15%.  
 The LLQ for 9AC lactone and 9AC total was 0.3 ng/mL, and the assay was linear from 
0.3 ng/mL to 30 ng/mL.  The average ± SD correlation coefficients for three successive 9AC 
lactone triplicate standard curves in plasma and 9AC total triplicate standard in plasma or ruine 
curves was > 0.99.  When expressed as a percentage coefficient of variation, the within-day and 
between day variation in 9AC lactone triplicate standards in plasma and total triplicate standards 
in plasma or urine was always < 15%.   
 
Phase I Study 9NC and 9AC Lactone Pharmacokinetics 
 
 A summary of 9NC and 9AC lactone pharmacokinetic parameters from the Phase I study 
is presented in Table 1, and AUC0-24h are presented in Table 2 and Table 3. There was no 
difference (P > 0.05) in the pharmacokinetic parameters after administration of different doses of 
9NC, thus data from all doses were pooled on day 1 or day 10 and 11.  Representative 
concentration versus time profiles of 9NC and 9AC total and lactone after administration of 9NC 
2.43 mg/m2/d on day 1 and day 11 of schedule A of the Phase I study within the same patient are 
presented in Figure 1 and Figure 2, respectively.  The 9NC and 9AC lactone AUC0-24h on day 1 
and day 10 or 11 of schedules A and B are represented in Figure 3 and Figure 4, respectively.  
 
 Table 1.  9NC and 9AC Lactone Pharmacokinetic Parameters for Phase I Schedules A and B and Phase II 
  Schedules A, B, & Phase 
II 
Schedule A Schedule B Phase II 
Parameter Units Day 1 
Mean ± SD  
Day 10 or 11 
Mean ± SD  
Day 10 or 11 
Mean ± SD  
Week 8 Day 1 
Mean ± SD  
 
Lactone 
  
(n = 34) 
 
(n = 11) 
 
(n = 9) 
 
(n = 4) 
 
9NC CL/F 
 
L/h/m2 
 
27.0 ± 33.7 
 
9.5 ± 16.2  
 
16.5 ± 32.5  
 
59.8 ± 45.8 
9AC CL/F L/h/m2 4.0 ± 8.8 0.4 ± 0.4  2.8 ± 5.5 1.2 ± 0.9 
ka h-1 0.3 ± 0.4 0.04 ± 0.04  0.1 ± 0.1a 0.3 ± 0.2  
τ h 0.5 ± 0.3 0.8 ± 1.3  0.2 ± 0.2 0.4 ± 0.1  
k12 h-1 0.04 ± 0.03 0.09 ± 0.08 0.3 ± 0.3a  0.1 ± 0.02 
Vc/F L/m2 37.5 ± 46.2 10.0 ± 0.1 4.9 ± 7.0 99.9 ± 98.4 
      
Total  (n = 39) (n = 13) (n = 9) (n = 4) 
 
9NC CL/F 
 
L/h/m2 
 
6.3 ± 6.2 
 
2.0 ± 3.1a 
 
1.4 ± 1.1a 
 
4.6 ± 6.6  
9AC CL/F L/h/m2 2.2 ± 3.6 0.3 ± 0.3a  0.2 ± 0.1 1.0 ± 1.5  
ka h-1 0.4 ± 0.7 0.02 ± 0.02a 0.03 ± 0.04a  0.1 ± 0.1  
τ h 0.4 ± 0.2 0.7 ± 0.6  0.2 ± 0.1  0.3 ± 0.1  
k12 h-1 0.04 ± 0.03 0.1 ± 0.1a  0.1 ± 0.1  0.1 ± 0.1 
Vc/F L/m2 27.5 ± 35.4   11.0 ± 10.0 10.2 ± 1.2 8.1 ± 12.4 
a P-values < 0.05 as determined by two-sided Wilcoxon signed rank test.  
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Table 2.   9NC and 9AC Lactone and Total AUCs on Phase I Schedule A 
 
  Day 1 Day 10 or 11 
  
 
Units 
2.00 mg/m2 
 
Mean ± SD  
(Range) 
2.43 mg/m2 
 
Mean ± SD 
(Range) 
2.68 mg/m2 
 
Mean ± SD 
(Range) 
2.00 mg/m2 
 
Mean ± SD 
(Range) 
2.43 mg/m2 
 
Mean ± SD 
(Range) 
2.68 mg/m2  
 
Mean ± SD  
(Range) 
 
Lactone 
 
 
 
(n = 6) 
 
(n = 7) 
 
(n = 4) 
 
(n = 6) 
 
(n = 7) 
 
(n = 3) 
 
9NC AUC0-24 h  
 
ng/mL·h 
 
183.1 ± 119.0 
 (78.4 – 412.7) 
 
78.9 ± 54.4 
(27.0 – 187.2) 
 
89.2 ± 90.9 
(45.8 – 287.9) 
 
254.7 ± 190.0 
(110.4 – 671.9) 
 
102.8 ± 121.0 
(11.0 – 360.7) 
 
229.6 ± 66.8 
(154.6 – 316.8) 
 
9AC AUC0-24 h  
 
ng/mL·h 
 
33.6 ± 20.7 
(10.81 – 66.14) 
 
17.3 ± 17.9 
(5.2 – 60.6) 
 
32.2 ± 16.1 
(7.3 – 51.5) 
 
45.1 ± 23.4 
(20.1 – 80.4) 
 
43.7 ± 42.5 
(8.3 – 136.1) 
 
88.8 ± 34.6 
(42.0 – 124.5) 
 
Ratio of  
9AC AUC0-24 h to 
9NC AUC0-24 h 
  
0.19 ± 0.07 
(0.11 – 0.29) 
 
0.23 ± 0.13 
(0.06 – 0.41) 
 
0.18 ± 0.04 
(0.11 – 0.21) 
 
0.21 ± 0.13 
(0.11 – 0.48) 
 
0.70 ± 0.66 
(0.14 – 2.06) 
 
0.41 ± 0.19 
(0.19 – 0.65) 
 
Total 
  
(n = 6) 
 
(n = 7) 
 
(n = 4) 
 
(n = 6) 
 
(n = 7) 
 
(n = 3) 
 
9NC AUC0-24 h  
 
ng/mL·h 
 
647.4 ± 294.5 
(136.3 – 1037.0) 
 
482.1 ± 597.6 
(109.0 – 1936.0) 
 
942.0 ± 443.6 
(292.0 – 1474.0) 
 
1075.3 ± 811.3 
(408.4 – 2646.0) 
 
651.6 ± 774.7 
(62.8 – 2487.0) 
 
1663.3 ± 556.8 
(1115.0 – 2427.0) 
 
9AC AUC0-24 h  
 
ng/mL·h 
 
196.4 ± 134.1 
(54.5 – 441.2) 
 
83.5 ± 78.9 
(31.1 – 274.0) 
 
245.5 ± 122.4 
(49.7 – 382.0) 
 
304.9 ± 197.1 
(112.9 – 668.0) 
 
178.3 ± 179.8 
(23.4 – 582.0) 
 
537.4 ± 238.9 
(201.9 – 739.4) 
 
Ratio of  
9AC AUC0-24 h to 
9NC AUC0-24 h 
  
0.30 ± 0.10 
(0.14 – 0.43) 
 
0.21 ± 0.05 
(0.14 – 0.29) 
 
0.25 ± 0.05 
(0.17 – 0.31) 
 
0.23 ± 0.05 
(0.15 – 0.29) 
 
0.33 ± 0.12 
(0.14 – 0.50) 
 
0.32 ± 0.12 
(0.18 – 0.46) 
 
* Area under the plasma concentration versus time curves were calculated from 0 to 24 h (AUC0-24 h). 
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Table 3.   9NC and 9AC Lactone and Total AUCs on Phase I Schedule B 
 
  Day 1 Day 10 or 11 
  
 
Units 
1.70 mg/m2 
 
Mean ± SD  
(Range) 
2.40 mg/m2 
 
Mean ± SD  
(Range) 
1.70 mg/m2 
 
Mean ± SD  
(Range) 
2.40 mg/m2 
 
Mean ± SD 
 (Range) 
Lactone  (n = 5) (n = 3) (n = 6) (n = 3) 
 
9NC AUC0-24 h  
 
ng/mL·h 
 
155.7 ± 112.8  
(45.2 – 359.2) 
 
277.9 ± 218.4  
(34.1 – 563.9) 
 
188.1 ± 112.3 
 (15.8 – 338.5) 
 
182.7 ± 25.1 
 (152.8 – 241.3) 
 
9AC AUC0-24 h  
 
ng/mL·h 
 
41.3 ± 16.6  
(13.1 – 58.3) 
 
75.4 ± 69.6  
(23.6 – 173.8) 
 
51.8 ± 21.2 
 (22.9 – 74.9) 
 
58.4 ± 17.7  
(40.3 – 82.5) 
 
Ratio of 
9AC AUC0-24 h to  
9NC AUC0-24 h 
  
0.38 ± 0.24 
 (0.13 – 0.79) 
 
0.37 ± 0.24 
 (0.12 – 0.69) 
 
0.62 ± 0.78  
(0.10 – 2.36) 
 
0.32 ± 0.10  
(0.25 – 0.46) 
 
Total 
  
(n = 5) 
 
(n = 3) 
 
(n = 6) 
 
(n = 3) 
 
9NC AUC0-24 h  
 
ng/mL·h 
 
431.0 ± 213.7 
 (91.0 – 737.4) 
 
289.5 ± 92.5 
 (161.8 – 377.7) 
 
534.3 ± 339.7  
(83.6 – 1065.0) 
 
337.4 ± 22.2 
 (321.7 – 368.8) 
 
9AC AUC0-24 h  
 
ng/mL·h 
 
183.8 ± 109.8  
(31.6 – 345.2) 
 
281.7 ± 198.3  
(114.1 – 560.2) 
 
233.6 ± 155.8  
(73.6 – 446.9) 
 
306.6 ± 123.3  
(218.7 – 481.0) 
 
Ratio of 
9AC AUC0-24 h to  
9NC AUC0-24 h 
  
0.46 ± 0.25 
 (0.15 – 0.90) 
 
0.95 ± 0.54 
 (0.45 – 1.70) 
 
0.51 ± 0.23  
(0.23 – 0.88) 
 
0.92 ± 0.41 
 (0.59 – 1.49) 
  
* Area under the plasma concentration versus time curves were calculated from 0 to 24 h (AUC0-24 h).
  
 
 
 
 
 
 
 
Figure 1.  Representative concentration versus time profiles of 9NC and 9AC total and lactone profiles in 
a single patient after oral administration of 9NC 2.43 mg/m2/d on day 1 of schedule A of the Phase I 
study.  The concentration versus time profiles in Figure 1 and 2 are from the same patient.  Individual 
data and best fit line for 9NC total (■, ___) and lactone (□, ---) concentration versus time profiles are 
presented.  Individual data and best fit line for 9AC total (● ,___) and lactone (○,---) concentration versus 
time profiles are also presented.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Representative concentration versus time profiles of 9NC and 9AC total and lactone profiles in 
a single patient after oral administration of 9NC 2.43 mg/m2/d on day 10 of schedule A of the Phase I 
study. The concentration versus time profiles in Figure 1 and 2 are from the same patient.  Individual data 
and best fit line for 9NC total (■, ___)  and lactone (□, ---)  concentration versus time profiles are 
presented.  Individual data and best fit line for 9AC total (●,___) and lactone (○,---) concentration versus 
time profiles are also presented.  
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Figure 3.  Inter- and intra-patient variability in 9NC and 9AC lactone AUCs on Schedule A of the Phase I 
study.  Individual 9NC and 9AC lactone AUC values for patients administered 2.00 mg/m2 (Δ), 2.43 
mg/m2 (○), and 2.68 mg/m2 (□) are presented.  Data within the same patient from day 1 to day 10 or 11 
are connected by solid lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Inter- and intra-patient variability in 9NC and 9AC lactone AUCs on Schedule B of the Phase I 
study.  Individual 9NC and 9AC lactone AUC values for patients administered 1.70 mg/m2  (Δ) and 2.40 
mg/m2 (○) are presented.  Data within the same patient from day 1 to day 10 or 11 are connected by solid 
lines. 
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 On schedule A, the mean ± SD ratio of 9NC lactone AUC0-24 h on day 10 or 11 to day 1 
was 1.27 ± 0.68. On schedule A, the mean ± SD ratio of 9AC lactone AUC0-24 h on day 10 or 11 
to day 1 was 2.23 ± 1.02.  On schedule B, the mean ± SD ratio of 9NC lactone AUC0-24 h on day 
10 to day 1 was 1.73 ± 1.56.  In addition, on schedule B the mean ± SD ratio of 9NC lactone 
AUC0-24 h simulated on day 10 to the AUC0-24 h measured on day 10 was 1.6 ± 1.1.  On schedule 
B, the mean ± SD ratio of 9AC lactone AUC0-24 h on day 10 to day 1 was 1.65 ± 0.97.  In 
addition, on schedule B the mean ± SD ratio of 9AC lactone AUC0-24 h simulated on day 10 to 
the AUC0-24 h measured on day 10 was 3.7 ± 4.2.  
 
Phase I Study 9NC and 9AC Total Pharmacokinetics 
 
 A summary of 9NC and 9AC total pharmacokinetic parameters is presented in Table 1 
and AUC0-24 h are presented in Table 2 and Table 3. There was no difference (P > 0.05) in the 
pharmacokinetic parameters after administration of different doses of 9NC, thus data from all 
doses were pooled on day 1 or day 10 and 11.  On schedule A, the mean ± SD ratio of 9NC total 
AUC0-24 h from day 10 or 11 to day 1 was 1.62 ± 0.57. On schedule A, the mean ± SD ratio of 
9AC total AUC0-24 h from day 10 or 11 to day 1 was 2.08 ± 0.75.  On schedule B, the mean ± SD 
ratio of 9NC total AUC0-24 h from day 10 to day 1 was 1.40 ± 0.61. In addition, on schedule B the 
mean ± SD ratio of 9NC total AUC0-24 h simulated on day 10 to the AUC0-24 h measured on day 
10 was 1.7 ± 1.0.  On schedule B, the mean ± SD ratio of 9AC total AUC0-24 h from day 10 to day 
1 was 1.50 ± 0.45.  In addition, on schedule B the mean ± SD ratio of 9AC total AUC0-24 h 
simulated on day 10 to the AUC0-24 h measured on day 10 was 6.5 ± 4.4.   
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Phase II 9NC and 9AC Lactone and Total Pharmacokinetics  
 
 Summaries of 9NC and 9AC pharmacokinetic parameters from the Phase II study are 
presented in Table 1 and Table 4.  The mean ± SD ratios of 9NC lactone AUC0-24 h on day 50 to 
day 1 was 1.16 ± 0.89.  The mean ± SD ratios of 9AC lactone AUC0-24 h on day 50 to day 1 was 
1.74 ± 0.13.  The mean ± SD ratio of 9NC total AUC0-24 h on day 50 to day 1 was 1.68 ± 0.61.  
The mean ± SD ratio of 9AC total AUC0-24 h on day 50 to day 1 was 1.50 ± 0.76. 
 
Table 4.   9NC and 9AC Lactone and Total AUCs on the Phase II Study 
 
  Day 1 Day 50 
  
 
 
Units 
1.50 mg/m2 
 
Mean ± SD 
(Range) 
1.50 mg/m2 
 
Mean ± SD 
(Range) 
 
Lactone 
  
(n = 5) 
 
(n = 3) 
 
9NC AUC0-24 h  ng/mL·h 48.3 ± 17.5  
(23.4 – 69.3) 
51.9 ± 31.1  
(11.9 – 87.7) 
 
9AC AUC0-24 h  ng/mL·h 31.3 ± 12.8  
(10.2 – 44.8) 
38.8 ± 19.7  
(19.1 – 58.5) 
 
9AC AUC0-24 h to  
9NC AUC0-24 h 
 0.81 ± 0.65 
 (0.28 – 1.92) 
0.63 ± 0.41 
 (0.22 – 1.04) 
 
Total  (n = 9) (n = 3) 
 
9NC AUC0-24 h  ng/mL·h 377.0 ± 221.2  
(90.7 – 798.1) 
310.7 ± 178.2  
(89.8 – 526.1) 
 
9AC AUC0-24 h  ng/mL·h 88.5 ± 41.32 
 (27.0 – 141.8) 
97.8 ± 79.5  
(16.1 – 205.5) 
 
9AC AUC0-24 h to  
9NC AUC0-24 h 
 0.31 ± 0.21  
(0.10 – 0.83) 
0.27 ± 0.09  
(0.18 – 0.39) 
* Area under the plasma concentration versus time curves were calculated  
from 0 to 24 h (AUC0-24 h). 
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Renal Elimination 
 
 On schedule A of the Phase I study, the percentage of the dose renally eliminated on day 
1 as 9NC total and 9AC total were 5.9 ± 4.3 % and 3.5 ± 1.7 %, respectively. On schedule A of 
the Phase I study, the percentage of the dose renally eliminated as 9NC total and 9AC total on 
day 10 or 11 was 5.6 ± 3.8 % and 4.2 ± 2.2 %, respectively.  On schedule B of the Phase I study, 
the percentage of the dose renally eliminated on day 1 as 9NC total and 9AC total was 11.3 ± 3.8 
% and 5.0 ± 2.6 %, respectively. On schedule B of the Phase I study, the percentage of the dose 
renally eliminated as 9NC total and 9AC total on day 10 or 11 was 9.0% ± 6.2 and 5.5% ± 1.9, 
respectively. 
 
4.5 DISCUSSION 
 
Although Phase III trials of 9NC have been completed, there is limited pharmacokinetic 
data on 9NC and its conversion to 9AC.  Prior studies have reported the pharmacokinetics of 
9NC after oral and inhaled administration (21,27-30,33,34).  However, this is the first  
pharmacokinetic study evaluating the inter- and intra-patient variability of 9NC and its 9AC 
metabolite on continuous and intermittent schedules of administration.  There was high inter-and 
intra-patient pharmacokinetic variability of 9NC and 9AC regardless of the schedule of 
administration (12-16).  The clinical importance of this study is underscored by the need to 
evaluate the pharmacokinetics of anticancer agents that are orally administered and have a steep 
relationship between exposure and response (ie, antitumor or toxicity). 
 Preliminary evidence suggests 9NC is metabolized extensively in the liver by an 
NADPH-dependent system, probably involving a cytochrome P450 isotype (30). Previous in 
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vitro studies have demonstrated the conversion of 9NC to 9AC was relatively minor (i.e. 12% - 
25%), but highly variable (30-32).  In our current study, most of the drug remained in the 9NC 
form with a mean ratio of 9NC to 9AC of 4 to 1, which is consistent with the previous studies. 
The fact that most of the administered drug remains in the 9NC form is significant because the 
development of 9AC was stopped due to lack efficacy (4-6). However, our studies also 
demonstrated highly variable conversion of 9NC to 9AC, as 2 patients had undetectable 9AC 
concentrations and 4 patients had higher exposures of 9AC compared to 9NC.  In addition, from 
day 1 to day 10 in the Phase I study or day 1 to day 50 in the Phase II study some patients had 
greater accumulation of 9NC compared to 9AC, whereas others had greater accumulation of 
9AC.  
 Although the complete metabolic pathway of 9NC and 9AC is unclear, our study 
suggests that the clearance of 9NC appears to be non-renal with possible biliary elimination.  The 
percentage of the dose recovered in the urine was low (i.e., < 15 %).  However, if the oral 
bioavailability, which is currently unknown because no IV formulation exists, is only 30 % then 
the percentage of the dose recovered in the urine would be 50 %.  Patients with who had elevated 
bilirubin levels related to biliary stent blocks or disease had the highest 9NC and 9AC exposures.  
A plateau of 9NC and 9AC concentrations from 6 to 24 hours, and Tmax which ranged from 0.5 
to 24 hr, suggests 9NC and 9AC may undergo enterohepatic circulation (28).  Similar results 
have been reported for 9NC and with other camptothecin analogues. However, the long duration 
of 9NC exposure was much greater than reported for other orally administered camptothecin 
analogues (12-16). 
 Several studies have reported significant interpatient variability in the pharmacokinetics 
of orally administered camptothecin analogues (11,13,14,15,16,31,32).  Our study also 
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demonstrated relatively high inter- and intra-patient pharmacokinetic variability of 9NC and 
9AC.  At individual doses there was 4 to 16-fold variability in 9NC and 9AC exposure among 
different patients and there was no relationship between dose and AUC0-24 h.  The ratio of 9NC or 
9AC AUC0-24 h from day 1 to day 10 in the Phase I study or day 50 in the Phase II study ranged 
from 0.6 to 4.  Some accumulation of 9NC was seen on both the intermittent and continuous 
schedules of administration.  However, the accumulation of 9NC or 9AC from day 1 to day 10 or 
11 in the Phase I studies or from day 1 to day 50 on the Phase II study was not as great as 
predicted by the pharmacokinetics on day 1.  This also suggests the disposition of 9NC and 9AC 
is not consistent over time. 
 The high inter- and intra-patient variability in 9NC and 9AC disposition could be due to 
variability in oral absorption, the affect of food, pH of the gastric tract, and hepatic and extra-
hepatic conversion of 9NC to 9AC (7,12-16,20,21).  The presence of a nitro group at the 9-
position makes 9NC water-insoluble and an intravenous formulation has not been developed.  
Thus, the absolute oral bioavailability of 9NC can not be determined in patients and the influence 
of oral absorption and systemic metabolism on the overall variability in 9NC and 9AC 
disposition can not be determined.  Schoffski and colleagues demonstrated that a meal consisting 
of 58% fat, 15% protein, and 27% carbohydrate, consumed 30 min prior to drug administration, 
led to a 50% reduction in the oral absorption of 9NC (21).  In our study 9NC was administered 
on an empty stomach.  In our study, 9NC was administered with an acidic beverage, however, it 
is still unclear if co-administration with an acidic beverage improves oral absorption and reduces 
variability (20,21).  Patients in this study were allowed to continue any routine medications, 
including histamine-2 blockers and proton pump inhibitors.  There was no relationship between 
the administration of these agents.  In addition, there was no relationship between the level of 
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compliance as documented by patient diaries and interviews and the exposure of 9NC and 9AC.  
Similar results have been seen with topotecan after administration of ranitidine (20).  Thus, the 
factors associated with the extensive variability in the disposition of 9NC and 9AC are unknown. 
 The results from our study are similar to the results of the studies  by Schoemaker et.al.  
and Raymond et.al (33,34). For example, the ka in our study and the study by Schoemaker et.al. 
were 0.4 ±  0.7 h-1 and 0.8 h-1, respectively.  In addition, the CL/F of 9NC in our study and the 
study by Schoemaker et.al. were 6.3 ± 6.2 L/h/m2 and 1.7 L/h, respectively.  The slight 
difference in CL/F may be explained by administration of different doses and slightly different 
model framework used between the 2 studies, and additional samples and evaluation of more 
patients in our study.  In the study by Raymond et.al., administration on 9NC at 1.5 mg/m2 x 1, 
the 9NC and 9AC AUC0-24 h were 231 ± 137 ng/mL·hr and 36.9 ± 28.5 ng/mL·hr, respectively, 
which are similar to the AUC0-24 h in our studies after administration of 9NC at 2.0 mg/m2.  In 
addition, the concentration versus time profiles of 9NC and 9AC, delayed absorption, increases 
in 9AC concentrations over the 24 hour period, and no drug accumulation over the 21 days of 
treatment in the study by Raymond et.al. are very similar to our study. 
 We used an HPLC assay with fluorescence detection to measure 9NC and 9AC.  As 
stated previously, 9NC was measured indirectly by chemically reducing 9NC to 9AC using an 
Fe-reduction reagent (23).  The need to convert 9NC to 9AC via Fe-reduction is highly 
complicated and logistically difficulty. Moreover, the conversion of 9NC to 9AC is only 
approximately 54% which requires the indirect estimation of 9NC concentrations by subtracting 
the concentration of 9AC present before conversion of 9NC to 9AC from the concentration of 
9AC after the conversion of 9NC to 9AC.  The use of an LC/MS or LC/MS/MS assay for 9NC 
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would not require the conversion of 9NC to 9AC and may allow for the simultaneous 
determination of lactone and hydroxy acid forms of 9NC and 9AC. 
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5.0 
CHAPTER 5: 
 
 
 
Clinical and Pharmacokinetic Study Evaluating the Effect of Food on the Disposition of  
9-Nitrocamptothecin and its 9-Aminocamptothecin Metabolite in Patients with Solid 
Tumors 
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5.1 ABSTRACT 
Purpose: 9-nitrocamptothecin (NC) is an orally administered camptothecin analogue that 
has completed phase III trials for pancreatic cancer.  In biological matrices, camptothecin 
analogues exist in equilibrium between the active-lactone (LAC) and inactive-hydroxy 
acid (HA) forms.  9NC has been administered on an empty stomach; however it is 
unclear if food alters the absorption and disposition of 9NC and its 9-aminocamptothecin 
(9AC) active-metabolite.  Thus, we evaluated the disposition of 9NC and 9AC after 
administration of 9NC under fasting conditions and after a standard meal.   
Methods: Patients were randomized to receive 9NC as a single oral dose at 1.5 mg/m
2
 
with 8 ounces of an acidic beverage under fasting conditions, or after a meal consisting of 
2 eggs, 8 ounces (oz) of orange juice, buttered toast, 8 oz of milk, and 4 oz of hash brown 
potatoes.  Following a 72-h washout period, 9NC was administered with the alternative 
condition (i.e., with food or fasting).  9NC was then continued for five days of every 
week.  Serial blood samples were obtained prior to and from 0.25 h to 24 h after 
administration of 9NC.  9NC and 9AC total (sum of LAC + HA) were measured by an 
LC-MS/MS assay.  Area under the plasma concentration versus time curve (AUC) for 
9NC and 9AC total were calculated.  After the pharmacokinetic section of the study, 
patients received 9NC 1.5 mg/m
2
 orally under fasting conditions daily for 5 days per 
week for 8 weeks. 
Results: Sixteen patients with median (range) age 62 (47-83) years, diagnoses of 
colorectal (6 patients), lung (2 patients), and other (8 patients) malignancies, received 83 
[median (range) 4 (2-9)] weeks of therapy.  Patients with toxicities greater than grade 2 
were diarrhea (1), nausea (2), vomiting (2), fatigue (2), anemia (3), neutropenia (3), and 
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febrile neutropenia (2).  Three patients (lung, unknown primary, and colon) had stable 
disease for eight weeks.  The mean ± SD of 9NC AUCfood and 9NC AUCfast were 300 ± 
182 and 569 ± 362 ng/ml·h, respectively (P < 0.05).  The mean ± SD of 9AC AUCfood and 
9AC AUCfast were 244 ± 60 and 291 ± 195 ng/ml·h, respectively (P > 0.05).  The mean ± 
SD ratio of 9NC AUCfood to AUCfasting in individual patients was 0.67 ± 0.22. The mean ± 
SD ratio of 9AC AUCfood to AUCfasting in individual patients was 1.14 ± 0.61. 
Conclusions: Co-administration of 9NC with food reduces the oral absorption of 9NC; 
however there was no difference in the exposure of 9AC.  The effect of food on the 
absorption of 9NC is highly variable and is less consistent for 9AC compared to 9NC. 
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5.2 INTRODUCTION 
The camptothecin analogues are topoisomerase I-interactive anticancer agents 
(16, 5, 19).  9-Nitrocamptothecin (9NC) is an orally administered camptothecin analogue 
(21, 35, 48).  In vitro and in vivo preclinical studies suggest protracted administration of 
low doses of camptothecin analogues produce greater anti-tumor activity than does less 
frequent administration of higher doses (9, 49).  Consistent with the mechanism of action 
of camptothecin analogues being cell-cycle-specific, prolonged exposures may be more 
effective than shorter exposures (17, 7, 15).  Daily oral administration of 9NC may mimic 
a protracted parenteral schedule, achieve prolonged exposure, and maximize patient 
convenience.  However, oral administration of camptothecin analogues, has been 
characterized by extensive inter-and intra-patient variability in bioavailability and may be 
clinically significant (51, 12, 8, 24, 23).   
9NC is partially converted to a 9-aminocamptothecin (9AC) active-metabolite (9, 
51, 1).  9NC and 9AC both occur in equilibrium between the active-lactone and inactive-
hydroxy acid forms (28, 29, 44).  In our previous pharmacokinetic studies of 9NC and its 
9AC metabolite, we found at any given dose of 9NC there was 4 to 16-fold variability in 
9NC and 9AC exposure (33).  The method of dose calculation (i.e., mg versus mg/m2) 
did not reduce the variability in drug exposure.  It is currently unclear whether the 
pharmacokinetic variability of 9NC and 9AC is due to variable gastrointestinal 
absorption, hepatic metabolism, and/or biliary elimination. 
 As is standard for orally administered drugs, the effect of food on the oral 
absorption and bioavailability of drugs should be evaluated (51, 12, 8, 24, 23).  Schoffski 
and colleagues evaluated the effect of food intake on the bioavailability of orally 
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administered 9NC in a randomized crossover study in which patients were administered 
9NC with and without food (43).  Because administration of 9NC with food resulted in a 
50% reduction in the exposure of 9NC, the authors concluded that 9NC should be 
administered under fasting conditions.  However, the study did not evaluate the 
disposition of 9AC which has ranged from 20% to 200% of the 9NC exposure in patients.  
Thus, we evaluated the disposition of 9NC and 9AC after administration of 9NC with and 
without a standard meal in a randomized cross over study. 
 
5.3 PATIENTS AND METHODS 
Patient Selection 
Eligible patients were required to have an advanced solid malignancy confirmed 
on histology and refractory to standard treatment; age greater than or equal to 18 years; 
measurable or evaluable disease; ECOG performance status (PS) < 2; and adequate organ 
function as defined by absolute neutrophil count (ANC) >1500/mm
3
, platelet count 
>100,000/mm
3
, hemoglobin > 9 gm/dl; creatinine clearance > 50 ml/minute; serum 
bilirubin within 1.5 X institutional normal limits (INL); and ALT and AST < 3 times 
INL.  In addition, patients were required to be able to swallow oral medication, and have 
adequate venous access to permit repeat blood sampling.  Patients with malabsorption 
syndrome or gastric or small bowel resection were excluded, as were pregnant or nursing 
women.  Patients of childbearing age were required to practice contraception.  Patients 
were required to have at least a 4-week interval from all previous surgery, chemotherapy, 
and radiotherapy prior to study initiation.  All patients gave written informed consent 
approved by the Institutional Review Boards at the Albert Einstein College of Medicine 
(AECOM) and Montefiore Medical Center (MMC).   
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Study Design  
This trial was a two-period crossover design with patients randomized to receive 
the study medication either in the "fasting” or the “fed” state (period 1).  They received 
one dose of the drug on the first day.  After a 72-hour washout, the patients were crossed 
over to the other arm (period 2).  After a repeat washout period of at least 72 hours, 
patients were entered on to period 3 of the study.  This entailed ingestion of 9NC for 5 
days on a weekly basis for a period of eight weeks.  It was an open-label, single-arm trial 
conducted at the AECOM and MMC from December 2002 to May 2004.   
 
Study Drugs and Administration  
9NC was supplied by Supergen, Inc (Dublin, CA) as 1.25 and 0.5 mg tablets.  The 
drug was stored in the outpatient pharmacy in a secure, limited access area at 15-25°C 
(59-77ºF) in a dry place protected from light.  The dose was calculated as 1.5 mg/m
2
 and 
rounded to the closest multiple of 0.25 mg.  9NC was administered by the study staff 
under supervision during periods 1 and 2.  The standard meal consisted of 2 eggs, 8 
ounces (oz) of orange juice, buttered toast, 8 oz of milk, and 4 oz of hash brown potatoes.  
During period 3, the patient was given a five-day supply each week and the drug was self 
administered at home.  Each dose was administered with six to eight oz of an acidic 
beverage, such as orange juice (51).  During the “fasting” period and in period 3, the dose 
of 9-NC was preceded and followed by a 2-hour fasting period.  During the “fed” period, 
the 9-NC was swallowed within 5 minutes of ingestion of the standard meal.  The study 
drug administration was repeated every 7 days, until disease progression or development 
of intolerable toxicities.  Objective disease evaluations were performed at the end of eight 
weeks of period 3.   
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Patient Evaluation and Follow-up 
All patients underwent a complete medical history, physical examination, and 
performance status evaluation within 2 weeks of entry into the study, prior to drug 
administration for periods 1 and 2, and at the start of every week of therapy during period 
3.  Complete blood count with differential (CBC), a complete chemistry profile, and a 
urinalysis were obtained with each physical examination.  Imaging studies of chest, 
abdomen and pelvis were performed as indicated for tumor measurements within 4 weeks 
of initiation of study drugs.  Toxicity assessments were performed weekly.  Tumor 
assessment was performed after every eight weeks of weekly therapy using the World 
Health Organization criteria.   
A complete response (CR) was defined as disappearance of all measurable lesions 
at two examinations at least 4 weeks apart.  Partial response (PR), stable disease (SD), 
and progressive disease (PD) were defined as >50% decrease, <25% decrease or <25% 
increase, and >25% increase in the sum of bi-dimensional measurements of tumor 
burden, respectively.  Appearance of any new lesion constituted disease progression.  
Response duration was the time from documentation of first response to the first date of 
objective progression of disease.  After removal from study, all patients underwent 
follow-up examinations and toxicity assessments every 2 months until death.   
 
Study Endpoints and Dose Modifications 
The primary and secondary endpoints of the study were to determine the effect 
of food on the oral absorption of 9NC and 9AC and to characterize toxicities, 
respectively.  The starting dose was 1.5 mg/m
2
 for all patients and for all periods 1-3.  If a 
patient tolerated the first four weeks of study drug without any grade 2 toxicities, the dose 
could be escalated to 2 mg/m
2
 for all subsequent administrations.  Appearance of grade 2 
thrombocytopenia, grade 3 neutropenia, grade 3 non-hematologic toxicity, or grades1-2 
chemical cystitis, necessitated dose reduction by one level, i.e. 1.5 mg/m
2
 administered 
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for 4 days every week.  Appearance of grade 3 thrombocytopenia, grade 4 neutropenia, 
grade 4 non-hematologic toxicity, or grade 3 chemical cystitis, necessitated dose 
reduction by 2 levels, i.e., 1 mg/m
2
 administered for 4 days every week.  Grade 4 
chemical cystitis required discontinuation of protocol therapy.  All toxicities were graded 
based on the Expanded NCI CTC version 2.0.   
 
Sample Collection and Preparation 
Blood samples (5 mL) were obtained after administration of 9NC, on an empty 
stomach or with a standard meal, prior to administration and at 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 
6 h, 8 h, 12 h, and 24 h after administration.  Blood was placed into heparinized tubes and 
immediately centrifuged at 1200 x g at 4ºC for 5 min.  The resulting plasma was 
processed via methanolic extraction to measure 9NC and 9AC total as previously 
described (51, 8, 33). 
 
Mass Spectrometric Assay 
In previous studies, 9NC was measured indirectly by conversion to 9AC via a 
logistically difficult iron-reduction process [33, 47].  To overcome these issues, we 
developed a highly sensitive and specific HPLC-tandem mass spectrometric assay to 
simultaneously and directly quantitate 9NC and 9AC total concentrations in human 
plasma.  Our assay was modified from the assay developed by Xenobiotics Laboratories, 
Inc. (Plainsboro, NJ) (32).  
Chromatography was performed on a Waters Alliance 2695 system (Milford, MA, 
USA) and a Phenomenex Luna C18 (5 µm, 150 x 2 mm) analytical column (Torrance, 
CA).  The isocratic mobile phase, consisting of 0.1% formic acid in acetonitrile: 50 µM 
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ammonium acetate buffer (40:60, v/v), was pumped at 0.2 mL/min, and the run time was 
7 min.  Mass detection was carried out using a Waters Quattro micro triple-stage, bench 
top quadrupole mass spectrometer with electrospray ionization in positive-ion, multiple 
reaction mode (MRM).  The settings of the mass spectrometer were as follows: capillary 
voltage 4 kV; cone voltage 40 V; source temperature 120°C; and desolvation temperature 
450°C.  The cone and desolvation gas flows were 110 and 550 L/h, respectively.  The 
collision voltage was 30 V.  9NC, 9AC, and camptothecin ions monitored in MRM scans 
were m/z 394 > 350, 364 > 320, and 349 > 304, respectively.  The LC system and mass 
spectrometer were controlled by Waters Mass Lynx software (version 4.0), and data were 
collected with the same software.  9NC, 9AC, and camptothecin eluted at 5.04, 2.70, and 
3.83 min, respectively.  The assay was linear from 0.5 ng/mL to 1000 ng/mL for both 
9NC and 9AC. 
 
Pharmacokinetic Analysis   
Compartmental pharmacokinetic analysis of 9NC and 9AC was performed using 
ADAPT II (6).  The estimation procedure and variance model used in the compartmental 
pharmacokinetic analysis was maximum likelihood estimation and linear models for the 
variance of the additive errors, respectively.  Different pharmacokinetic model structures 
were considered to characterize the disposition of 9NC and 9AC in plasma.  In the model 
development, one- and two-compartments models were evaluated to describe the 
systemic disposition of 9NC and 9AC.  In addition, we evaluated the use of single and 
separate apparent volumes of the central compartments for 9NC and 9AC.  Akaike’s 
Information Criteria (AIC), estimated error of the model parameters, and residual 
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analysis were used to select the model structure maximizing the fit accuracy while 
simultaneously minimizing the number of model parameters.  The final model structure 
used for the pharmacokinetic analysis produced identifiable parameters in all patients as 
described below. 
 A linear PK model describing oral administration of 9NC was simultaneously fit 
to 9NC and 9AC concentration versus time profiles. The model contained one-
compartment for 9NC systemic disposition, subsequent conversion of 9NC to 9AC, and 
one-compartment for 9AC systemic disposition.  Individual parameters estimated were 
the absorption rate constant (ka), the lag time prior to absorption (τ), the apparent volume 
of the central compartment (Vc/F), the rate constant describing conversion of 9NC to 
9AC (k12), and the elimination rate constants for 9NC (k10) and 9AC (k20).  The apparent 
clearance of 9NC (9NC CL/F) and 9AC (9AC CL/F) total were calculated using standard 
equations [i.e. Vc/F x (k10 + k12) and Vc/F x k20, respectively] [6, 40].  The area under the 
9NC and 9AC plasma concentration versus time curves (9NC AUC0-24 h and 9AC AUC0-
24 h) from zero to 24 hours were calculated using the log trapezoidal method by simulating 
the concentration versus time data from each patient using patient-specific parameters 
(6).  Effect of food on the disposition of 9NC and 9AC was evaluated as the ratio of AUC 
with food (AUCfood) to AUC without food (AUCfasting).  
 
Statistical Analysis 
 
Statistical analysis was performed comparing all parameters for 9NC and 9AC 
after administration with and without food.  The mean and standard deviation for all 
parameters were calculated and the values were evaluated for normalcy.  The log of the 
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values were used for the non-parametric Wilcoxon signed rank test.  All analysis was 
performed using the SPSS version 10.0 (Chicago, IL).   
 
 
5.4 RESULTS 
Patient characteristics  
Sixteen patients with a median (range) age of 62 (29-85) years and ECOG PS of 1 
(15 pts) or 2 (1 pt) were enrolled onto this trial (Table 1).  All patients had received prior 
treatment with 3(1-4) [median (range)] chemotherapy regimens.  The primary sites 
included patients with colorectal (n = 6), lung (n = 2), and others (n = 8).   
 
Table 1: Patient Characteristics 
 
  
Patient characteristics       # of patients 
 
Patients enrolled     16 
 Males        5 
 Females     11 
Age - median (range), years   62 (29-85) 
ECOG performance status 
 1      15 
 2        1 
# Prior chemotherapy regimens 
1      2 
 2      3 
 3      8 
 4      3 
Primary site 
 Colorectal     6 
 NSCLC     2 
 Others*      8 
Evaluable for PK     12 
 
 
*Other sites (8): pancreas (1), esophageal (1), ovarian (1), cervix (1), endometrial (1), 
adenocarcinoma of unknown primary (1), thyroid (1) and head and neck (1) 
Abbreviation: ECOG, Eastern Cooperative Oncology Group; #, number; PK, pharmacokinetics 
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Pharmacokinetic studies were performed in 16 patients.  Samples from the first 
five patients were inadequate for analysis due to a storage malfunction.  One patient had 
pharmacokinetic studies performed after administration of 9NC with food and then 
withdrew from the study prior to the crossover to administration of 9NC without food.  
One patient only had blood samples obtained from 0 to 6 h after administration of 9NC 
with and without food and thus an AUC from 0 to 24 h could not be determined.  In 2 
patients administered 9NC with food, AUC from 0 to 24 h could not be estimated due to 
a limited number of samples from 1 to 6 h after administration.  Thus, complete sets of 
plasma samples were available for 9 and 11 patients after administration of 9NC with 
food and without food, respectively.  
 
 
Pharmacokinetics 
 Pharmacokinetics studies of 9NC and 9AC were available for 9 and 11 patients 
after administration of 9NC with food and without food, respectively.  9NC and 9AC 
pharmacokinetic parameters after administration of 9NC with a standard meal and under 
fasting conditions are presented in Table 2.  9NC and 9AC AUCs after administration of 
9NC with food and under fasting conditions are presented in Figure 1 and Figure 2.  The 
ratio of 9AC AUC to 9NC AUC after administration of 9NC with food and under fasting 
conditions is presented in Figure 3.   
 The mean ± SD of the ratio of 9NC AUCfood to 9NC AUCfasting in individual 
patients was 0.67 ± 0.22.   The mean ± SD of the ratio of 9AC AUCfood to 9AC AUCfasting 
in individual patients was 1.14 ± 0.61.  The mean ± SD of the ratio of 9AC AUCfood / 
AUCfasting to 9NC AUCfood  / AUCfasting in individual patients was 1.80 ± 0.99. 
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Table 2.  9NC and 9AC Pharmacokinetic Parameters after Administration of 9NC 
with Food and Under Fasting Conditions 
 
 
Parameters Units 
Food   
Mean ± SD 
(n = 9) 
Fasting   
Mean ± SD 
(n = 11) 
9NC    
ka h-1 0.12  ±  0.11a 1.45  ±  1.25a 
τ h 0.26  ±  0.31 0.14  ±  0.27 
k13 h-1 0.21  ±  0.17 0.12  ±  0.18 
ke h-1 0.23  ±  0.38 0.26  ±  212 
Vd L 16.0  ±  12.5 26.7  ±  23.9 
CL/F L/h/m2 2.1 ± 1.9 1.6 ± 1.3 
Cmax ng/mL 28.3  ±  14.1a 54.7  ±  27.2a 
Tmax h 5.47  ±  1.45 a 3.61  ±  2.95 a 
AUC0-24 ng/ml·h 330  ±  182 a 569  ±  362 a 
9AC    
k30 h-1 0.33  ±  0.56 0.11  ±  0.11 
CL/F L/h/m2 2.2 ± 1.6 2.6 ± 2.5 
Cmax ng/mL 15.1  ±  5.6 18.8  ±  11.9 
Tmax h 13.3  ±  6.4 12.3  ±  6.6 
AUC0-24 ng/ml·h 244  ±  60 291  ±  195 
a Values for 9NC administered under fasting conditions are significantly different (P < 0.05) than 
for 9NC administered with food. 
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Figure 1. 9NC AUCs in individual patients when 9NC was administered with food (n = 9) and 
under fasting conditions (n = 11).  Individual data points are presented by ○ and data within a 
single patient are connected by a solid line.  The mean value for each group is presented by ▲ 
and connected by a dashed line. 
 
 
 
 
 
 
 
 
 
Figure 2. 9AC AUCs in individual patients when 9NC was administered with food (n = 9) and 
under fasting conditions (n = 11).  Individual data points are presented by ○ and data within a 
single patient are connected by a solid line.  The mean value for each group is presented by ▲ 
and connected by a dashed line. 
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Figure 3. The ratio of 9AC AUC to 9NC AUC patients when 9NC was administered with food (n 
= 9) and under fasting conditions (n = 11).  Individual data points are presented by ○ and data 
within a single patient are connected by a solid line.  The mean value for each group is presented 
by ▲ and connected by a dashed line. 
 
Toxicities 
Overall, non-hematologic toxicity was more common than hematologic toxicity 
(Table 3 and Table 4).  The most common non-hematologic toxicity observed was 
nausea, which occurred in 8 patients.  Other grade 2 toxicities included vomiting, 
diarrhea, fatigue, urinary infection (UTI), and anorexia.  Skin rash was observed in 2 
patients and resulted in interruption of therapy for a week until the spontaneous 
resolution of the rash.  This was a diffuse, macular-papular rash, more prominent on the 
trunk and the back, associated with itching, and resolved within 1-2 weeks, and did not 
reappear with the reintroduction of the drug at a lower dose.  Also observed were renal 
changes as evidenced by hematuria, proteinurea, dysuria and UTI.  One patient, a 64-year 
woman with metastatic colon cancer, had grade 3 diabetic nephropathy-induced 
proteinurea at baseline, which did not appear to worsen during administration of 9NC.   
0.0
0.5
1.0
1.5
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9AC AUC  
to  
9NC AUC 
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Table 3. Non-hematologic toxicities (by number of patients) 
 
Toxicity (CTC)      Grade 1       Grade 2       Grade 3      Grade 4 
 
Nausea   5  1  2    
Vomiting  2    2    
Diarrhea  1  3  2    
Fatigue   5  2  2    
Anorexia  3    1    
Mucositis    1      
Dysuria     2      
Proteinuria  4        
Hematuria  4  3      
UTI     2  1    
Skin rash    2      
______________________________________________________________________________ 
 
Abbreviation: UTI, urinary tract infection; CTC, common toxicity criteria version 2.0 
 
 
Table 4. Hematologic toxicities (by number of patients) 
______________________________________________________________________________ 
Toxicity (CTC)       Grade 1       Grade 2       Grade 3       Grade 4  
 
Neutropenia  2  1  1  2  
Febrile neutropenia     2    
Anemia   3  6  3    
Thrombocytopenia 3  1      
 
Abbreviation: CTC, common toxicity criteria version 2.0 
 
Grade 3-4 neutropenia was observed in 3 patients (Table 4).  Two patients 
experienced febrile neutropenia.  Both patients recovered with appropriate antibiotics and 
without any sequelae.  The median (interquartile range) of the nadir neutrophil count was 
2400/mm
3
 (1200-3600/mm
3
).  One patient experienced grade 2 thrombocytopenia.  Grade 
3 anemia, requiring transfusion, occurred in 3 patients.  One of these patients was a 
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patient with metastatic colon cancer that developed episodes of gastrointestinal bleeding 
which contributed to the anemia.   
 
Antitumor Response 
Although response evaluation was not the primary end point of this study, 13 
patients were evaluable for objective response.  Of the 3 patients not evaluable for 
response, one was withdrawn from study after only 4 weeks of therapy because of 
cystitis, and 2 patients withdrew consent and did not complete the planned 8 weeks of 
therapy.  There was no objective tumor response observed.  Three patients (lung, 
unknown primary, and colon) had stable disease for a period of 8 weeks.   
 
 
 
5.5 DISCUSSION 
 
 
 Previous studies evaluated the oral bioavailability of camptothecin analogues 
administered with and without food (24, 23, 31, 22, 13).  Schoffski and colleagues 
reported that the oral bioavailability of 9NC was found to be strongly dependent on the 
timing of food intake (43).  The plasma exposure of 9NC was approximately half when 
administered with food as compared to fasting conditions.  However, that study did not 
evaluate the disposition of 9AC, the major metabolite of 9NC, which has ranged from 
20% to 200% of the 9NC exposure in patients (33, 10, 34, 13).  Thus, our study is the 
first report evaluating the disposition of 9NC and 9AC when administered with and 
without food.  In our study, food inhibited the oral absorption of 9NC with a mean ± SD 
ratio of 9NC AUCfood to 9NC AUCfasting of 0.67 ± 0.22.  Administration of 9NC with 
food did not alter the exposure of 9AC with a mean ± SD ratio of 9AC AUCfood to 9AC 
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AUCfasting of 1.14 ± 0.61.  However, the effect of food on the absorption of 9NC is highly 
variable and is less consistent for 9AC compared to 9NC.  The mechanism associated 
with differential effects of food on the exposure of 9NC and 9AC are currently unclear.  
One potential explanation is that 9NC is converted to 9AC in the gastrointestinal tract, in 
addition to the liver, and food does not alter the absorption of 9AC (10, 34, 11).  The 
differential effects of food on 9NC and 9AC is significant because the development of 
9AC was stopped due to lack of efficacy and significant toxicity in clinical trials (21, 36, 
50).  Thus, to maximize the exposure of 9NC relative to 9AC, 9NC should be 
administered orally without food (38). 
The results from our study are similar to previous studies evaluating the 
pharmacokinetics of 9NC when administered under fasting conditions (43, 10, 34, 14, 42, 
38). For example, the ka in our study and the study by Schoemaker et.al. were 1.4 ± 1.2 h-
1 and 0.8 h-1, respectively (42).  In addition, the CL/F of 9NC in our study and the study 
by Schoemaker et.al. were 1.6 ± 1.4 L/h/m2 and 1.7 L/h, respectively.  In the study by 
Raymond et.al., in which 9NC was administered at 1.5 mg/m2 x 1, the 9NC and 9AC 
AUC0-24 h were 231 ± 137 ng/mL·hr and 36.9 ± 28.5 ng/mL·hr, respectively, which are 
similar to the 9NC and 9AC AUC0-24 h in this current study and our prior phase I study 
after administration of 9NC at 2.0 mg/m2 (38).  In addition, the concentration versus time 
profiles of 9NC and 9AC were representative of delayed absorption, and the 9AC 
concentrations increase over the 24-hour period. 
9NC is an orally administered camptothecin analogue with significant interpatient 
variability in drug disposition (33, 34, 14, 42, 38).  The interpatient variability in 9NC 
was similar when administered with (8.0-fold) and without food (6.2-fold).  In addition, 
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the interpatient variability in 9AC was similar when administered with (3.9-fold) and 
without (6.4-fold) food.  Thus, there is still a need to identify factors responsible for the 
variability and develop techniques to reduce the interpatient variability in the exposure of 
9NC and 9AC (23, 33, 43,20).  The interpatient variability in the exposure of 9NC and 
9AC may be explained by variability in the expression and function of the ATP-binding 
cassette (ABC) transporters (23, 46,37,30,26,3,18).  The ABC transporters are membrane 
proteins that modulate a wide variety of substrates, including metabolic products, lipids 
and sterols, and drugs, across extra-and intracellular membranes, such as the 
gastrointestinal tract (25,45).  ABC transporters have been reported to modulate 
camptothecin analogues and are associated with camptothecin resistance in cancer cell 
lines (46,37,30,26,3,18).  Fumitremorgin C, a potent and specific inhibitor of ABCG2, 
has been evaluated as a way to increase the absolute oral bioavailability and reduce 
interpatient variability in oral absorption of camptothecins analogues (2).  Future studies 
evaluating the effects of fumitremorgin C on 9NC should be performed. 
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6.0 
CHAPTER 6: 
 
 
 
Disposition of 9-Nitrocamptothecin and its 9-Aminocamptothecin Metabolite 
In relation to ABC Transporter Genotypes 
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6.1 ABSTRACT 
Purpose: The source of the pharmacokinetic variability of 9-nitrocamptothecin (9NC) 
and its 9-aminocamptothecin (9AC) metabolite is unknown. ATP-binding cassette (ABC) 
transporters have been reported to modulate camptothecin analogues, are associated with 
camptothecin resistance, and might also affect 9NC and 9AC pharmacokinetics.  The aim 
of this study was to evaluate the functional consequence of known single nucleotide 
polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the 
pharmacokinetic disposition of 9NC and 9AC.   
Methods: Pharmacokinetic and genotyping studies were performed in 55 patients as part 
of  two phase I studies of 9NC in patients with refractory solid tumors, a phase II study of 
9NC in patients with advanced colon cancer, and a study evaluating the disposition of 
9NC after administration of a single dose under fasting conditions.  DNA was isolated 
from plasma and analyzed for variants in ABCB1, ABCC2, and ABCG2 genes.  The 
ABCB1 1236C>T, ABCB1 2677G>T/A, ABCB1 3435C>T, ABCC2 3972C>T, and 
ABCG2 421C>A variants were analyzed using Pyrosequencing. 
Results: The ABCG2 421C>A genotype significantly affected the pharmacokinetics of 
9AC.  The mean 9AC lactone AUC/dose for wild-type (n = 25) and heterozygous (n = 2) 
patients were 14.3 ng/mL·h and 51.1 ng/mL·h, respectively (P = 0.032).  The mean ± SD 
9AC total AUC/dose for wild-type (n = 39) and heterozygous (n = 3) patients were 91.9 ± 
78.3 ng/mL·h and 129.0 ± 90.5 ng/mL·h, respectively (P = 0.40).  9NC and 9AC 
disposition were not significantly influenced by variants in ABCB1, ABCC2, and ABCG2, 
and ABCB1 and ABCC2, respectively (P > 0.05). 
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Conclusion: These findings suggest that inter-individual variability in 9AC disposition, 
but not 9NC, may be influenced, in part, by ABCG2 genotype.   
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6.2 INTRODUCTION 
Several studies have reported significant interpatient variability in the 
pharmacokinetics of some orally administered drugs, including camptothecin analogues 
(1-7).  In our previous pharmacokinetic studies of 9-nitrocamptothecin (9NC, rubitecan, 
RFS2000) and its 9-aminocamptothecin (9AC) metabolite, we found that at any given 
dose of 9NC there was 4 to 16-fold variability in 9NC and 9AC exposure, and that no 
relationship between dose and AUC was detectable (8).  The method of dose calculation 
(i.e., mg versus mg/m2) did not affect the variability in 9NC and 9AC exposure after 
administration of 9NC at doses ranging from 1.7 to 2.7 mg/m2.  It is currently unclear 
whether the pharmacokinetic variability of 9NC and 9AC is due to variable 
gastrointestinal absorption, hepatic metabolism, and/or biliary elimination (8-10). 
 In our previous studies with 9NC, most of the drug remained in the 9NC form, 
with a mean 9NC to 9AC ratio of 4 to 1, which is consistent with the previous studies (6-
8). The fact that most of the administered drug remains in the 9NC form is important 
because the development of 9AC was stopped due to lack of efficacy (11-13). However, 
our studies also demonstrated highly variable conversion of 9NC to 9AC, as 2 patients 
had undetectable 9AC concentrations and 4 patients had higher exposures to 9AC than to 
9NC (8).   
The ATP-binding cassette (ABC) transporter superfamily contains membrane 
proteins that transport a wide variety of substrates across extra-and intracellular 
membranes.  These substrates include metabolic products, lipids and sterols, and drugs 
(14,15).  Over-expression of certain ABC transporters occurs in cancer cell lines and 
tumors that are multidrug resistant (16-20).  Phylogenetic analysis has identified 48 
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human ABC transporters and assigned them to seven distinct subfamilies of proteins (21).  
ABC transporters have been reported to alter the pharmacokinetics of camptothecin 
analogues and are associated with camptothecin resistance (22,23). 
 ABCB1 (PGP/MDR1) was the first human ABC transporter to be cloned and also 
to be identified as conferring an MDR phenotype to cancer cells (16-22).  ABCB1 is 
expressed in the kidney, liver, intestine, adrenal gland, blood brain barrier and 
hematopoetic stem cells (20). ABCB1 transports colchicine, etoposide, doxorubicin, and 
vinblastine, as well as lipids and steroids.  The effects of three single nucleotide 
polymorphisms (SNPs) of ABCB1 (1236C>T, 3435C>T, 2677G>A/T) have been 
evaluated in preclinical and clinical trials (23).  ABCC2 (MRP2/cMOAT) is expressed in 
canalicular cells in the liver (24,25).  It functions as an important efflux pump that 
transports organic ions from the liver to the bile.  This may especially important for 
drugs, such as 9NC, that undergo primarily biliary elimination (8).  The ABCG2 gene 
(formally known as the MXR/BCRP/ABCP) encodes a half transporter with a nucleotide-
binding fold-transmembrane domain orientation (16,24).  ABCG2 is expressed in stem 
cells, the placenta, and the intestine (26,27).  ABCG2-associated proteins transport 
mitoxantrone, methotrexate, and camptothecin analogues such as topotecan, 
diflomotecan, and SN-38 (16,28,29).   
The aim of this study was to perform an exploratory and retrospective evaluation 
of the functional consequence of known SNPs in the ABCB1, ABCC2, and ABCG2 genes 
on the pharmacokinetic disposition of 9NC and its 9AC metabolite.  Pharmacokinetic 
studies of 9NC and 9AC were carried out and DNA samples were obtained in two phase I 
studies of 9NC in patients with refractory solid tumors, a phase II study of 9NC in 
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patients with advanced colon cancer, and a study evaluating the disposition of 9NC after 
administration of a single-dose under fasting conditions. 
 
6.3 PATIENTS AND METHODS 
Patients and Treatment 
All patients were deceased prior to the initiation of the genotyping studies.  Thus, 
the genotyping studies were approved by the Committee for Oversight of Research 
Involving the Dead at UPMC.  For the pharmacokinetic and clinical studies written 
informed consent, approved by the Institutional Review board of the University of 
Pittsburgh Medical Center (UMPC), was obtained from all patients before they entered 
each study.  The eligible patients for the Phase I studies and single dose pharmacokinetic 
study were 18 years of age or older and had a histologically or cytologically confirmed 
malignancy for which no curative or effective therapy was available.  Other eligibility 
criteria included an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 
2 and adequate bone marrow, hepatic, and renal function defined as: absolute neutrophil 
count (ANC) ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; total bilirubin ≤ 1.5 x upper limit of 
the institutional normal (ULN) range; aspartate aminotransferase (AST) ≤ 1.5 x ULN if 
liver metastases were not present and ≤ 4 x ULN if liver metastases were present; and the 
absence of microscopic hematuria.  Prior treatment with camptothecin analogues, except 
9NC, was permitted.  
Patients eligible for the phase II study had histologically or cytologically 
confirmed advanced colon carcinoma with measurable disease that had failed to respond 
or relapsed after receiving at least one prior 5-fluorouracil-based chemotherapy regimen 
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for advanced disease or had evidence of metastatic disease within 6 months of 
completion of adjuvant therapy.  Other eligibility criteria included an ECOG performance 
status ≤ 2 and adequate bone marrow, hepatic, and renal function defined as:  absolute 
neutrophil count (ANC) ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; hemoglobin > 10 g/dl; 
total bilirubin ≤ 2.0 mg/dL; AST and ALT ≤ 3 x ULN if liver metastases were not present 
and ≤ 5 x ULN if liver metastases were present; and serum creatinine ≤ 2.0 mg/dL.   
Patients with hematuria and those that had previously been treated with 9NC or any other 
camptothecin analogue were excluded from the Phase II study.   
 
Dosage and Administration 
9NC was supplied by the manufacturer, Supergen Inc. (Dublin, CA), as a 
crystalline powder in hard gelatin capsules that contained active drug and lactose 
excipient.  The capsule strengths were 0.5 mg and 1.25 mg.  All doses of 9NC were 
rounded to the nearest 0.25 mg.  9NC was administered orally on an empty stomach with 
an acidic beverage (e.g. orange juice, cola) (20,21).  Patients were also instructed to drink 
2 to 3 L of fluid per day. 
Pharmacokinetic studies of 9NC and 9AC were performed as part each study.  In 
the phase I studies, intermittent schedules of 9NC were evaluated.  The phase I study 
evaluating schedule A was completed prior to the initiation of schedule B.  On schedule 
A, 9NC was administered orally at 2.0, 2.4, and 2.7 mg/m2/d for 5 days per week for 2 
consecutive weeks and repeated every 4 weeks (one cycle). On schedule B, 9NC was 
administered orally at 1.7 and 2.4 mg/m2/d for 14 days and repeated every 4 weeks (one 
cycle).  In the phase II study, 9NC was administered at 1.5 mg/m2/d for 5 days per week 
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for 8 weeks (one cycle).  In the single-dose study, the pharmacokinetics of 9NC and 9AC 
were also evaluated after administration of 9NC at 1.5 mg/m2 under fasting conditions.  
For all studies, patient diaries and interviews were used as documentation of 9NC 
administration.   
 
Sample Collection and Preparation. 
On schedules A and B of the phase I studies and the phase II study, serial blood 
samples for pharmacokinetic analysis were obtained on day 1.  For each pharmacokinetic 
study day, blood samples (5 mL) were obtained before administration of 9NC, and 0.25, 
0.5, 1, 2, 3, 6, 8, and 24 h after administration.  On the single-dose pharmacokinetic 
study, blood samples (5 mL) were obtained before administration of 9NC, and 5 min, 
0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12 h, 24, and 48 h after administration.    
In all studies, blood was collected in heparinized tubes and centrifuged within 5 
min at 1200 x g at 4ºC for 5 min.  In the Phase I and II studies, the resulting plasma 
sample was then processed immediately using solid phase extraction in order to separate 
the lactone and hydroxy acid forms of 9NC and 9AC as previously described (8).  In the 
single-dose pharmacokinetic study, the plasma was processed via methanolic extraction 
to measure 9NC and 9AC total as previously described (6,7,8,13). 
 
Analytical Assays 
In the phase I and II studies, the 9NC and 9AC lactone and total (sum of lactone 
plus hydroxyl acid) plasma concentrations were measured using an HPLC assay with 
fluorescence detection as described previously (8). Because 9NC lactone and hydroxy 
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acid are not highly fluorescent, 9NC lactone and total concentrations were measured by 
chemically reducing 9NC to 9AC.  The concentration of 9NC was calculated by 
subtracting the concentration of 9AC from the concentration of 9NC plus 9AC after the 
conversion of 9NC to 9AC using iron reduction.  
 The HPLC system consisted of a Waters 2695 separation module (Waters, Inc. 
Milford, MA), a C18 reverse column (Ultrasphere 5 μm ODS 4.6 x 250 mm, Beckman 
Coulter, Inc., Fullerton, CA), and a C18 guard column (Brownlee C18 7 μm, 15 x 3.2 
mm, PerkinElmer Corp., Norwalk, CT).  Samples were injected by an autosampler set at 
4° C.  The isocratic mobile phase consisted of methanol; acetonitrile; ammonium acetate 
(10:23:97, v/v/v), pH 5.5, at a flow rate of 1.0 mL/min.  Post-column acidification (pH 2 
– 3) was performed using 0.3 M trifluoroacetic acid at 0.3 mL/min (8).  9AC was 
detected by a Waters 474 fluorescence detector with excitation wavelength of 365 nm 
and emission wavelength of 440 nm, 18-nm bandwidth, gain 1000, attenuation 16, with 
RC filter with fast response setting.  MILLENIUM 32 software (Waters, Inc.) was used 
for data collection and analysis.  All the glassware, including the injection vials, was 
treated with 3% surfasil in toluene (Fisher Scientific Inc., Fair Lawn, NJ).  The lower 
limit of quantitation (LLQ) for 9NC lactone and total was 0.5 ng/mL, and the assays were 
linear from 0.5 ng/mL to 100 ng/mL.  The LLQ for 9AC lactone and total was 0.3 ng/mL, 
and the assays were linear from 0.3 ng/mL to 100 ng/mL. 
 9NC and 9AC total plasma concentrations from the single-dose pharmacokinetic 
study were simultaneously and directly quantitated using a highly sensitive and specific 
HPLC-tandem mass spectrometric assay (LC-MS) that we developed (30).  
Chromatography was performed on a Waters Alliance 2695 system (Milford, MA, USA) 
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and a Luna C18 (5 µm, 150 x 2 mm) analytical column (Phenomenex, Torrance, CA).  
The isocratic mobile phase, consisting of 0.1% formic acid in acetonitrile:50 µM 
ammonium acetate buffer (40:60, v/v), was pumped at 0.2 mL/min, and the run time was 
7 min.  Mass detection was carried out using a Waters Quattro micro triple-stage, bench 
top quadrupole mass spectrometer with electrospray ionization in positive-ion, multiple 
reaction mode (MRM).  The settings of the mass spectrometer were as follows: capillary 
voltage 4 kV; cone voltage 40 V; source temperature 120°C; and desolvation temperature 
450°C.  The cone and desolvation gas flows were 110 and 550 L/h, respectively.  The 
collision voltage was 30 V.  9NC, 9AC, and camptothecin internal standard ions 
monitored in MRM scans were m/z 394 > 350, 364 > 320, and 349 > 304, respectively.  
The LC system and mass spectrometer were controlled by Waters MassLynx software 
(version 4.0), and data were collected with the same software.  9NC, 9AC, and 
camptothecin eluted at 5.04, 2.70, and 3.83 min, respectively.  The assay was linear from 
0.5 ng/mL to 1000 ng/mL for both 9NC and 9AC.  The concentrations of 9NC and 9AC 
in plasma as estimated by the HPLC and LC-MS were not directly compared in the same 
sample from this study.  However, in a prior study the plasma concentration of 9NC and 
9AC as estimated by our HPLC and an LC-MS assay developed by Xenobiotics were < 
15% different for all samples.  
 
Pharmacokinetic Analysis 
Compartmental pharmacokinetic analysis of 9NC and 9AC was performed using 
ADAPT II (31).  Parameters were estimated using maximum likelihood estimation.  
Different pharmacokinetic model structures were considered to characterize the 
 181
disposition of 9NC and 9AC in plasma.  In the model development, one- and two-
compartments models were evaluated to describe the plasma disposition of 9NC and 9AC 
lactone and total.  In addition, we evaluated the use of single and separate apparent 
volumes of the central compartments for 9NC and 9AC.  Akaike’s Information Criteria 
was used to select the model.  The final model structure used for the pharmacokinetic 
analysis produced identifiable parameters in all patients. 
 A linear pharmacokinetic model describing oral administration of 9NC was 
simultaneously fit to 9NC and 9AC plasma concentration versus time profiles (31). The 
model contained one-compartment for 9NC plasma disposition, subsequent conversion of 
9NC to 9AC, and one-compartment for 9AC plasma disposition.  The individual 
parameters estimated were the absorption rate constant (ka), the lag time prior to 
absorption (τ), the apparent volume of the central compartment (Vc/F), the rate constant 
describing conversion of 9NC to 9AC (k12), and the elimination rate constants for 9NC 
(k10) and 9AC (k20).  The apparent clearances of 9NC (9NC CL/F) and 9AC (9AC CL/F) 
total and lactone were calculated using standard equations [i.e. Vc/F x (k10 + k12) and 
Vc/F x k20, respectively] (31,32).  The area under the 9NC and 9AC plasma concentration 
versus time curves (9NC AUC0-24 h and 9AC AUC0-24 h) from zero to 24 hours were 
calculated using the log trapezoidal method by simulating the concentration versus time 
data from each patient using patient-specific parameters (31).   
 
Analysis of Genotypes 
DNA was isolated from plasma using the QIAamp DNA Blood midi kit (Qiagen 
Inc, Valencia, CA, USA) following the manufacturers instructions, and analyzed for 
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variants in ABCB1, ABCC2, and ABCG2 genes.  The PCR reactions for ABCB1 
1236C>T, ABCB1 2677G>T/A, ABCB1 3435C>T, ABCC2 3972C>T, and ABCG2 
421C>A were performed using primers and conditions as previously described (33,35). 
Pyrosequencing for all variants was carried out using the Pyrosequencing PSQ hs96A 
instrument and software (Biotage, Uppsala, Sweden), as previously described (27). 
 
Statistical Analysis 
Hardy-Weinberg equilibrium was determined using HWSIM 
(http://krunch.med.yale.edu/hwsim).  Haplotype for ABCB1 was inferred using the 
Polymorphism and Haplotype Analysis Suite (34).  For each of the 3 genes, association 
between genotype (or haplotype pair, in the case of ABCB1) and pharmacokinetic 
variables were evaluated with the exact Kruskal-Wallis test.  Each genotype or haplotype 
pair was treated as a distinct group.  The a priori level of significance was P < 0.05.  
Because this was an exploratory study intended to be hypothesis-generating, no 
corrections for multiple comparisons were made.    
 
6.4 RESULTS 
Patient Characteristics 
Pharmacokinetic and genotyping studies were performed on 55 patients.  Of the 
patients, 33 and 22 were male and female, respectively.  The median (range) for age was 
57 yrs (29 to 85 yrs).  There were 43 Caucasians, 7 African Americans, and 5 Hispanics.  
There was no relationship between genotype and sex or race.   
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Genotype Analysis 
The allele frequencies for ABCB1 1236C>T, ABCC2 3972C>T, and ABCG2 
421C>A are presented in Table 1, and are similar to those previouly reported (35).  No 
patient was homozygous for a mutant allele in ABCG2, which was expected based upon 
previously published frequency data (35,36).  All of the observed allele frequencies were 
in Hardy-Weinberg equilibrium.   
 
 
Table 1. Frequencies for studied variant genes and genotype-phenotype relationships 
 Allele Frequencies 
Polymorphism p>q p q 
   
   
ABCB1 1236 C>T 0.56 0.44 
ABCB1 2677 G>A/T 0.60 0.01/0.39 
ABCB1 3435 C>T 0.49 0.51 
   
ABCC2 3972 C>T 0.71 0.29 
   
ABCG2 421 C>A 0.97 0.03 
   
 
 
ABCB1 haplotypes for the 1236C>T, 3435C>T, and 2677G>A/T SNPs were 
defined using standard criteria (34).  The ABCB1 A/A haplotype consisted of 1236C/C, 
3435C/C, and 2677G/G.  The ABCB1 A/B haplotype consisted of 1236C/T, 3435C/T, 
and 2677G/T.  The ABCB1 A/C haplotype consisted of 1236C/C, 3435C/T, and 
2677G/G.  The ABCB1 B/B haplotype consisted of 1236T/T, 3435T/T, and 2677T/T.  All 
remaining combinations were combined and listed as miscellaneous.   
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Functional Significance of Variant Allele 
Summaries for 9NC and 9AC lactone pharmacokinetics as a function of ABCB1 
haplotype, ABCC2 genotype and ABCG2 genotype are presented in Table 2, Table 3, and 
Table 4 respectively.  We also evaluated the relationship between 9NC and 9AC 
disposition and ABCB1 3435C>T genotype; however, there were no significant 
differences in the pharmacokinetic parameters for this SNP, and thus, only the summaries 
of 9NC and 9AC pharmacokinetics by ABCB haplotype are presented.  The relationship 
between 9NC lactone AUC/Dose and 9NC total AUC/Dose and ABCG2 genotype are 
presented in Figure 1 and Figure 2, respectively.  The relationship between 9AC lactone 
AUC/Dose and 9AC total AUC/Dose and ABCG2 genotype are presented in Figure 3 and 
Figure 4, respectively.   
Among the genetic variants, only the ABCG2 421C>A genotype significantly 
affected the disposition of 9AC lactone.  For ABCG2 421C>A, the mean 9AC lactone 
AUC/dose for wild-type (n = 25) and heterozygous (n = 2) patients were 14.3 ng/mL·h 
and 51.1 ng/mL·h, respectively (P = 0.032).  For ABCG2 421C>A, the mean ± SD 9AC 
total AUC/dose for wild-type (n = 39) and heterozygous (n = 3) patients were 91.9 ± 78.3 
ng/mL·h and 129.0 ± 90.5 ng/mL·h, respectively (P = 0.40).  The disposition of 9AC was 
not significantly influenced by variants in ABCB1 or ABCC2 (P > 0.05).  The disposition 
of 9NC was not significantly influenced by variants in ABCB1, ABCC2, and ABCG2 (P > 
0.05).   
In the phase I study, there was no relationship between response and ABCB1 
haplotype, ABCC2 genotype and ABCG2 genotype or a relationship between toxicity and 
ABCC2 and ABCG2 genotypes.  However, four of the five patients who experienced 
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dose-limiting toxicities (DLT) and also had genotyping studies performed were 
heterozygous for the three SNPs of ABCB1 (1236C>T, 3435C>T, 2677G>A/T) evaluated 
in this study.  The DLT in these four patients were grade 4 neutropenia and 
thrombocytopenia (n = 3) and grade 3 diarrhea (n = 1).  The fifth patient who experienced 
DLT (grade 4 neutropenia and thrombocytopenia) was homozygous wild-type for the 
three SNPs of ABCB1. 
 
Table 2. 9NC and 9AC pharmacokinetics as a function of ABCB1 haplotype  
Parameter Units Haplotype  
A/A 
(Mean ± 
SD) 
Haplotype  
A/B 
(Mean ± 
SD) 
Haplotype  
A/C 
(Mean ± 
SD) 
Haplotype  
B/B 
(Mean ± 
SD) 
Haplotype  
Miscellaneous 
(Mean ± SD) 
       
Lactone  (n = 6) (n = 9) (n = 4) (n = 5) (n = 6) 
9NC 
AUC/Dose 
 
ng/mL·h / 
mg/m2 
148.0 ± 
82.5  
79.0 ± 70.5 34.5 ± 36.9 60.7 ± 84.3 61.6 ± 35.9 
9NC CL/F L/h/m2 29.3 ± 41.1 22.8 ± 25.4 29.2 ± 26.4 36.6 ± 21.8 0.05 ± 0.03 
ka h-1 0.40 ± 0.28 0.17 ± 0.21 0.55 ± 0.87 0.17 ± 0.08 0.18 ± 0.23 
k13 h-1 0.03 ± 0.01 0.04 ± 0.01 0.04 ± 0.02 0.06 ± 0.06 0.05 ± 0.03 
9AC 
AUC/Dose 
 
ng/mL·h / 
mg/m2 
22.7 ± 4.6 22.2 ± 22.6 11.8 ± 11.4 14.8 ± 12.8 12.8 ± 12.4 
9AC CL/F L/h/m2 1.8 ± 2.0 2.7 ± 4.1 10.4 ± 20.1 2.7 ± 3.5 6.8 ± 11.9 
       
Total  (n = 11) (n = 10) (n = 5) (n = 7) (n = 10) 
9NC 
AUC/Dose 
 
ng/mL·h / 
mg/m2 
291.2 ± 
184.2 
252.4 ± 
192.5 
322.5 ± 
328.8 
238.7 ± 
207.7 
236.2 ± 107.0 
9NC CL/F L/h/m2 81.9 ± 88.9 8.1 ± 8.4 5.3 ± 3.9 0.05 ± 0.03 10.0 ± 18.4 
ka h-1 0.42 ± 0.61 0.23 ± 0.27 1.1 ± 1.7 0.48 ± 0.45 0.27 ± 0.21 
k13 h-1 0.04 ± 0.03 0.05 ± 0.05 0.04 ± 0.03 0.05 ± 0.03 0.09 ± 0.01 
9AC 
AUC/Dose 
 
ng/mL·h / 
mg/m2 
94.5 ± 67.8 100.7 ± 
78.7 
54.9 ± 42.3 84.6 ± 91.6 77.6 ± 40.3 
9AC CL/F L/h/m2 1.7 ± 2.4 0.97 ± 0.79 3.4 ± 3.7 1.8 ± 1.6 2.2 ± 2.5 
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Table 3. 9NC and 9AC pharmacokinetics as a function of ABCC2 genotype  
Parameter Units Wt 
Homozygote 
 
(Mean ± SD) 
Heterozygote 
 
 
(Mean ± SD) 
Variant 
Homozygote 
 
(Mean ± SD) 
     
Lactone  (n = 18) (n = 14) (n = 1) 
9NC AUC/Dose ng/mL·h / mg/m2 77.5 ± 72.4 55.9 ± 31.7 15.6 
9NC CL/F L/h/m2 24.6 ± 26.8 17.9 ± 17.2 63.5 
ka h-1 0.22 ± 0.25 0.31 ± 0.49 0.20 
k13 h-1 0.04 ± 0.02 0.04 ± 0.02 0.17 
9AC AUC/Dose ng/mL·h / mg/m2 16.2 ± 17.2 17.6 ± 11.4 30.0 
9AC CL/F L/h/m2 3.5 ± 7.4 4.6 ± 10.9 0.13 
     
Total  (n = 22) (n = 14) (n = 3) 
9NC AUC/Dose ng/mL·h / mg/m2 226.3 ± 148.0 320.0 ± 222.1 190.6 ± 96.4 
9NC CL/F L/h/m2 10.8 ± 16.0 7.7 ± 7.7 25.8 ± 30.8 
ka h-1 0.39 ± 0.52 0.56 ± 0.95 0.57 ± 0.65 
k13 h-1 0.04 ± 0.04 0.04 ± 0.01 0.24 ± 0.35 
9AC AUC/Dose ng/mL·h / mg/m2 82.5 ± 68.6 95.3 ± 74.2 109.2 ± 46.9 
9AC CL/F L/h/m2 1.3 ± 2.0 3.2 ± 4.9 4.1 ± 3.5 
     
 
Table 4. 9NC and 9AC pharmacokinetics as a function of ABCG2 genotype 
Parameter Units Wt 
Homozygote 
 
(Mean ± SD) 
Heterzygote 
 
 
(Mean ± SD) 
    
Lactone  (n = 26) (n = 2) 
9NC AUC/Dose ng/mL·h / mg/m2 58.6 ± 45.1 125.3 
9NC CL/F L/h/m2 22.9 ± 23.3 33.3 
ka h-1 0.26 ± 0.39 0.22 
k13 h-1 0.04 ± 0.02 0.11 
9AC AUC/Dose ng/mL·h / mg/m2 14.3 ± 10.4 a 51.2 a 
9AC CL/F L/h/m2 3.8 ± 9.3 2.7  
    
Total  (n = 39) (n = 3) 
9NC AUC/Dose ng/mL·h / mg/m2 267.8 ± 185.4 201.3 ± 130.3 
9NC CL/F L/h/m2 11.2 ± 15.0  4.1 ± 4.3 
ka h-1 0.44 ± 0.71 0.25 ± 0.34 
k13 h-1 0.05 ± 0.09 0.12 ± 0.09 
9AC AUC/Dose ng/mL·h / mg/m2 91.9 ± 78.3 129.0 ± 90.5 
9AC CL/F L/h/m2 2.2 ± 3.5 2.3 ± 3.0 
    
a P = 0.032
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Figure 1. Relationship between 9NC lactone AUC divided by dose and ABCG2 genotype.  Data 
are presented for C/C (n = 26) and C/A (n = 2) genotyptes.  Individual 9NC lactone AUC data are 
listed for each patient are represented by ○.  Mean data for each group is represented by ▲.   
 
 
 
 
 
 
 
 
 
Figure 2. Relationship between 9NC total AUC divided by dose and ABCG2 genotype.  Data are 
presented for C/C (n = 39) and C/A (n = 3) genotyptes.  Individual 9NC lactone AUC data are 
listed for each patient are represented by ○.  Mean data for each group is represented by ▲.   
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Figure 3. Relationship between 9AC lactone AUC divided by dose and ABCG2 genotype.  Data 
are presented for C/C (n = 26) and C/A (n = 2) genotyptes.  Individual 9NC lactone AUC data are 
listed for each patient are represented by ○.  Mean data for each group is represented by ▲.  The 
9AC lactone AUC  was significantly higher for the C/A genotype compared to the C/C genotype 
(P = 0.032).  
 
 
 
 
 
 
 
 
 
 
Figure 4. Relationship between 9AC total AUC divided by dose and ABCG2 genotype.  Data are 
presented for C/C (n = 39) and C/A (n = 3) genotyptes.  Individual 9NC lactone AUC data are 
listed for each patient are represented by ○.  Mean data for each group is represented by ▲.   
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6.5 DISCUSSION 
 Relatively high pharmacokinetic variability has been reported after intravenous 
and oral administration of camptothecins analogues (1-7,35,36).  Several studies have 
evaluated the relationship between ABC genotypes and disposition of camptothecin 
analogues (5,22,23,35-39).  9NC is an orally administered camptothecin analogue with 
significant interpatient variability in drug disposition (6-10).  This is the first study that 
compares the disposition of 9NC and its 9AC metabolite to the ABCB1, ABCC2, and 
ABCG2 genotypes in patients.  Our findings suggest that interpatient variability in 9AC 
disposition is influenced, in part, by ABCG2; however, in this exploratory study we 
performed many statistical tests, and thus can not rule out the possibility that this 
association is due to chance.  In contrast, there was no evidence for a relationship 
between ABCG2 and the disposition of 9NC, or for relationships between ABCB1 and 
ABCC2 genotypes and the disposition of 9NC or 9AC.  The effects of ABCG2 SNPs on 
the disposition of 9NC and 9AC are consistent with the previous in vitro study reporting 
that wild-type forms of ABCG2 mediates the cellular efflux of 9AC, but not 9NC (37).  
The results of the in vitro study and our clinical study suggest that ABCG2 genetic 
variants may explain the variable ratio of 9NC to 9AC exposure.  However as related to 
the ABCG2 421C>A genotype, it is possible that in patients with the variant allele there 
was also a reduction in the excretion of 9NC that was not detected because 9NC was 
subsequently converted to 9AC.  There was no relationship between ABC genotypes and 
response; however, 4 of 5 patients developing DLTs were heterozygous for the three 
SNPs of ABCB1. 
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The study by Sparreboom and colleagues evaluated the relationship between ABC 
genotypes and diflomotecan pharmacokinetics after IV and oral administration (35).  This 
was the first reported evidence linking the variant ABCG2 421C>A allele to altered drug 
exposure and suggested that interpatient variability in substrate drug effects might be 
influenced, in part, by ABCG2 genotype.  These results are consistent with the results of 
our 9NC study.  Among the genetic variants studied by Sparreboom, only the ABCG2 
421C>A genotype significantly affected the pharmacokinetics of diflomotecan after IV, 
but not oral administration.  In addition, there was no relationship between ABCB1 and 
ABCC2 genotypes and the disposition of diflomotecan after IV or oral administration. 
de Jong and colleagues evaluated ethnic differences in ABCG2 allele frequency 
and the influence on irinotecan disposition (38).  ABCG2 genotyping was performed on 
88 Caucasian Americans, 94 African Americans, 938 African, and 95 Han Chinese, as 
well as in 84 European Caucasians who were treated with irinotecan and underwent 
blood sampling as part of pharmacokinetic studies.  There were significant differences in 
allele frequencies among the populations.  The variant allele was most common in the 
Han Chinese population with a frequency as high as 34%.  In addition, the frequency of 
the variant allele (10.7%) was in line with results in American Caucasians.  The variation 
in allele frequency in various ethnic populations is very interesting, and should be 
evaluated in future studies of 9NC, especially in Han Chinese populations.  The authors 
concluded that the ABCG2 421C>A polymorphism appears to play a limited role in the 
disposition of irinotecan in European Caucasians and that the contribution of this genetic 
variant is obscured by a functional role of other polymorphic proteins.  There was no 
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relationship between allele frequency and race in our study.  However, 43 of the 55 
patients in our study were Caucasian and no patients were Chinese.   
ABCB1 is a known transporter of hydrophobic substrates including drugs such as 
colchicine, etoposide, adriamycin, and vincristine (19-22).  However, consistent with the 
result of our 9NC study, there have been no reports of a functional consequence of 
ABCB1 as related to the disposition of camptothecin analogues (35,38).  Innocenti and 
colleagues reported the first evidence for a functional variant of ABCC2 and its influence 
on interindividual irinotecan pharmacokinetic variability (39).  That study identified 
3972C>T as a variant potentially affecting ABCC2 activity and suggested that ABCC2 
may have a significant impact on clearance of irinotecan.  There was no relationship 
between ABCC2 variant alleles and the disposition of 9NC and 9AC in our study. 
There is a need to perform pharmacogenetic studies of anticancer agents that are 
orally administered and have a steep relationship between exposure and response (i.e., 
antitumor or toxicity) so that factors related to the pharmacokinetic variability may be 
determined (8,36).  It is likely that the contributions of the genetic variants evaluated in 
this study are obscured by the functional role of an undiscovered or unevaluated 
polymorphic protein with a transport or metabolic function (e.g., cytochrome P450) (40).  
This is especially important for 9NC because the enzyme that converts 9NC to its major 
metabolite, 9AC, has not been identified (41,42).  In addition, as new transporters and 
associated genes are discovered, future studies should evaluate the influences of variant 
alleles of these genes and the disposition of 9NC and 9AC and other camptothecin 
analogues, especially in various ethnic populations (38).  Moreover, as number of 
patients undergoing pharmacogenetic studies of 9NC and ABC transporters expands, 
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there is a greater likelihood that patients will be discovered who are homozygous for the 
variant allele and thus may be more likely to experience an alteration in the disposition of 
9NC and 9AC and toxicity and response (35,38,39).  These studies may also explain the 
highly variable response and toxicity associated with 9NC treatment of patients with 
advanced pancreatic cancer and with other camptothecin analogues used in a wide variety 
of tumor types (43,44). 
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CHAPTER 7: 
 
 
 
 
 
Summary and Future Directions for the Development of 9-Nitrocamptothecin 
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7.1 SUMMARY 
9-nitrocamptothecin (9NC) has completed phase III studies in patients with newly 
diagnosed and refractory pancreatic cancer, however the optimal 9NC regimen is unclear.  
The primary objective of this dissertation research was to evaluate the pharmacokinetics, 
pharmacodynamics, and pharmacogenetics of 9NC and its 9AC metabolite in preclinical 
models and in patients as part of phase I and II trails.  Information obtained from 
preclinical and clinical translational studies can greatly add to the understanding of the 
pharmacology of 9NC and allow for the rational design of therapeutic regimens.  To 
address these issues in the development of 9NC we performed preclinical and clinical 
pharmacologic studies of 9NC   
The aim of Chapter 2 was to compare the 9NC and 9AC systemic exposure 
associated with antitumor response in mice bearing human tumor xenografts to those 
reported in a phase I study of 9NC that used the same intermittent schedule as in the 
xenografts studies and use allometric scaling analysis to normalize the data.  The 
responses seen in these xenograft models occurred at systemic exposures that are 
tolerable in adult patients.  These results suggest that the intermittent schedule of 9NC 
may be an active-regimen in patients with colo-rectal cacinoma.  However, there are 
several potential limitations to this study.  The overall lack of 9NC response in patients 
with refractory colon carcinoma raises concerns about the ability of mice bearing human 
colon xenografts to predict 9NC response in humans.  In addition, the relationship 
between 9NC and 9AC exposure and response may be different for specific tumors, and 
thus these types of studies may need to be performed for each tumor type, especially 
pancreatic cancer.  The tumor exposures of anticancer agents in xenografts located on the 
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flank of mice may be different than the exposure in tumors of patients, and thus 
evaluating plasma exposures in mice and man may not be an accurate comparison 
(45,46). 
The pharmacologic goals of Chapters 3 and 4 were to examine the inter- and 
intra-patient pharmacokinetic variability of 9NC and 9AC.  There was significant inter-
and intra-patient variability in the disposition of 9NC and 9AC.  Dosing 9NC on a mg/m2 
basis does not reduce pharmacokinetic variability.  Because no IV formulation of 9NC is 
available it is unclear if the inter- and intra-patient variability in the pharmacokinetics of 
9NC or 9AC is due to gastrointestinal and absorption related factors and/or systemic 
disposition and elimination. 
The aim of Chapter 5 was to evaluate the plasma disposition of 9NC and 9AC 
after administration of 9NC with and without food in a randomized cross over study.  Co-
administration of 9NC with food reduces the oral absorption of 9NC; however there was 
no difference in the exposure of 9AC.  The effect of food on the absorption of 9NC is 
highly variable and is less consistent for 9AC compared to 9NC.  The mechanism 
associated with differential effects of food on the exposure of 9NC and 9AC are currently 
unclear.  One potential explanation is that 9NC is converted to 9AC in the gastrointestinal 
tract, in addition to the liver, and food does not alter the absorption of 9AC.  Additional 
preclinical and clinical studies are needed to identify the mechanism associated with the 
differential effects of food on the disposition of 9NC and 9AC, especially regarding the 
conversion of 9NC to 9AC in the gastrointestinal tract and to identify the location of the 
absorption of 9NC and 9AC. 
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The goal of Chapter 6 was to evaluate the functional consequence of known SNP 
polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the 
pharmacokinetic disposition of 9NC and 9AC.  9NC and 9AC disposition were not 
significantly influenced by variants in ABCB1, ABCC2, and ABCG2, and ABCB1 and 
ABCC2, respectively (P > 0.05).  These findings suggest that inter-individual variability 
in 9AC disposition, but not 9NC, may be influenced, in part, by ABCG2 genotype.  
Because all patients did not have studies evaluating the pharmacokinetics of the lactone 
and total forms of 9NC and 9AC, it is unclear if the lactone and hydoxyacid forms are 
handled differently by ABC transporters.  It is likely that the contributions of the genetic 
variants evaluated in this study are obscured by the functional role of an undiscovered or 
unevaluated polymorphic protein with a transport or metabolic function (e.g., cytochrome 
P450).  This is especially important for 9NC because the enzyme that converts 9NC to its 
major metabolite, 9AC, has not been identifie.  In addition, as new transporters and 
associated genes are discovered, future studies should evaluate the influences of variant 
alleles of these genes and the disposition of 9NC and 9AC and other camptothecin 
analogues.  The primary limitation of this study and most pharmacogenetic studies is a 
limited sample size and a low frequency of the variant allele in the study population (e.g., 
the predominantly Caucasian population in our study).  For example, studies evaluating 
the relationship between ABC genotypes and pharmacokinetic variability of 
camptothecins required approximately 100 to 120 patients, where as our study only 
included 55 patients.  In addition, because this pharmacogenetic study was performed on 
patients enrolled on 2 phase I studies, a phase II study, and a single dose pharmacokinetic 
study, the relationship between ABC genotypes and response (i.e., toxicity or antitumor) 
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could not be made.  Ideally, effective pharmacogenetic studies will need to be performed 
in large phase II studies or even as part of phase III studies,  
7.2 FUTURE DIRECTIONS 
The NDA filed at the US FDA for 9NC (Orathecin, rubitecan) has been 
withdrawn by SuperGen, Inc.  This NDA included studies evaluating 9NC for the 
treatment of patients with newly diagnosed pancreatic cancer and in patients with 
pancreatic cancer who failed first line and second line therapy.  The regimen used in 
these studies was 9NC administered orally daily for 5 days per week for 8 consecutive 
weeks.  The results of our studies suggest that the intermittent regimen of 9NC (i.e., 
orally daily for 5 days per week for 2 weeks repeated every 4 weeks) may be more 
effective than the 8 week continuous schedule of regimen.  SuperGen is currently 
reviewing the possibility of performing a phase II study of 9NC in patients with 
refractory pancreatic cancer using the intermittent regimen evaluated in our preclinical 
and clinical studies.  If this phase II study is performed, my research group will be 
involved in pharmacologic studies associated with this study.  In addition, a randomized 
phase II study 9NC in combination with gemcitabine compared to gemcitabine alone is 
currently being performed in patients with newly diagnosed pancreatic cancer.  Thus, the 
clinical development of 9NC in pancreatic cancer continues. 
As described in our studies, the factors associated with the high inter- and intra-
patient variability in the disposition of 9NC and 9AC are currently unclear.  Future 
studies evaluating the effect of CYP3A4/5 and additional ABC genotypes on the 
pharmacokinetics of 9NC and 9AC are planned.  The effect of ABCG2 genotypes should 
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be further evaluated in Chinese patients.  In addition, studies evaluating the ability of 
fumitremorgin-C, an inhibitor of efflux by ABC transporters, to reduce the 
pharmacokinetic variability of 9NC and 9AC in patients are also being planned.  These 
studies will compare the pharmacokinetics of 9NC and 9AC when 9NC is administered 
alone and in combination with fumitremorgin C.  The studies described here for the 
preclinical and clinical development of 9NC can also be used for other camptothecin 
analogues. 
 
 
 
 
 
